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Abstract 
Abstract 
This thesis mainly describes a series of Phase I pharmacokinetic studies conducted on 
the TDS® delivery system which combined with lidocaine, testosterone, and a new drug, 
Melanotan-I for the transdermal drug delivery. Pharmacodynamic studies have also 
been carried out in certain areas to support the pharmacokinetics. 
The initial challenge was the development and validation of a method to analyse 
lidocaine in human plasma by LCMS-MS. The sensitivity and reliability of the 
developed method has enabled the analysis of lidocaine plasma levels from the TDS®- 
Lidocaine study. The results from the study have shown that the TDS® system has been 
able to deliver the drug effectively through the skin. This finding had a positive impact 
on the future development of the TDS® system in combination with other drugs. 
The combination of the TDS® system with testosterone had been successfully tested in 
12 healthy male subjects. TDS®-Testosterone was found to be bioequivalent to 
Androgel®. This result gave an insight into further development of this preparation if it 
is to be regarded as an alternative treatment for hypogonadism. Various methods of 
correcting for endogenous testosterone were performed on the data and the influence on 
bioequivalence was studied. Testosterone was used as a model drug and used to explore 
potential guidelines for the bioequivalence assessment of endogenous compounds. 
Finally, the TDS® system has been combined with a new, peptide derived drug, 
Melanotan-I (MT-I). This drug is currently under development for the cosmetic 
purposes and the treatment of various skin conditions related to sun allergies. A dose 
escalation study of TDS®-Melanotan for the protective tanning of skin was carried out 
and the result was presented. In addition, in vivo techniques, such as microdialysis and 
tape stripping, have also been explored to investigate the feasibility of measuring 
pharmacokinetic of a transdermal drug instead of using the conventional systemic 
measurements. 
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Chapter 1 Introduction 
1.1 The skin 
In the study of transdermal drug delivery, understanding the nature and the structure of 
the skin is vital. Skin is man's largest organ providing around 10% of the body mass of 
an average individual. Skin has many essential functions, including protection, 
thermoregulation, immune responsiveness, biochemical synthesis, sensory detection, 
and social and sexual communication. Although the skin is a large and easily accessible 
area for the administration of therapeutic agents, it also forms a highly efficient barrier 
between internal and external parts of the body. Skin is highly resistant to the 
penetration by any exogenous compound including chemicals and also organisms such 
as bacteria and viruses. The structure of human skin can be divided into three distinct 
layers, which are epidermis, dermis and hypodermis (subcutaneous adipose tissue) 
(Figure 1.1) 
Epidermis 
Dermis 
Subcutaneous 
Figure 1.1 A diagram of skin structure showing the three main layers of the skin 
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1.1.1 The epidermis 
The epidermis originally from the Greek word, ('epi', on top and `derma', the skin) is 
the outermost layer of the skin. The epidermis is a multiple layered membrane and its 
thickness varies depending upon the part of the body, from around 0.06mm on the 
eyelids to around 0.8mm on the palms of the hand and soles of the feet. It contains no 
blood vessels and is built up by several cells which can be further divided into: 1) 
Stratum germinativum or stratum basale, followed by 2) Stratum spinosum, 3) Stratum 
granulosum and, 4) Stratum corneum, from the inside to the outside of the skin. 
1) Stratum germinativum 
The stratum germinativum is also referred to as the stratum basale is the basal layer 
which contains cells similar to other tissues in the body. It also contains keratinocytes, 
melanocytes, Langerhans' cells, and Merkel cells (sensory). The main skin cells are 
keratinocytes, thus named because they produce keratin, also a basic component of hair 
and nails. Melanocytes are responsible for production of melanin, the pigment that gives 
skin its colour and protects the body from the actions of UV light. All people have 
roughly the same number of melanocytes, however those people who are dark-skinned 
normally produce more melanin. Exposure to sunlight can increase the production of 
melanin, which is why people develop a tan. Langerhans cells help to protect the body 
from infection and Merkel cells have a role in cutaneous sensation. 
2) Stratum spinosum 
On the top of the basale layer is the stratum spinosum. Within this layer, the 
keratinocytes begin to differentiate and synthesise keratins that aggregate to form 
tonofilaments. Stratum basale and spinosum together form the Malpighian layer. 
3) Stratum granulosum 
From the stratum spinosum to the stratum granulosum, the keratinocytes continue to 
differentiate, synthesise keratin and start to flatten. It also contains keratohyalin 
granules which are composed of profillagrin, loricrin, and cystein-rich protein. The 
fillaggrin subunits of profillagrin play the important role of matrix molecule to 
aggregate and align the keratin filaments. 
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4) Stratum corneum 
The stratum corneum is the outermost part containing a dry keratinized layer of dead 
cells and are represented as a `brick and mortar' model (Elias, 1981; Williams and Elias, 
1987). The layers of flat keratinized dead cells are vertically stacked to form a highly 
organised tissue structure. Its thickness varies between different parts of the body 
between approximately 10 to 50µm thick. It is thickest on the palms and soles and 
thinnest on the lips. The stratum corneum provides a pricipal barrier to the permeation 
of drugs through the skin (Harry E. Bodde, 1989), and it also assists in regulation of 
water loss from the body. 
1.1.2 The dermis 
The dermis is typically 3-5mm thick, and is made up of blood vessels, nerve endings, 
and connective tissue. Collagen and elastin, which combine in fibres are the compounds 
in the dermis which provide support and also elastic tissue to give man flexibility in the 
movement. Collagen is strong and hard to stretch whilst elastin, is elastic. In older 
people, some of the elastin-containing fibres disappear, which is one reason why the 
skin looks wrinkled. 
The dermis also contains a person's sebaceous glands and sweat producing glands. 
Sebaceous glands, which surround and empty their secretions into our hair follicles and 
pores, produce oil called sebum that lubricates the skin and hair. Sebaceous glands are 
found mostly in the skin on the face, upper back, shoulders, and chest. Sweat glands 
(eccrine and apocrine) are helpful in regulating the body temperature by-producing 
sweat. Eccrine glands can be found almost everywhere in our bodies, although they are 
mostly located in the forehead, palms, and soles of the feet. Apocrine glands become 
active at puberty and are concentrated in the armpits and pubic region. The sweat from 
the apocrine glands is more copious than that produced by the eccrine glands. 
1.1.3 The subcutaneous tissue 
The subcutaneous tissue can be considered as the bottom layer of the skin. This layer is 
made up of connective tissue, and cells that store fat. This layer also sometimes calls as 
hypodermis. Due to the existence of fat, this layer helps to retain the body's heat. The 
subcutaneous fatty layer can also provide a readily available supply of high-energy 
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molecules, whilst the principal blood vessels and nerves are carried to the skin in this 
layer. 
1.2 Drug Delivery 
Drug delivery is one of the most important subjects in pharmacology. The discussion of 
drug delivery normally involves the nature of a drug's formulation and how drugs can 
be delivered into the body to exert their action. Drugs can be delivered into the body by 
several mechanisms, depending upon the nature of drugs and the route of 
administration. The routes of administration are the pathways by which a drug or any 
other substances are brought into the body to exert their pharmacologic effects. 
Normally a substance needs to be transported from the site of administration to the site 
of action. 
The route of administration can be divided into three classifications: 
Enteral - oral, rectal, gastric feeding tube etc. 
Parenteral - intravenous, intramuscular injection or infusion, subcutaneous 
implant, etc. 
Topical/transdermal - epicutaneous (application on the skin), inhalation, intranasal, 
buccal mucosa, etc. 
From the three major routes listed above, the enteral route, especially oral delivery of 
drug is the most commonly used and least invasive. The villi of the upper intestine 
provide an extremely large surface area (- 200m) (Snyder, 2001) for the absorptions of 
drug into circulation. Most of the drugs need to be absorbed into the systemic 
circulation for drugs to reach the site of action. 
However, there are certain cases where a drug cannot be taken orally due to the 
physicochemical properties of the drugs. Some drugs such as insulin are partly 
destroyed or neutralised in the stomach or intestine, and some of them such as 
propranolol, lidocaine, propafenone, verapamil, and nitroglycerin has been extensively 
metabolised by the liver before reaching systemic circulations (Lalka et al., 1993). The 
bioavailability of a drug may be low, which means that a higher dose is needed to 
ensure efficacy. The higher dose of a drug could increase the risk of side effects or 
adverse events. A very common example of the unwanted side effects of an orally 
administered drug is hepatic toxicity. The liver is the first major organ to be exposed to 
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the ingested drug due to its portal blood supply. A drug is normally metabolised and 
excreted by the liver in the process known as first pass metabolism. However this 
process sometimes can cause liver injury such as necrosis, lipidosis, cholestasis, 
chirrhosis, etc. For example, many of the diverse group of pharmacologic agents 
available for the treatment of rheumatic diseases such as most of the NSAIDS (Non 
steroidal anti inflammatory drugs) have the potential to cause serious hepatotoxicity 
(Brass, 1993; Tolman, 1998). 
A drug may be administered via the rectal mucosa for the systemic effects if the oral or 
another parenteral route is not available. Rectal administration is not a common route 
for drug delivery in the United Kingdom, and only used for certain types of drugs for 
the treatment of sedation, seizures control, analgesia, etc. (Beebe et al., 
1992; Malinovsky et al., 1995; Pannuti et al., 1982; Uthman and Wilder, 1989). The 
rectum has a rich of blood supply and a thin wall which facilitates drug absorption. In 
some cases drug uptake can be almost as rapid as intravenous administration. This may 
cause adverse events in the cardiovascular or central nervous systems (American 
Academy of Pediatric, 1997). A consequence of this can be seen in the death reported 
after rectal administration of multiple doses of morphine (Gourlay and Boas, 1992). 
Although the rectal route can achieve rapid drug absorption, the irregular uptake, 
patient-to-patient variability and patient acceptability limits its usefulness (American 
Academy of Pediatrics, 1997). 
To avoid the first pass metabolism by the liver, other routes of drug delivery can be 
considered, such as parenteral and topical administration. However, parenteral 
administration such as intravenous injection or infusion and subcutaneous implant, are 
invasive and inconvenient for some patients especially children. Needle phobia, which 
affects many children and some adults, can limit the usefulness of this method. 
Intravenous injection also has the possibility of introducing infection. There are a few 
systems that have been developed recently to overcome needle phobia, such as a 
needleless injection and microneedles. The companies marketing the devices claim the 
systems are successful in delivering a therapeutic dosage through the skin. However, 
there are still some problems to be resolved when using these techniques. These include 
proper handling of the device which is necessary to avoid loss of the drug dosage 
entering the body which could result in high variability. Also the systems have a higher 
cost of manufacture, which in turn passes on extra costs to the users. Therefore, another 
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alternative such as topical or transdermal delivery has became increasingly popular for 
certain drugs. 
1.3 Transdermal Delivery 
Many terms have been used to describe transdermal delivery of drugs, i. e., penetration 
of a substance from outer skin through the skin layers and into the blood stream. Some 
people have used other terms such as percutaneous absorption, sorption, and 
permeation. However, transdermal delivery can be defined as a passive movement of 
the substance such as a drug through the outer and middle structure of the skin until the 
systemic circulation is attained (Scheuplein and Blank, 1971) or produces the local 
effect. Transdermal drug delivery can be used as alternative for systemic delivery of 
very potent drugs with low oral bioavailability such as protein and peptide (Lambkin 
and Pinilla, 2002), as this route avoids hepatic first-pass metabolism. Also potential for 
long-term controlled release such as patches system, which is unoffered by the usual 
gastrointestinal transit of oral dosage forms. Furthermore it offers a few other 
advantages over the oral route. These are listed by Berner and John (Berner and John, 
1994), as: 
9 The ability to discontinue administration by removal of the system 
The ability to modify the properties of the biological barrier to absorption (i. e 
stratum corneum) without any serious damage to the organ. 
" The ability to avoid a changing physiological environment, avoiding chemical or 
metabolic degradation (e. g. changing pH, luminal microflora involvement, etc., 
in the gut) 
" The ability to change the site of drug delivery, thereby reducing the risks of 
adverse reaction or toxicity due to repeated exposure at a single site. 
"A relatively large area of application and absorption compared to oral transit 
system. 
Various types of transdermal drug delivery are widely used currently including liquid 
formulation, ointment, gel and cream or lotion. Liquid formulation can be a simple 
single phase solution - either aqueous, solvent or miscible co-solvents. It can also be 
two phase systems, such as oil in water or water in oil emulsions. However emulsions 
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are more widely used in creams. An ointment can be explained as a greasy or semi-solid 
preparation. Ointment may contain other excipients such as silicone to improve the 
spreadibility of the formulations. Gels are normally formed from a liquid that has been 
thickened with other component(s). The liquid essentially forms a continous phase, with 
thickening agent providing a porous scaffold to maintain the semi-solid consistency. 
Also proving to be quite popular recently are transdermal patches which can be applied 
to the skin via adhesive action. The drug content in the patches can be locally or 
systemically delivered for a certain period of time. The delivery of drug also can be 
terminated by the removal of the system. 
The releases of drug from transdermal formulations and the penetration of drug through 
the skin is usually driven by using certain mechanism such as penetration enhancers, 
particles, laser ablation, ultrasound, electricals (iontophoresis and electroporation), etc. 
However, penetration enhancers are known to be widely used in the transdermal 
formulations. 
1.3.1 Transdermal delivery pathways 
When the topical drug products are applied on the skin, three processes involve; 
i) The drug releases from the formulation 
ii) Penetration / diffusion of drug through viable epidermis 
iii) Movements of drug to the site of action or reaching systemic circulations 
There are a multiple steps between the first drug apply on the skin until it appears in the 
systemic circulations or in the local tissues. The drug applied on the skin in the vehicle 
such as liquid formulation, emulsion, gel, etc. The molecules adjacent to the stratum 
corneum will partition into the membrane based on their physicochemical properties. 
Lipophilic molecules have a better partition in the stratum corneum due to the lipid 
properties of the stratum comeum. However the drug must possess both lipoidal and 
aqueous solubilities. Too hydrophilic molecule is unable to permeat through stratum 
corneum and too lipophilic molecule tends to retain in the stratum corneum (Naik et al., 
2000). There are two potential pathways of drug to penetrate the skin (Barry, 2002), 
(Figure 1.2); 
i) Passive movement across the stratum corneum 
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ii) 'T'hrough the shunt route. hair Iollicles or via the sweat duct. 
Passive movement through the stratum corneurn is often regarded as the main route of 
drug across the skin 
Figure 1.2 Skin structure shows the penetration routes through the skin 
The shunt route, hair follicles and sweat ducts normally offer pores for the drug to 
bypass the barrier function of the stratum corneum. However, shunt pathways only 
account for approximately 0.1 % of the total skin surface (Scheuplein, 1967). Therefore 
their contributions to the permeation of drug through the skin are small (Scheuplein and 
Blank, 1971). Large molecules such as peptides and proteins may require this 
transappendageal route as they permeate poorly through the stratum corneum. For the 
molecules cross passively through stratum corneum, they can either diffuse through 
corneocytes (highly hydrated keratin) in a transcellular route, or by intercellular route, 
between lipid bilayers. However, intercellular lipid route is the most proposed 
mechanism for most of the drugs (Albery and Hadgraft, 1979). 
1.3.2 Stratum corneum barrier properties 
I Iealthy human skin presents a natural barrier to exogenous chemical agents, including 
many pharmaceuticals, presenting a clinical problem in the delivery of drugs via this 
route. In general, the epidermis (specifically, the stratum corneum) provides the major 
control element of percutaneous absorption. A few studies have been conducted to 
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monitor the role of stratum corneum as an effective barrier for any exogenous 
compound to penetrate the skin. A study by Morgan et al. (Morgan et al., 2003), showed 
that the absorption of penciclovir and aciclovir increased by 1300 and 440-fold, 
respectively, when the stratum corneum removed by tape stripping prior application. In 
another study by Singer et al. (Singer et al., 1998), they have shown that the absorption 
of EMLATM cream was accelerated by the removal of the stratum corneum. The pain 
assessment at 15 minutes after EMLATM applications was less for tape strips (stratum 
corneum removal) patients compared to patients without tape strips. Therefore, the 
successful indicator of transdermal drug is the ability of the compound to penetrate the 
stratum corneum, act locally in the tissue or enter the systemic circulation. 
Many systems have been currently developed to overcome the limitation of the stratum 
corneum as a barrier including drug/vehicle interactions (e. g. eutectic system), vesicles 
and particles (e. g. liposomes and analogues), stratum corneum modification (e. g. 
chemical enhancers), stratum corneum bypass (e. g. laser ablation), and electrically 
assisted methods (e. g. ultrasound, iontophoresis etc. ) (Barry, 2001). Stratum corneum 
modifications, by using the penetration enhancer are widely used at present in the 
development of a transdermal delivery system. The penetration enhancers use 
substances that can temporarily diminish the barrier of the skin such as water, 
sulphoxides and their analogues, pyrrolidones, esters and alcohols, azone and its 
derivatives, surfactant (anionic, cationic and non-ionic), etc. (Barry, 2001). It therefore 
can enhance the drug flux. Hadgraft (Hadgraft J., 1984) defined the term penetration 
enhancer as a substance that increases the permeability of skin without severe irritation 
or damage to its structure. The ideal properties of a penetration enhancer as described 
by Hadgraft, are as follows: 
0 Elicit no pharmacological response 
0 Specific in its action 
0 Immediate acting with a predictable duration; its action should be reversible 
" Chemically and physically stable and compatible with formulation 
0 Odourless, colourless, and tasteless 
" Non-toxic, non-allergic, and non-irritant, both acute and chronically 
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" Systemically non-toxic 
1.4 Another transdermal routes 
Another transdermal route that avoided the stratum corneum barrier properties is the 
delivery of drug through mucosal membrane. The respiratory tract including nasal 
mucosa, hypopharynx, etc. provides a large area for drug absorption. The drug can be 
absorbed systemically through inhalation process. Drugs for asthma treatment such as 
salbutamol are normally given through inhalation. Drug also can be applied directly on 
the mucosal surface in the nasal mucosa administration. Applications via the liquid 
spray on the mucosa surface has shown rapid systemic response after the application of 
intranasal midazolam (Karl et al., 1992). However, this method of application is not 
favourable for children due to the discomfort and unpleasant taste of the formulations. 
Another mucosa surface is the oral transmucosal route. The drug administers through 
this route also known as sublingual or buccal. There are several drugs have been used 
for the delivery through this route such as midazolam (Karl et al., 1993), opioid 
(Weinberg et al., 1988), etomidate (Streisand et al., 1998), testosterone etc. (Stuenkel et 
al., 1991). 
1.5 TDS® delivery system 
In this project, we have studied a proprietary liquid formulation, TDS® (Transdermal 
Delivery System), which can be applied to the skin via a metered pump dispenser, to 
deliver a drug locally and systemically. The TDS® (Transdermal Technologies Inc, 
Florida, USA) is a drug delivery system using a novel technology, which has been 
developed for use in pharmaceutical, cosmetic and over-the-counter products. The 
system is composed of substances which are nutritional and / or neutral and harmless at 
their respective concentrations. The TDS® is typically composed of a compatible 
solvent such as ethanol and propylene glycol, supplemented by other excipients such as 
cationic surfactants (quaternary ammonium compounds) and non-ionic surfactants (long 
chain fatty acids) that enable a sufficient dose of the drug to be put into a relatively 
small volume of liquid. TDS® also contains other excipients, designed to support the 
skin and maintain the integrity of the barrier and the health of the skin. The application 
of quaternary ammonium compound, later developed as TDS® system, was claimed 
effective in the temporary relief of pain associated with arthritis, tendonitis, and bursitis 
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(Hadley et al., 1998a). Penetran Plus®, which contains this quaternary ammonium 
compound, has recently been approved as over-the-counter self-administered analgesic 
(http: //www. penetran. com/). 
The TDS® enables skin penetration by altering the fluidity of the lipid layers in the 
stratum corneum. The way lipids surround the skin cells of the stratum corneum is the 
way mortar surrounds bricks in a wall. The TDS® temporarily and reversibly alters the 
alignment of those lipids allowing drug molecules to slip through. It camouflages the 
drug protecting it from the skin and the skin from it. This means that the TDS® should 
be safe and deliver drugs without causing any damage to the skin (Transdermal 
Technologies Inc., 2006). The safety of TDS® system has been evaluated and confirmed 
by the Institute for In Vitro Sciences in Gaithersburg, Maryland USA for primary 
dermal irritation, skin sensitisation and toxicity (Raabe and Nathan, 2005). 
The above formulation of the TDS® has been shown to enable rapid delivery and is 
capable of delivering large (greater than 400 Daltons) drug molecules, proteins, as well 
as lipophobic and non-polar molecules in doses sufficient to reach therapeutic levels 
(Alam and Willoughby, 2002). The system uses a liquid vehicle to deliver drug across 
skin, measured by unit dose or metered pump spray. The dose is routinely compounded 
into approximately 1 mL of very stable fluid. There is no patch or application appliance 
required other than unit dose packaging or metered pump sprayer. 
1.6 Lidocaine 
9 
/C2H5 
H-C-C H2 N( 
CA H3C 
_, 
CH3 
Figure 1.3 Lidocaine structure 
Lidocaine (2-diethylaminoaceto-2', 6'-xylidide), (Figure 1.3), an amino ethyl amide, is a 
commonly administered drug widely used as a local anaesthetic and antiarrhythmic for 
the treatment of ventricular arrythmias (Ellenhorn MJ, 1998). It has also been used as an 
anticonvulsant, an analgesic and in the management of neuropathic pain. Local 
anesthetics are drugs used clinically to reversibly block the conduction of impulses in 
peripheral nerves, leaving a loss of feeling (numbness) at the application area especially 
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the skin. The chronological discovery of local anesthetics began the centuries ago, when 
the Peruvian Indians had discovered that chewing "khoka" leaves produced exhilaration 
and relief from fatigue and hunger (Liljestrand, 1967). In 1884, Carl Koller 
demonstrated the extract from these leaves (cocaine) had a benefit as a local anesthetic 
for the eyes, and earned him the distinction of the "Father of Local Anesthesia". Few 
compounds had been synthesised until the discovery of procaine in 1904, which was 
accepted to replace cocaine. Procaine, an ester type was used as local anesthetic until 
the discovery of lidocaine. Lidocaine was discovered in 1943 by the Swedish chemist 
Nils Lofgren and since then remains one of the most popular local anesthetic agents. 
Lidocaine is the alternative choice for individuals sensitive to ester-type local 
anaesthetics such as procaine and amethocaine or tetracaine. The amides are preferable 
to the esters because their metabolites are less likely to cause an allergic reaction. This 
is the first amide anesthetic derived from xylidine. It has more intense, longer lasting 
and more extensive anaesthesia than does an equal concentration of procaine but has 
shorter action than those of bupivacaine and prilocaine (Martindale, 1982). It is 
moderately lipid soluble with pKa of 7.9. It's duration of action of about 1-2 hours 
(Covino, 1986), indicate it is desirable when used for treatment requiring a rapid 
recovery (e. g. ambulatory surgery) but in less desirable for prolonged anesthesia. 
Pharmacokinetics of lidocaine in human can be described from the application 
EMLATM cream on the human skin. Absorption of lidocaine through the skin from 
EMLATM application is directly related to both the duration and the area of application. 
When 60g of EMLATM cream (1.5g lidocaine and 1.5g prilocaine) applied to 400cm2 of 
the skin (lateral thigh) for 3 hours, the Cmax achieved was 120ng/mL and for 24 hours 
application the Cm. was 280ng/mL (AstraZeneca, 2005). Similarly, when lOg of 
EMLATM cream applied onto facial skin for 2 hours, the Cmax achieved was 150ng/mL, 
but for the same dosage and application time onto the forearm, the Cm was only 
l8ng/mL (Juhlin et al., 1989). 
The pharmacological and toxic effects of lidocaine depend on the concentrations of drug 
in plasma. At therapeutic plasma concentration about 64% is bound to plasma protein 
(Covino, 1986). High concentration of lidocaine in plasma (- 5.3gg/mL) can cause 
toxicity such as methemoglobinemia (Bangha et al., 1996). Lidocaine is metabolised in 
the liver through dealkylation by mixed-function oxidases to monoethylglycine xylidide 
(MEGX) and glycine xylidide (GX). Both monoethylglycine xylidide and glycine 
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xylidide retain local anesthetic activity as potent as lidocaine (Catterall W and Mackie 
K, 2001) but its relative toxicity is approximately that of lidocaine (Kenkel et al., 2004). 
These metabolites are also responsible for the occurrence of toxicity which can occur 
during lidocaine therapy (Boyes et al., 1971). When administered intravenously, the 
steady state volume of distribution is 1.1 to 2.1L/kg. The elimination half - life from the 
plasma following IV administration is approximately 65 to 150 minutes. 
1.7 Testosterone 
OH 
0 
Figure 1.4 Testosterone structure 
Testosterone (17 a-hydroxyandrost-4-ene-3-one) (Figure 1.4), an endogenous hormone 
is the most important androgen secreted into the blood by Leydig cells of the testes in 
man and corpus luteum and the adrenal cortex of ovaries in woman (Snyder, 2001). The 
magnitude of testosterone secretion is greater in men than in women at all stages of life. 
This is the differences between men and women. Testosterone is the principle male sex 
hormone which plays an important role in male development. In healthy young men, 
testes produce between 3 and 10mg (average of 6mg) of testosterone per day (Mazer, 
2000) and the normal range is between 3-l Ong/mL. Testosterone is responsible for the 
three major functions in animals; 
" The development of secondary male sex characteristics such as, increased 
growth of body hair, beard growth, deep voice, penis development, 
aggressiveness, sexual behaviour, libido and the maturation of the sperm. 
Testosterone measurements are helpful in evaluating the hypogonadal states 
0 Promotion of the protein biosynthesis that is responsible for the highly anabolic 
functions of testosterone such as, accelerates muscle build-up, increases the 
formation of red blood cells, speeds up recovery time after injuries or illness etc. 
0 10 
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" Inhibition of the gonad regulating cycle, including the hypothalamohypophysial 
testicular axis. This function is to control the production of testosterone. If the 
body produce enough testosterone, the testes will signal the hypothalamus to 
release less LH (luteinizing hormone) and FSH (follicle stimulating hormone) 
result in the reduction of testosterone productions. 
LH is a major stimulus of testosterone production in men. Testosterone concentrations 
are higher during puberty, but decline with age (Bremner et al., 1983). Testosterone 
secretion is also pulsatile and diurnal, with the highest plasma concentrations attained in 
early morning and minimal levels in the evening. Testosterone is metabolised to two 
other active metabolites, dihydrotestosterone and estradiol. Both metabolites are as 
active as testosterone. Therefore some effects of testosterone are by itself, but some 
effects are from these two metabolites. Testosterone is also metabolised in the liver to 
another two inactive metabolite, androsterone and etiocholanolone (Snyder, 2001). 
Male hypogonadism is the state where the production of testosterone is below the 
normal level (testosterone deficiency). At this stage, testosterone replacement therapy 
may be indicated. Testosterone replacement therapy can increase and maintain the 
testosterone at the normal level in hypogonadal man. A number of testosterone 
preparations have been studied and are currently available for replacement therapy. 
1.8 Melanotan 
a-MSH (melanocyte stimulating hormone), a tridecapeptide (Ac-Ser-Tyr-Ser-Met-Glu- 
His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) is the pigmentary hormone that is released 
from the pars intermedia of the pituitary gland in some animals and keratinocytes and 
melanocytes in human skin. A major role of this hormone is to regulate integumental 
melanin pigmentation of the skin and hair in many species including human and some 
animals (Bolognia et al., 1989; Hadley M. E., 1996). 
The substitution of the amino acid methionine (Met) with norleucine (Nle) at position 4 
and L-phenylalanine (L-Phe) with D-phenylalanine (D-Phe) at position 7, give an 
analogue of a-MSH called Melanotan or more specifically as Melanotan-I (MT-I), 
(Figure 1.5). These substitutions make this analogue 26 times as potent as a-MSH in the 
adenylate cyclase assay (Sawyer et al., 1980). Melanotan was previously synthesized in 
the mid 1980's by a group of scientists at the University of Arizona, USA for the 
A 10 
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treatment of skin cancer. After synthesizing hundreds of molecules the compound which 
is now known as MT-I which is commonly identified as [N1e4-D-Phe7] - a-MSH was 
found which enhanced the potency and prolonged the biological activity of a-MSH 
(Abdel Malek et al., 1985; Hadley et al., 1985). In addition, these analogues also 
exhibited prolonged (residual) melanotropic activity, as evidenced by sustained 
maximal tyrosinase stimulation in cultured mouse melanoma cells (Abdel Malek et al., 
1985). Unlike a-MSH, MT-I is resistant to inactivation by serum enzymes or by 
purified proteolytic enzymes (eg., a-chymotrypsin) (Castrucci et al., 1984). 
The above results have very important impacts for the use of MT-I in the therapeutic 
darkening of the skin to protect it from harmful ultraviolet (UV) light. In response to the 
sun exposure, UV radiation induces a-MSH to stimulate the melanocyte in the skin to 
produce melanin, the pigment that gives the skin its colour (Bolognia et al., 1989). The 
fact that melanocytes can induce melanin pigmentation of the human skin can be 
described in Addison's disease where the direct action of ACTH (a melanotropic 
peptide) results in hyperpigmentation of the patient's skin especially in the mouth, hand, 
face and all flexural regions (Kumar and Clark, 1998). Melanin acts as a shield to 
protect the body from dangerous level of UV light. When exposed to the sunlight, the 
body is protected. It can be considered as an internal sunscreen. Since melanin 
pigmentation is considered to be the most effective mechanism the body has to protect 
against radiation-induced damage, it is important to stimulate the skin's own `protective 
mechanism' of tanning without exposure to the sunlight. MT-I, like sunlight (or UV 
lights), induces the production of melanin in the skin, resulting in a tan. By producing 
melanin without exposing the skin to dangerous levels of UV light, MT-I has the 
potential to reduce skin damage and thus to reduce the incidence of associated skin 
cancer. 
Fitzpatrick (Fitzpatrick, 1988) has classified the individual skin type in relation to their 
susceptibility to sunburn by the following criteria: 
Type 1: The skin that never tans, but always burns 
Type 2: The skin that sometimes tans, but mostly burns 
Type 3: The skin that mostly tans, but sometimes bums 
Type 4: The skin that always tans, and never burns 
10 
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Several studies have suggested that individuals whose skin tends to burn easily on 
exposure to the sun and who do not tan readily are at higher risk of both non-melanoma 
skin tumours and of cutaneous melanoma (Gilchrest and Eller, 1999). UV radiation has 
many harmful effects and is now identified as a major risk factor in the etiology of skin 
cancers, including malignant melanoma (Farmer and Naylor, 1996; Holman et al., 1983). 
Skin cancer is a global health issue affecting millions of lives. Non-melanoma skin 
cancer is the most common cancer in the UK. Official figures have over 62,000 cases 
diagnosed in the UK in 2001. But this figure is an underestimate as registration is 
generally incomplete (Cancer Research, 2005). There are also a few more common 
types of sun allergies that are caused by or aggravated by exposure of the skin to 
sunlight, such as Polymorphous Light Eruption (PMLE), Actinic Prurigo (hereditary 
PMLE), Photoallergic Eruption, Solar Urticaria, etc. Beside to induce the skin tanning, 
the development of MT-I is hoped to reduce the number of diseases associated with the 
sun exposure. 
The pharmacokinetic and safety of MT-I have been reported in a few studies. The MT-I 
doses of 0.16mg/kg were administered intravenously (IV) and orally (PO), and doses 
from 0.08 to 0.21mg/kg subcutaneously in three healthy volunteers for ten days (Ugwu 
et al., 1997). The results showed that the bioavailability of SC doses was comparable to 
IV doses, but no drug levels were observed in plasma following oral doses. The 
pharmacokinetic parameters obtained from SC and IV doses were summarised in Table 
1.1 and Table 1.2, respectively. The doses given were well tolerated with minimal side 
effects such as mild dermatologic and gastrointestinal effects. Two subjects became 
visibly flushed in the face and neck area within minutes after SC dosing and one of 
them experienced mild nausea after oral and IV dose. 
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Table 1.1 Pharmacokinetic parameters for Melanotan-I following SC 
administration to humans (n=3) (Ugwu et al., 1997). 
Parameter Subject 1 Subject 2 Subject 3 
Dose (mg/kg) 0.08 0.21 0.20 
Half-lives (h) 
absorption (a) 0.07 0.79 0.16 
beta (ß) 0.78 1.47 1.66 
AUCo-. (ng/mL/h) 427.2 1802.3 1226.1 
MRT (h) 1.21 2.74 2.59 
CL, (L/kg/h) 0.19 0.12 0.16 
Vd(3 (L/kg) 0.21 0.25 0.39 
Table 1.2 Pharmacokinetic parameters for Melanotan-I following IV administration 
to humans (n=3) (Ugwu et al., 1997). 
Parameter Subject 1 Subject 2 Subject 3 
Dose (mg/kg) 0.16 0.16 0.15 
Half-lives (h) 
alpha (a) 0.25 0.14 0.52 
beta (ß) 0.48 0.66 2.08 
AUC0.. (ng/mL/h) 296.7 405.1 518.9 
CLS (L/kg/h) 0.54 0.39 0.29 
V43 (Lfkg) 0.38 0.38 0.87 
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Figure 1.5 Structure of Melanotan-I (EpiTan Limited, 2004) 
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1.9 Pharmacokinetic studies 
Pharmacokinetics involves the kinetic study of drug absorption, distribution, 
metabolism, and elimination (ADME). The study of pharmacokinetics must involves 
both the theory and experimental. The theoretical aspects involve the design of the study 
and the prediction of the model to use in the experimental phase. Experimental aspects 
of the study involve the conduct of the clinical trial, sample collection, analytical 
methods development and validation, and statistical analysis of pharmacokinetic data. 
Pharmacokinetic studies or clinical trials are normally conducted in several phases - 
Phase I, II, III, and IV. 
Phase I is an early phase trial normally conducted in a small number of healthy subjects. 
These trials investigate how the human body handles the new drug or new formulations. 
Where possible the studies include an assessment the pharmacologic activity, side 
effects and the effectiveness of a drug in the human body. Most of the pharmacologic 
activity studies in phase I are to obtain the pharmacokinetic and pharmacodynamic 
properties of a drug. The information obtained from these studies can be used to design 
a Phase II study, normally conducted in a bigger number of patients. Phase II trials aim 
to give an idea of efficacy and safety of the drug in patients. During the early stages of 
Phase II, a limited number of patients may be given a low dose of drug and closely 
monitored for their tolerability with the treatment. During this phase, the suitable dosage 
and adverse effects shoud be identified and observed. 
If the study is successful and adequate degree of efficacy exists with the acceptable 
adverse effects, the bigger trials involving hundreds to thousands of patients will be 
conducted in Phase III in order to obtain the necessary marketing approval. Phase III is 
the main safety and efficacy study to optimise the drug effectively and may involve a 
multi centre studies. Phase IV trials are normally performed after the drug has been 
approved for marketing. They may be used to clarify some questions that may remain 
unanswered after finish the Phase III, such as effectiveness and safety on certain groups 
of people. These groups of people include children, the elderly, etc. 
1.10 Good Clinical Practice (GCP) 
Good Clinical Practice is an international ethical and scientific quality standard for 
design, conduct, performance, monitoring, auditing, recording, analyses, and reporting 
0 
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of clinical trials. It provides assurance that the data and reported results are credible and 
accurate and the rights, integrity and confidentiality of trial subjects are protected 
[EMEA, ICH GCP, 1.24] (EMEA, 2002). GCP compliance is now a legal requirement 
in the EU as of May 2004 which means that everyone involved in the investigation of 
medicinal products has the legal duty to ensure that all of the research processes are 
carried out in compliance with these regulations (HMSO, 2004). 
1.11 Objectives of the project 
This PhD project involved a series of pharmacokinetic studies conducted in healthy 
volunteers. The studies conducted were involved the transdermal delivery of a number 
of drugs currently used as a topical administration such as testosterone, lidocaine and 
new drug formulation, melanotan-I in order to improve the current problem or limitation 
associated with these products. 
The aim of this project is to: 
1) Conduct pharmacokinetic studies in healthy human subjects for the development 
of a novel transdermal drug delivery system, TDS® which are combined with a 
few drugs currently use for transdermal delivery. Pharmacodynamic aspects of 
the treatments also have been investigated in certain areas to support the 
pharmacokinetic findings. The pharmacokinetic and other information obtained 
will be used for future development of the TDS® system. 
2) Explore, develope, improve and validate the analytical tools available for the 
analysis of drugs in different matrixes obtained from all the clinical studies 
conducted such as analysis of lidocaine in plasma from TDS®-Lidocaine and 
EMLATM cream studies, lidocaine in dialysate and tape from microdialysis and 
tape stripping studies, respectively. 
3) Explore and compare the various methods available to measure pharmacokinetic 
profiles of transdermal or topical drugs such as conventional systemic 
measurement in blood, microdialysis and the tape stripping techniques. The 
outcome from this study may contribute the finding towards the establishment of 
the pharmacokinetic methods for topical drug administration. 
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Chapter 2 Lidocaine 
2.1 Introduction 
In percutaneous local anaesthetic, the drugs targets are the pain receptors (nociceptors), 
located at the dermo-epidermal junction. Local anaesthetic agents stabilize neuronal 
membranes by inhibiting the ionic fluxes required for the initiation and conduction of 
impulses for the local anaesthetic action. For this purposes, local anaesthetic is normally 
given by subcutaneous injection. When administered via subcutaneous injection, it 
produces a rapid onset of action and rapidly spreads through surrounding tissue for the 
anaesthetic effect. However, procedures involving the insertion of a needle through the 
skin are painful and may induce great fear and anxiety, especially in children. For the 
above reasons, many researchers have searched for a local anaesthetic method which is 
needleless and pain free via topical application. Many researches have been conducted 
and published on lidocaine and other agents for development of a topical local 
anaesthetic. 
0 
The investigations into the efficacy of topically applied local anaesthetics were first 
carried out by Monash in 1957 (MONASH, 1957). He showed that application of a 2% 
alcoholic solution of several local anaesthetic bases, produced percutaneous local 
anaesthesia within 45 - 60 minutes application. Since then, many formulations have 
been tested including the used of dimethyl sulfoxide, dimethyl acetamide and other 
solvents to increase the permeability of the solution into the skin (Brechner et al., 1967). 
The introduction of Eutectic Mixture of Local Anaesthetics (EMLA'') cream (Astra 
Pharmaceutical Ltd. ) represented a major advance in the investigation of transdermal 
local anesthetics. EMLATM cream (5% lidocaine: prilocaine) was developed in the 1980s 
(Evers et al., 1985), and is now in clinical use and has contributed to reducing the 
needle phobia in many European countries. The most common use of EMLATM cream is 
for the management of pain associated with venepuncture or intravenous cannulation, 
especially in children. Several studies have been conducted to assess the effectiveness 
of EMLATM as a local anaesthetic. Hopkins et al. (Hopkins et al., 1988) have evaluated 
the efficacy of EMLATM in 111 young children, ages 1-5 years in the alleviation of 
venipuncture pain at intravenous induction using 27-gauge needles. 75 children received 
EMLATM cream and 36, placebo. Pain was assessed by VAS and VRS and the result 
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showed that the EMLATM treated group had significantly lower rating score (no pain) 
than who received placebo. 
Although EMLATM is effectively used as local anaesthetic, long application times (at 
least 1 hour) for it to achieve acceptable analgesia, limit its usefulness. Another local 
anaesthetic agent, amethocaine or tetracaine (U. S. P) has been extensively studied 
(McCafferty D. F., 1995; McCafferty et al., 2000) to overcome the slow onset time of 
EMLATM. Amethocaine is a potent ester type local anaesthetic. Its local anaesthetic 
action is greater than that of lidocaine and normally used in lower concentrations 
(Martindale, 1982). The development of Amethocaine gel in Belfast in 1980's, has led 
to the introduction of Ametop Gel and is now also in clinical use as a topical local 
anesthetic (Smith & Nephew Healthcare Ltd. ). Ametop, contained 4% amethocaine has 
been claimed that more effective than EMLATM in providing skin anaesthesia. In the 
double blinded study involving 20 healthy volunteers, the various concentrations of 
amethocaine gel to provide anaesthesia were assessed. The study concluded that the 3% 
and above of gel concentrations are effective in providing skin anaesthesia after 30 
minutes application time (Woolfson and McCafferty, 1996) In another comparison 
study between EMLATM and Ametop gel in 110 children, the 40 minutes application of 
EMLATM and Ametop on the skin resulted in Ametop the most effective than EMLA. In 
the pain assessment, 62% of the subject treated by Ametop scored no pain compared to 
only 32% in the EMLATM treated group (Morton NS, 1996). 
The delivery of lidocaine through the skin by iontophoresis has also been investigated 
recently by a few researchers (Galinkin et al:, 2002; Rose et al., 2002; Zempsky and 
Parkinson, 2003). In two studies conducted by Rose et al. (2002) and Galinkin et al. 
(2002), iontophoresis local anesthetic system has shown to be more effective than 
placebo and comparable to EMLA. However it still requires at least 15 minutes of onset 
time (Zempsky et al., 1998). Nitric Oxide generating system (sodium nitrite + ascorbic 
acid + KY jellyTM) when combined with lidocaine also shown to be able to produce skin 
analgesia when applied on the skin (Tucker et al., 2002). The 10 minutes application of 
this system on the dorsal hand can significantly reduced the pain caused by venous 
cannulation, compared to placebo. Giving thorough consideration, this system is 
potential to be a topical local anaesthetic with a fast onset time. There are other systems 
currently under investigation such as lidocaine patches (Padula et al., 2003) and 
liposomal system (Bucalo et al., 1998; Eichenfield et al., 2002). 
Page 41 of 249 
Lidocaine 
2.2 Objectives 
This study had two main objectives. The first objective was to develop and validate the 
sensitive and accurate liquid chromatography-mass spectrometry (LC-MS-MS) method 
to measure low levels of lidocaine in human plasma. The second objective was to 
determine the ability and the effectiveness of the TDS® local anaesthetic system to 
anaesthetise the skin. Also to determine which anaesthetic system, the TDS®a 
Anaesthetic System (alcohol based) or the TDS®ß Anaesthetic System (water based) is 
effective in producing skin anaesthesia. 
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2.3 Validation of Liquid Chromatography - Mass 
Spectrometry (LC-MS-MS) method for the analysis of Lidocaine 
in human plasma. 
2.3.1 Introduction 
The absorption of lidocaine from intact skin into the blood circulation for transdermal 
delivery is very poor compared to intravenous injection. Therefore the systemic level of 
lidocaine is considerably lower. To analyse the plasma samples obtained from the 
clinical study of transdermal delivery of lidocaine, the sensitive and accurate method 
should be applied. Various analytical methods based on High Performance Liquid 
Chromatography (HPLC) with UV detection (Abraham et al., 1997; Adams et al., 
1989; Chen et al., 1992; Kang et al., 1999; Klein et al., 1994; Lotfi et al., 1997), Liquid 
Chromatography-Mass Spectrometry (LC-MS-MS) (Abdel-Rehim et al., 2000; Bo et al., 
1999), and Gas Chromatography (GC) (Watanabe et al., 1998) have been used in the 
quantification of lidocaine. Regardless the LC-MS-MS and GC-MS method, the HPLC 
with UV detection was not sensitive enough to detect low concentration of lidocaine 
which all the papers above claimed the LOQ ranging from 4 to I OOng/mL. In this study, 
the simple and rapid LC-MS-MS method for the analysis of lidocaine in human plasma 
using bupivacaine as an internal standard has been developed and validated. 
2.3.2 The principle of LC-MS-MS 
LC-MS-MS is a combination - of two techniques to identify and analyse chemical 
compounds. Liquid chromatography can separate a component of a mixture into 
separate compounds and then characterise them by mass spectrometry by their 
molecular weight. The separation of a mixture by liquid chromatography can be 
achieved by using a column. A column is normally packed with certain materials form 
different types of phases, such as normal phase, reverse phase, ion exchange, etc. After 
separation in the column, the samples are then introduced into the mass spectrometer's 
ion source, where the molecular components are ionised. The mass spectrometer will 
separate these ions based on their mass to charge ratio. For the purpose of simplicity, 
assume that all ion forms are singly charged, therefore the denominator of the mass to 
charge ratio (m/z) is always 1. Consequently, any ion observed at a particular mass is 
that mass. Therefore a compound can be identified either to confirm the presence of the 
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compound, quantitation by using standard curve or determine the elements within the 
sample, if unknown. 
2.3.3 Good Laboratory Practice (GLP) 
This validation was conducted at the Analytical Unit, St. George's Hospital Medical 
School in accordance with United Kingdom Statutory Instrument 1999, No. 3106, The 
Good Laboratory Practice Regulations, Department of Health, London, and the OECD 
Principles on Good Laboratory Practice (revised 1997, Issued Jan 1998) 
ENV/MC/CHEM (98) 17. 
2.3.4 Experimentals 
2.3.4.1 Chemicals 
Lidocaine hydrochloride and bupivacaine hydrochloride (internal standard) was 
obtained as a white powder from the Sigma-Aldrich Company, Poole, UK. All HPLC 
grade solvents were obtained from Rathburn Chemicals Limited, Walkerburn, Scotland. 
All AnalaR grade reagents were obtained from Merck (BDH) Limited, Poole, Dorset, 
England. The high purity air and nitrogen was generated using generators obtained from 
Peak Scientific Instruments Ltd., Renfrew, Scotland. 
2.3.4.2 Apparatus 
Solvent delivery was achieved using a Perkin Elmer series 200 pump set at 1 mL/min. 
Sample injection was performed by using a Perkin Elmer series 200 auto injector. A 
Shimadzu CTO-1OA was used as a column oven. Detection was by PE SCIEX API2000 
Mass Spectrometer. All PE SCIEX software was supplied by Perkin Elmer, England. 
The NM20ZA high purity nitrogen and air generators were supplied by Peak Scientific 
Instruments Ltd., Renfrew, Scotland. 
2.3.4.3 Chromatographic system 
The analytical column, a Supelcosil LC-Si (4.6mm ID x 100mm), obtained from Merck 
(BDH) Limited, Dorset, England, was maintained at 50° C. The mobile phase was 2% 
formic acid in acetonitrile: water (50: 50). The flow rate was fixed at 1mL/min. A PE 
SCIEX API2000 triple quadrupole mass spectrometer equipped with a turbo-ion spray 
(heated electro-spray, ESI) was used to introduce the sample into the mass spectrometer 
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through off-axis at an angle of 45°. The sample was introduced through a 10: 1 splitter, 
which meant only 10µL of the sample entered the mass spectrometer. Nitrogen was 
used as the collision gas. PE SCIEX Analyst software (1.3 Version) was used to control 
the HPLC/MS, record the output from the detector, perform integration of peak areas 
and calculate the lidocaine concentrations. 
Bupivacaine was used as an internal standard. All calculations were based on peak area 
ratios of lidocaine and internal standard. The precursor ion for lidocaine and 
bupivacaine were m/z 234.99 and 289.09, respectively and after collisional dissociation 
the product ions were 85.98 and 140.09, respectively. Molecular structure and the 
molecular weight of precursor and product ions are shown in Figure 2.2. The retention 
time for lidocaine and bupivacaine during the assay were 4.9 and 5.1 minutes, 
respectively. 
2.3.5 Assay Procedures 
2.3.5.1 Preparation of stock solutions 
2.3.5.1.1 Lidocaine Calibrator 
A stock solution of lidocaine was prepared by dissolving 5.8mg lidocaine hydrochloride 
in 100mL 50% methanol. The concentration of the stock solution was (after correcting 
for the salt and assuming a purity 100 %) 50µg/mL. 
2.3.5.1.2 Lidocaine Quality Control (QC) 
A stock solution of lidocaine was prepared by dissolving 5.7mg lidocaine hydrochloride 
in 100mL of 50% methanol. The concentration of the stock solution was (after 
correcting for the salt and assuming a purity 100.0%) 49.1 µg/mL. 
2.3.5.1.3 Bupivacaine (Internal Standard) 
A stock solution of bupivacaine was prepared by dissolving 5.8mg bupivacaine 
hydrochloride in 100mL of 50% methanol. The concentration of the stock solution was 
(after correcting for the salt and assuming a purity of 99.9%) 50µg/mL. A working 
strength solution was prepared by diluting 1 mL of the stock to 100mL with de-ionised 
water giving a final concentration of 500ng/mL. 
All the above stock solutions were stored at approximately -20°C. 
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2.3.5.2 Plasma Aliquots 
2.3.5.2.1 Calibrators 
250µL of the lidocaine stock solution was pipetted into a 50mL volumetric flask and 
made up to the mark with analyte free plasma to produce a sub-stock (Cal 1). Working 
calibration solutions were prepared by diluting the sub stock with plasma as tabulated in 
Table 2.1. 
Table 2.1 Working calibration solution (cal. ) with related dilution in plasma. 
Volume of Volume of Total Nominal Measured Inaccuracy Cal. 
sub stock plasma volume concentration concentration No. 
(plasma) added (plasma) 
(mL) (mL) (mL) (ng/mL) (ng/mL) % 
0.00 20 20.00 0.0 0.00 9 
0.05 25 25.05 0.5 0.50 0.0 8 
0.10 25 25.10 1.0 1.00 0.0 7 
0.20 20 20.20 2.5 2.48 -0.8 6 
0.80 20 20.80 10.0 9.62 -3.8 5 
2.25 20 22.25 25.0 25.28 1.1 4 
4.00 16 20.00 50.0 50.00 0.0 3 
10.00 15 25.00 100.0 100.00 0.0 2 
250µL 49.750 50.00 250.0 250.00 0.0 1 
stock (Sub 
solution stock) 
Calibrator 1 and calibrator 8 were used as upper limit of quantitation (ULOQ) and lower 
limit of quantitation (LLOQ), respectively. 
2.3.5.2.2 Quality Control (QC) samples 
500µL of the lidocaine stock solution was pipetted into a 25mL volumetric flask and 
made up to the mark with analyte free plasma to produce a sub-stock (QC 4, 
982ng/mL). 
Working controls were prepared by diluting the sub stock with plasma as tabulated in 
Table 2.2. 
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Table 2.2 Working control solution (ctrl. ) with related dilution in plasma. 
Volume of Volume of Total Nominal Measured Inaccuracy Ctrl. 
sub stock plasma volume concentration concentration 
No. 
(plasma) added (plasma) 
(mL) (mL) (mL) (ng/mL) (ng/mL) % 
0.075 50.0 50.075 1.5 1.47 -2.0 1 
1.20 25.0 26.2 45 44.98 0.0 2 
4.50 25.0 29.5 150 149.8 -0.1 3 
5001. tL 24.5 25.0 1000 982 -1.8 4 
stock (Sub 
solution stock) 
2.3.5.3 Extraction 
A simple liquid-liquid extraction was performed for this assay. A 0.5mL volume of 
plasma, O. 1mL internal standard (I. S) solution (500ng/mL), O. 1mL 1M NaOH and 3mL 
of methyl-tert-butyl ether (MTBE) were placed in a 4.5mL propylene tube. The content 
was mixed for the minimum of 5 minutes by the shaker and then centrifuged at 3000- 
3500rpm for 5 minutes. The top layer was then transferred to a 4.5mL propylene tube 
containing 0.25mL of 0.1% Formic acid. The tube was mixed again for the minimum of 
5 minutes by the shaker and then centrifuged at 3000-3500rpm for 5 minutes. The top 
solvent layer was discarded by vacuum and the remaining solution was transferred into 
an autosampler vial. A 100µL volume was injected into the analytical column. Figure 
2.1 shows the schematic diagram of the extraction procedure. 
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Lidocaine LC/MS/MS 
To a 4.5mL propylene tube add 
500pL Calibrator/ control sample 
100NL Internal standard (Bupivacaine, 500ng/ml) 
100NL 1M Sodium Hydroxide 
3mL Methyl-tert-Butyl Ether 
Mix for 5 minutes (minimum) 
Centrifuge for approximately 5 minutes (3000 - 3500 rpm) 
Transfer top layer to a 4.5mL conical propylene tube 
containing 0.25mL 0.1% Formic acid 
Mix for 5 minutes (minimum) 
Centrifuge for approximately 5 minutes (3000 - 3500 rpm) 
Discard top solvent layer 
Transfer all the extract to labelled autosampler tubes 
Inject 10 -100NL each extract onto the analytical column 
HPLC Conditions: 
Column: Supelcosil LC-Si (100cm x 4.6mm) 
Mobile phase: 
Acetonitrile 50% 
2% Formic Acid 50% 
Flow rate: I. OmL/minute (range allowed 0.8 - 1.2mL)" 
MS detection 
Figure 2.1 Schematic diagram of the lidocaine extraction procedures 
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2.3.6 Method Validation 
All the validation procedures and the acceptance criteria used in this study were adapted 
from the Food and Drug Administration (FDA) and The European Agency for the 
Evaluation of Medicinal Products (EMEA) guideline for method validation (EMEA, 
1995; FDA, 2001b). 
2.3.6.1 Specificity 
Six samples of blank plasma and six samples of plasma spiked with lidocaine and the 
internal standard were prepared and the extraction was carried out. The nominal 
concentration of lidocaine used was 0.5ng/ml (LLOQ) and the internal standard was 
500ng/mL. The signal to noise ratio for lidocaine and internal standard should be greater 
than 5. 
2.3.6.2 Calibration I linearity 
The calibration consists of eight non zero, calibrators assayed in duplicate (nominal 
values 0.5,1.0,2.5,10,25,50,100 and 250ng/mL). Two lidocaine free samples were 
analysed, one with the internal standard and one without the internal standard; neither 
being included when fitting the calibration line. The correlation coefficient (r) between 
concentration and peak area ratio should be equivalent to, or better than, 0.98. The 
simplest mathematical model that adequately describes the concentration-response 
relationship was used. 
The following conditions should be met in developing a calibration curve: 
" No more than 20% deviation of the LLOQ from nominal concentration. 
" No more than 15% deviation of standards other than LLOQ from nominal 
concentration. 
At least 66% of the non-zero standards must meet the above criteria, including the 
LLOQ and the calibration standard at the highest concentration. Excluding any 
calibrators should not change the model used. 
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2.3.6.3 Inaccuracy and Imprecision 
Inaccuracy was tested by determinations of low, medium and high quality control 
samples, together with the LLOQ and ULOQ samples. The nominal values for low, 
medium and high control samples were 1.5,45 and 150ng/mL, respectively. The 
nominal values for the ULOQ and LLOQ were the same nominal concentration as the 
highest and the lowest calibration standards, respectively. 
Assay imprecision were measured both within-batch and between-batch by the analysis 
of the three control samples, the LLOQ and the ULOQ. For within-batch and between- 
batch imprecision the LLOQ, ULOQ and the three control samples was each assayed six 
times in three separate assays. Each assay has an individual calibration curve. 
The within- and between-batch mean inaccuracy for the high and medium control 
sample concentration must be within ±15% of the expected or nominal concentration 
and within ±20% of the expected or nominal concentration for the lowest control 
sample. The within-batch and between-batch imprecision for the high and medium 
control sample concentration must be within ±15% and within ±20% for the lowest 
control sample. 
At the LLOQ, the mean inaccuracy and imprecision must be within ±20% of the 
expected or nominal concentration for at least five of the six control samples. At the 
ULOQ, the mean inaccuracy and imprecision must be within ±15% of the expected or 
nominal concentration for at least five of the six control samples. At least 66% of the 
controls must meet the above criteria. 
2.3.6.4 Recovery 
Absolute recovery of lidocaine was tested using human plasma spiked with lidocaine at 
the same nominal concentrations as the quality control samples. Absolute recovery of 
bupivacaine, (internal standard) was tested at a nominal concentration of 100ng/mL. 
Peak area measurements obtained from the extracted samples were compared to the 
peak area measurements obtained from direct solvent injection of the test compounds. 
Mean and standard deviation were calculated from at least three measurements at each 
level. 
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2.3.6.4.1 Extracted control sample: 
100µL of each aquoues control sample, 500µL blank plasma, 100µL internal standard 
solution were processed as the extraction method. 
2.3.6.4.2 Non-extracted control sample: 
100µL of each control sample (aqueous) was mixed with 100µL internal standard 
solution and 50µL 0.1% formic acid. 
2.3.6.5 Sample stability 
2.3.6.5.1 Freeze and thaw stability 
Stability of lidocaine was measured in a sample of analyte-free human plasma spiked 
with lidocaine at the same nominal concentrations as the quality control samples. These 
samples were subjected to repeated freezing and thawing. A minimum of three 
freeze/thaw cycles were tested. The storage conditions were representative of normal 
conditions (domestic freezer, nominally -20°C). The maximum and minimum 
temperatures during this period were recorded. The mean and the standard deviation 
were calculated from at least three measurements of each sample, for each freeze/thaw 
cycle. 
2.3.6.5.2 Stability at ambient and 4°C 
The stability of these control samples were examined at ambient temperature, 
approximately 20°C, and at approximately 4°C, for a period of at least 24 hours. The 
mean and the standard deviation were calculated from at least three measurements of 
each sample. The maximum and minimum temperatures at which both sets of samples 
were held during this period were recorded. 
2.3.6.5.3 Stability of the sample extracts 
The stability of the sample extracts were tested at the same nominal concentrations as 
the quality control samples. The three control samples, prepared in human plasma, was 
each extracted in such a way as to yield a total volume of extract sufficient to allow 
aliquots to be placed in the auto-sampler at room temperature and injected over a period 
of not less than 24 hours. A minimum of six measurements were made at each 
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concentration. The maximum and minimum temperatures during this period were 
recorded. 
2.3.7 Results and discussions 
2.3.7.1 Selection of operating protonated ions 
Figure 2.2 shows the chemical structure and the protonated ions of lidocaine and 
bupivacaine used in this study related to their mass. The fragment ions at 86 m/z for 
lidocaine and 139.7 m/z for bupivacaine were selected for the assay. The mass spectrum 
scans for the above two analytes are shown in Figure 2.3. 
H+ 
1 
/C2H5 NH-C-CH2 N\ 
H3C CH3 
CA 5+ 
/2H5 
H2C=N 
C2H5 
m/z 235 m/z 86 
LIDOCAINE 
H 
CH2-(CH2)2 CH3 
ON 
NH-C 
CH2-(CH2)2-CH3 
H3C CH3 + 
m/z 289 m/z 140 
BUPIVACAINE 
Figure 2.2 Chemical structures of precursor and product ions of protonated lidocaine 
and bupivacaine 
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Figure 2.3 Masss spectra of precursor and products ion scan for lidocaine and 
bupivacaine 
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2.3.7.2 Specificity 
No significant interfering peaks were found at the retention time of lidocaine or the 
internal standard. The signal to noise ratio for both lidocaine and the internal standard 
were both greater than 5. Figure 2.4 shows the chromatogram obtained from the blank 
plasma, blank plasma spiked with 0.5ng/mL lidocaine and blank plasma spiked with 
500ng/mL bupivacaine. 
2.3.7.3 Calibration 
The concentration range of lidocaine measurement was 0.5 to 250ng/mL. To correctly 
weight the quadratic regression line for this 500 fold range the residuals were weighted 
by the reciprocal of the nominal concentration value squared. This achieves an 
allocation of equal importance to each standard value. That is, a constant coefficient of 
variation is assumed across the calibration range. The peak area ratio, regression 
coefficient and the slope of the calibration line etc. were calculated from the peak area 
data by the Analyst program. The regression coefficient for all the calibration curves 
were greater than 0.99. Mean results obtained from five curves are summarized in Table 
2.3. 
Table 2.3 Regression parameters for five calibration curves during validation 
Batch (C) (A) Intercept(B) 
1 6.12 E-6 0.00743 0.000394 0.9995 
2 7.75 E-6 0.00772 0.000682 0.9995 
3 7.51 E-6 0.00783 0.000210 0.9987 
4 7.79 E-6 0.00816 0.000282 0.9994 
5 8.52 E-6 0.00830 0.000434 0.9997 
y=Cx2+Ax+B 
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Figure 2.4 Chromatograms obtained from extracted blank plasma, blank plasma 
spiked with 0.5ng/mL lidocaine, and blank plasma spiked with 500 
ng/mL bupivacaine. 
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2.3.7.4 Imprecision and Inaccuracy 
2.3.7.4.1 Within-assay reproducibility 
The CV% and the percentage for within assay imprecision and inaccuracy including 
LLOQ and ULOQ were all within the accepted range with ranging from 1.7 to 13% and 
0 to 10%, respectively. 
2.3.7.4.2 Between assay repeatability 
The CV% and the percentage for between assay imprecision and inaccuracy including 
LLOQ and ULOQ were all within the accepted ranges of between 1.9 to 8.3% and 1 to 
5%, respectively. From the nested Analysis of Variance, the within and between-batch 
and the total variability for all the QC samples including ULOQ and LLOQ were all 
below 11%. Table 2.4 and Table 2.5 summarises the within and between assay 
imprecision and inaccuracy achieved during the validation study, whilst Table 2.6 
summarises the within and between-batch, and the total variability obtained from the 
nested analysis of variance. All the results obtained were below than the limit accepted 
for validation. 
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Table 2.4 Within assay imprecision and inaccuracy in plasma 
Batch Nominal Mean SD CV Mean 
No concentrations n=6 inaccuracy 
(ng/mL) (ng/mL) (%) (%) 
0.50 0.54 0.03 6.44 7 
(S/N* ratio > 5) 
1.47 1.34 0.09 6.77 -10 
1 44.98 45.58 0.95 2.08 1 
149.8 151.25 4.04 2.67 1 
250.00 250.01 6.91 2.76 0 
0.50 0.46 0.06 13.33 -10 
(S/N ratio > 5) 
1.47 1.52 0.09 5.69 3 
2 44.98 47.48 1.71 3.60 5 
149.8 156.01 8.17 5.24 4 
250.00 267.10 9.73 3.64 6 
0.50 0.52 0.03 5.28 4 
(S/N ratio > 5) 
1.47 1.46 0.09 5.88 0 
3 44.98 44.09 1.09 2.47 -2 
149.8 156.37 2.83 1.81 4 
250.00 272.00 4.49 1.65 8 
* S/N : Signal to noise ratio 
Table 2.5 Between assay imprecision and inaccuracy in plasma 
Nominal 
concentration 
Mean (n=18) SD CV Mean 
inaccuracy 
(ng/mL) (ng/mL) (%) (%) 
0.50 0.50 0.04 8.34 1 
1.47 1.44 0.09 6.40 -2 
44.98 45.72 1.70 3.72 2 
149.8 154.54 2.86 1.85 3 
250.00 263.04 11.55 4.39 5 
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Table 2.6 Within and between batches variability from the nested analysis of 
variance (ANOVA). 
LLOQ QC1 QC2 QC3 ULOQ 
Nominal concentration 
(ng/mL) 
0.5 1.47 44.98 149.8 250 
Mean (ng/mL); n= 18 
0.50 1.43 45.72 154.54 263.04 
SDw 
0.03 0.09 1.34 5.34 6.99 
SDb 
0.04 0.08 1.55 2.38 11.18 
SDt 
0.06 0.12 2.05 5.88 13.18 
CVw (%) 
6.6 6.1 2.9 3.5 2.7 
CVb (%) 
8.7 5.9 3.4 1.5 4.2 
CVt (%) 
10.9 8.5 4.5 3.8 5.0 
w= within batch; b= between batch; t= totai 
2.3.7.5 Recovery 
The absolute recovery of lidocaine and bupivacaine ranged from 84 to 89% and 82 to 
86%, respectively. All the values are summarised in Table 2.7. 
2.3.7.6 Stability 
Table 2.8 lists the stability data for lidocaine in plasma after three freeze and thaw 
cycles, after 48 hours at room temperature, and after 48 hours at 4°C. The stability of the 
sample extract (in autosampler) was summarized in Table 2.9. Figure 2.5 shows the 
graph of log concentration (ng/mL) versus time (h) for autosampler stability test. 
Stability data shows that lidocaine was stable for all of the parameters mentioned above. 
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Table 2.9 Autosampler stability data 
Sample type Expected concentration Measured concentration Elapsed time 
(ng/mL) (ng/mL) (h) 
1.33 0 
1.68 4.3 
QC1 1.47 1.36 8.7 
1.59 17.0 
1.28 22.1 
1.37 24.5 
40.24 0 
41.53 4.3 
QC 2 44.98 41.33 8.7 
39.7 17.0 
40.07 22.2 
40.3 24.6 
148.95 0 
138.49 4.3 
QC 3 149.8 138.47 8.7 
139.71 17.0 
142.79 22.1 
142.31 24.5 
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Autos ampler stability test 
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Figure 2.5 Graph of log concentration (ng/mL) versus time (h) for autosampler 
stability test 
2.3.8 Discussion and conclusion 
All of the validation results met the international requirements as outlined in the 
Guideline for Analytical method validation (EMEA, 1995; FDA, 2001b). In this study, a 
simple liquid-liquid extraction which only needs 0.5mL of plasma has been developed 
and validated. The small amount of plasma used in the extraction procedure is suitable 
for analysis of the small volume of blood samples, especially from pediatric patients. 
Back extraction methods used in this study offered advantages in getting the clean final 
effluent to be injected into the chromatographic system, therefore reducing impurity 
peaks. The sensitivity, precision and accuracy achieved by this method enabled then 
analysis of very low serum lidocaine concentrations obtained from the pilot study of 
two TDS®-Lidocaine local anaesthetic system, which was conducted in 100 healthy 
volunteers. 
Vage 62 of 249 
Lidocaine 
2.4 Study of a combined percutaneous local anaesthetic 
and the TDS® System for venepuncture. 
2.4.1 Introduction 
The pain caused by common minor procedures such as venepuncture and minor surgery, 
is often ignored by clinicians. While it may be a trivial problem in adults, for young 
people, especially children, the pain is significant and can lead to the development of 
"needle phobia", an intense fear of needles that triggers immediate anxiety. This also 
affects some adults. Local anaesthetics are normally given by injection and are used to 
reduce the pain by inducing a loss of feeling (numbness) of skin and mucous 
membranes. To avoid the pain and anxiety of venipuncture, topical anaesthetics have 
been in use to provide needleless induction of local anaesthesia. 
Current topical local anaesthetics such as EMLA®, Astra Pharmaceuticals Ltd. (Evers et 
al., 1985) and AMETOP® gel, Smith & Nephew Healthcare Ltd. (Browne et al., 1999) 
are effective but require long onset time. The one hour prior application of EMLA® 
(AstraZeneca, 2005) and the 30 to 45 minutes for AMETOP® (Smith & Nephew 
Healthcare Ltd., 2005), limit clinical and patient acceptance. Thus topical anaesthetics 
are excluded from the procedures requiring acute anaesthesia, as well as those outside 
the institutional environment. The development of a topical delivery system with faster 
time of anaesthetic onset would be helpful in emergency cases and for increasing the 
number of surgical day cases seen, especially in paediatrics. Shortening the period of 
anticipatory anxiety while achieving the maximal desensitising of the skin would be 
advantageous. 
As the TDS® system had shown in the earlier study was able to deliver drug molecules 
through the skin (Hadley et al., 1998a), we therefore combined this system with 
lidocaine as local anaesthetic in order to overcome the slow onset time of some of the 
currently available systems as described above. This was a pilot study to evaluate the 
ability of our new local anaesthetic system to give the anaesthetic effect and also to 
deliver the lidocaine across the skin. 
2.4.2 Study Approval 
The study was approved by the North East London Research Ethics Committee. 
Reference no. RS/SA/P/02/087, dated 8th. August 2002. 
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2.4.3 Materials and Methods. 
2.4.3.1 Study materials 
Study Materials were supplied by Transdermal Technologies Inc. Florida USA. 
1) TDS®a Anaesthetic System (alcohol based) containing 4% w/v lidocaine and 
2% w/v tetracaine. 
2) TDS®ß Anaesthetic System (water based) containing 4% w/v lidocaine and 2% 
w/v tetracaine. 
3) TDS®a and TDS®ß placebo. 
2.4.3.2 Study design 
This was a double blinded and placebo controlled study, with a one week washout 
period, involving 100 healthy volunteers. Based on the previous study on the 
combination of lidocaine with a nitric oxide generating system (Tucker et al., 2002), 
100 subjects recruited in this study would be sufficient to produce an 80% power to 
detect a difference of 25% in the primary outcome measures at p<0.05. 
2.4.3.3 Subject recruitment I screening 
Each subject was screened for standard blood biochemistry, drugs of abuse, and 
answered a health questionnaire including demographic. Skin was assessed for 
erythema, oedema, itching, broken skin, or other signs of pathology. Body mass, height, 
body mass index, and blood pressure were recorded. Only subjects age range of 20-40, 
were included in the study. Subjects were not permitted any form of analgesia within 1 
week of the trial. 
2.4.3.4 Admission and procedures 
2.4.3.4.1 Study Protocol 
Subjects were admitted to the Study Unit having fulfilled all the inclusion criteria 
assessed during screening. Blood pressure and heart rate were measured after the 
subjects had rested for 10 minutes. A blood sample was taken from an antecubital vein 
to establish a baseline measurement of plasma lidocaine concentration. TDS®ß (active) 
was applied to the dorsal surface of a right hand and the TDS® (placebo) was applied on 
the left hand. The treatments were blinded from the volunteers. Administrations of the 
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formulations were achieved by metered pump spray of 1 mL to the area of 4cm2. Five 
minutes after application the hands were routinely cleaned using Alcowipes prior to 
venepuncture. 
A vein on each hand within the treatment area was then cannulated using a 20G 
butterfly needle. The success of cannulation was confirmed by the ability to withdraw 1- 
2mL of blood. Two methods of pain assessment, a Likert Verbal Rating Score (VRS) 
and a Visual Analogue Scale (VAS) were used to assess the pain of the procedure. Both 
systems have been fully validated in the literature (McCafferty et al., 1989; Woolfson et 
al., 1990). Following successful bilateral cannulation, a VRS and VAS pain 
classifications were used with respect to each hand. 
Two hours after the treatment application, another blood sample was taken to assess the 
systemic concentration of lidocaine. The plasma was transferred to cryo-vials and stored 
at -20°C until analysis. All the procedures, including treatment applications and 
bilateral 
cannulation were each performed blindly by separate investigators. One week later, the 
volunteers repeated the above procedure using the second formulation (TDS®ß). For 
TDS®ß application, the order of the treatment was changed to the active treatment on 
the left hand and the placebo on the right hand. 
2.4.3.4.2 Verbal Rating Score (VRS) 
The volunteers were asked the following question: "How strong was the pain of the 
procedure? " and provided with a choice of five categories: 1, no pain; 2, minimal 
sensation; 3, mild pain; 4, moderate pain; 5, severe pain. The volunteer selected one 
answer for each hand by circling the number. 
2.4.3.4.3 Visual Analogue Scale (VAS) 
In the VAS assessment, a 100mm horizontal line with endpoints that are anchored by 
descriptors `no pain' and `severe pain' was used. For each hand, the volunteer was 
asked "What did the procedure feel like? " and then requested to make a vertical line on 
the horizontal line which represented the intensity or unpleasantness of their pain 
experienced during the procedure. Values were measured in millimeters from the left 
hand edge of the horizontal line that is 0mm represented no pain and 100mm 
represented severe pain. 
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2.4.3.5 Analytical Method 
Plasma concentration of lidocaine was analysed by using the liquid chromatography- 
mass spectrometry (LC - MS - MS) method as described previously. 
2.4.3.6 Statistical analysis 
All of the data was analysed using Microsoft Excel worksheet, 2003 and Minitab 14 
statistical software (www. minitab. com/). The VRS and VAS score of active treatments 
were compared to the placebo control using Wilcoxon's Signed Rank test. The lidocaine 
concentrations at 2 hour post dose for TDS®a and TDS®ß were also compared by using 
Wilcoxon's Signed Rank test. 
2.4.4 Results 
One hundred healthy volunteers (41 males and 59 females) were successfully recruited, 
and the demographic data is presented in Table 2.10. Of the 100 subjects, 65 were 
Caucasian, 22 Asian, 4 African/Caribbean, and 9 from other ethnic groups. The 
cannulation procedures were successfully completed at the first attempt for all 100 
volunteers. All of the subjects tolerated the procedure well and complied with the study 
protocol. 
In the VRS pain classification, the active treatment of TDS®a was not significantly 
different to that of the placebo (estimated median = 0.0; p= 0.64 (NS); Figure 2.6). 
However the active treatment of TDS®ß resulted in a significant reduction in pain 
response to cannulation compared to the placebo treatment (estimated median = -0.5; p 
= 0.018; Figure 2.7). 
Similarly, the VAS also showed no significant different between placebo and active for 
TDS®a (estimated median = -0.5; p=0.827 (NS); Figure 2.8) but significantly different 
for TDS®ß (estimated median = -6.0; p=0.016; Figure 2.8). The distribution of scores 
for the active treatment group in Phase II (TDS®ß) was generally shifted from the two 
highest scores (moderate and severe) to the lower level of score (mild), with no subjects 
on the active treatment rating the pain as severe and reducing the numbers of those who 
scored the pain as moderate by 36.4% (Figure 2.7). 
However, the analysis of plasma samples for TDS®a and TDS®ß at 2 hour post dose 
were found no significant difference between TDS®a and TDS®ß (Wilcoxon's Sign 
Page 66 of 249 
Liclocaine 
Rank test; p=0.574). The median plasma level for "I-DS"a was slightly higher than 
TDS'R (3 with the median [IQR] were 0.930 [1.930] ng/mL and 0.560 [2.185] ng/mL. 
respectively. 
Table 2.10 Demographic data of study volunteers 
Parameters Mean (SD) Median [range] 
Sex; M: F 41: 59 
- ge: years 26.45 (5.2) 25.0 [20-401 
Body mass index(BMI) 23.3 (3.9) 22.6[15.2-')7.5] 
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Figure 2.6 Verbal Rating Score (VRS) for TDSu. Values are subjects percentage vs. 
categories, n= 100, p=NS, Wilcoxon's Signed Rank test 
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Figure 2.7 Verbal Rating Score (VRS) for TDS(3. Values are subjects percentage vs. 
categories; n= 100; P=0.018, Wilcoxon's Signed Rank test. 
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Figure 2.8 The median differences in VAS score of active and placebo (a = TDS(x 
and ß= TDS(3). Values are median ± 95% Cl; n=100; p= NS for TDSa 
and p< 0.0 16 for TDS(3, Wilcoxon's Signed Rank test. 
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2.4.5 Discussion 
For many years, the cycle of needle phobia affected many people especially children 
and the elderly. The introduction of EMLA cream and Ametop gel has finally broke the 
needle phobia, but the slow onset time of both anaesthetics remained a critical point that 
need to be resolved. In this project, the TDS lidocaine local anaesthetic system has been 
successfully tested in 100 healthy subjects for the skin anaesthesia. In this study, we 
have developed and validated an improved LC-MS-MS method validation to analyse 
lidocaine in human plasma in accordance to the UK GLP requirements which meets the 
internationally accepted method for validation. The used of LCMS-MS in this study is 
very important as the plasma samples contained very low concentration of lidocaine as 
many other analytical methods are not capable in performing this task. This method has 
been successfully applied in the analysis of plasma samples from TDS®-Lidocaine 
study. 
The result from this study suggests that immediately following application of a TDS® 
anaesthetic system, there is a fast onset of effective anaesthesia for the venous 
cannulation in adults. The fact that five minutes application of TDS® anaesthetic system 
can produce acceptable level of anaesthesia is a major advance in anaesthetic system 
compared to EMLA® and AMETOP® gel which require 1 hour and 30 to 45 minutes, 
respectively, before cannulation is attempted. However, the design of this study has a 
few major flaws such as the subjects were not randomised and the application between 
the left hand and the right hand for active and placebo also was not randomised. This 
study was designed to avoid having the active treatment on the same hand, but without 
randomisation, this study was exposed to bias. The blood samples taken at two hours 
post application also was not necessary as the main question of this study was to assess 
the pain after 5 minutes application. Therefore, the information obtained from 2 hours 
blood sample was not relevant to the current study. Various sampling points for blood 
was necessary to investigate the amount of lidocaine absorb from both formulations. 
The used of 5 minutes application time was also arguable. This was an exploratory 
study to compare the two TDS® systems (water and alcohol base). A future study 
should be designed to assess various application times and using the pin prick test to 
assess the pain. 
Between the two TDS® systems tested, the water based anaesthetic system (TDS®ß) was 
found to be effectives in providing dermal anaesthesia, whereas the alcohol based 
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(TDS®a) was ineffectives and no different from placebo. However, from the plasma 
lidocaine analysis, the median concentration of TDS®a was slightly higher than TDS®ß 
at 2 hours post dose suggesting that TDS®a may be able to deliver lidocaine through the 
skin but needs longer onset time for the anaesthesia. Therefore TDS® anaesthetic system 
can be manipulated to adjust the onset and degree of topical anaesthesia, and will be 
used as a basis for investigations into application periods and increased levels of 
anaesthesia. Other TDS® anaesthetic systems, such as using alternative combinations of 
local anaesthetic agents rather than the lidocaine/tetracaine used in this study are 
currently under investigation. The development of a rapid onset topical local anaesthetic 
would enable the replacement of invasive method of local anaesthesia, consequently 
increases the effectiveness of clinic or day surgery centre in the management of pain 
associated with local anaesthetic. 
2.4.6 Conclusions 
The result from TDS®-Lidocaine study, which has shown that the water based (TDS®ß) 
local anaesthetic system has been able to give skin anaesthesia after 5 minutes 
application time, was a major achievement in the development of local anaesthetic 
system. This result has a significant contribution on the future development of more 
effective local anaesthetic system compared to currently available treatments. The 
bigger and proper phase 1 pharmacokinetic study in healthy subjects is needed in the 
development of this system. 
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Chapter 3 Testosterone 
3.1 Introduction 
Testosterone deficiency in men or hypogonadism is a syndrome that can be defined by 
low level of testosterone (i. e. serum total testosterone < lOnmol/L or < -2.88ng/mL). 
This condition may result from a primary defect of the testes, or from a disorder of the 
hypothalamus or anterior pituitary resulting in inadequate gonadotrophic stimulation of 
the testes (Arver et al., 1997). Klinefelter syndrome also can caused hypogonadism 
(Nieschlag et al., 2004). Primary hypogonadism, always associated with raised level of 
luteinizing hormone (LH) and follicle-stimulating hormone (FSH) due to diminish 
testosterone productions and secondary hypogonadism with low testosterone and low or 
normal LH and/or FSH (Nieschlag et al., 2004). There are also a number of conditions 
that can cause decreasing amount of testosterone in men, such as diabetes mellitus, 
atheroschlerosis, myocardial infarction, chronic heart failure, chronic renal failure, 
AIDS, alcohol abuse, etc. (Kaufman and Vermeulen, 1997). At this stage, testosterone 
replacement therapy may be indicated. 
There are a few treatments currently available to increase the amount of testosterone in 
the systemic circulation such as oral and sublingual preparations (Johnsen et al., 
1974; Stuenkel et al., 1991), transdermal patches (Dobs et al., 1999; Korenman et al., 
1987), subcutaneous implants (Handelsman et al., 1990), testosterone esters, enanthate 
and cypionate (Matsumoto, 1994) and also the gel applications (Jockenhovel, 
2003; Swerdloff and Wang, 2003). Free, unesterified testosterone was absorbed well, but 
undergone hepatic catabolism in the liver rapidly following oral ingestion (Gluud et al., 
1983; Snyder, 2001). Behre (Behre H. M., 1998) reported that oral administration of 
testosterone gives rise to wide fluctuations with high within and between individual 
variability in serum testosterone concentrations. It has been reported that the methyl - 
testosterone can cause hepatic toxicity and adversely affects cholesterol concentrations 
following long-term usage (Bird and Vowles, 1977; Lowdell and Murray-Lyon, 
1985; Westaby et al., 1977). 
To avoid first-pass metabolism, testosterone rectal preparations was developed. The 
systemic absorption was high, but lasting for only 4 hours. Therefore needs to 
administer frequently to maintain the level. This is not ideal for testosterone 
replacemement therapy (Nieschlag et al., 1976). Intra nasal application also has been 
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studied, but the same result as rectal has been observed (Danner and Frick, 1980). 
Sublingual preparations of testosterone also resulted in rapid increases in serum 
concentrations, unfortunately decline to below the normal range after 2 hours (Stuenkel 
et al., 1991). Since free testosterone undergone rapid metabolism, testosterone esters 
have been evaluated for intramuscular injection, such as testosterone enanthate, 
propionate. However, the testosterone level declines to very low level before the next 
injection. This meant that the substance needs frequent injections, and do not suitable 
for long term therapy (Betire H. M., 1998). Another testosterone ester cypionate , and 
undecanoate, however can maintain the testosterone level for up to two weeks, and 12 
weeks within injection interval, respectively (Nankin, 1987; Nieschlag et al., 1999). 
Subdermal testosterone implants also have been evaluated for their efficacy 
(Handelsman et al., 1990; Kelleher et al., 2004). Implants are using stainless steel and 
administered under sterile conditions under routine minor surgery. The procedure is 
usually completed within 10-15 minutes (Handelsman et al., 1997). In a 
pharmacokinetic study on three different regiments of pellets (6 x 100mg, 6x 200mg, 3 
x 200mg), 43 androgen-deficient men were implanted for the period of 6 months. 
Testosterone levels peaked at the first month and were maintained at physiological 
levels for 4 to 5 (600mg doses) or 6 (1200mg dose) months after a single implantation 
(Handelsman et al., 1990). In another study comparison study between, intramuscular 
injection of testosterone ester, oral testosterone undecanoate, and subcutaneous pellet, 
the results showed that the testosterone was elevated for up to 4 months. The patients 
treated with intramuscular injection and oral only showed the testosterone peaked at the 
first treatment week and fell down with some fluctuations and most variables plasma 
level in orally treated group (Conway et al., 1988). Since the procedure to apply and 
removal of the implant is inconvenient, some patients may not prefer this method for 
testosterone replacement therapy. 
Transdermal delivery of testosterone has been found to be an effective and more 
convenient for testosterone replacement therapy. The advantages of transdermal 
delivery are the avoidance of hepatic first pass effect and the testosterone level obtained 
from the treatments closely mimic the circadian rhythm of testosterone secretion in 
healthy males. The first ever transdermal application is the scrotal patches which can be 
applied on the scrotal skin. This system is available as Testoderm®, and consists of a 
film containing 10 or 15mg testosterone (Zitzmann and Nieschlag, 2000). The result 
from the study conducted on healthy and hypogonadal males subject found testosterone 
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levels maintained in the normal range during a 12-week treatment period. No side- 
effects or adverse events have been observed. This type of application offers a new 
approach to androgen substitution therapy (Bals-Pratsch et al., 1986). In a long term 
study of this system, scrotal patches were been applied everyday for 14 months in seven 
hypogonadal men. The result showed that all patients were clinically well substituted 
and responded with good compliance (Bals-Pratsch et al., 1988). 
Another form of transdermal patch, Androderm® which can be applied on the non- 
scrotal skin has been developed recently. To optimise testosterone delivery and 
hormone normalizations, the preferred sites for applying the system are the back, thigh, 
upper arm, and abdomen (Meikle et al., 1996). The long term study which applies the 
treatment for up to 12 months had shown that the morning serum testosterone levels has 
been normalized in 93% of the patients treated. Majority of the patients treated also 
showed improvement in the hypogonadism symptoms such as decreased libido and 
fatigued, after 2-4 weeks treatment (Arver et al., 1997). However the further studies on 
Androderm® had found that some patients experienced local skin irritation or local 
contact dermatitis (Arver et al., 1997; Rolf et al., 1999). Occasional mild redness or 
itching of the skin is also common with transdermal patches. Although scrotal patches 
causes less skin irritation than conventional transdermal preparations, usage of the 
forma leads to an increase in dihydro-testosterone (DHT) concentrations after 3 months 
of treatment (Behre et al., 1999). 
Testosterone in a hydroalcoholic gel, AndroGel® (Unimed Pharmaceutical Inc. ) has 
been evaluated for the replacement therapy. The delivery of testosterone is generally 
good with increases in testosterone level up to 5 fold after application of 100 mg 
testosterone gel. Serum testosterone level reached steady state and remained at the same 
level for the duration of gel application and returned to baseline after stopping 
application (Wang et al., 2000a). Another version of testosterone gel, TestimTM 
(Auxilium Pharmaceuticals, Inc. ) was recently approved for used in the USA (Tenover, 
2003). The pharmacokinetic study to compare the bioavailability of Testim and 
AndroGel® has been conducted in 29 hypogonadal men. The results showed that 
TestimTM was not bioequivalent to AndroGel® where TestimTM providing higher 
serum levels and greater bioavailability than AndroGel® (Marbury et al., 2003). 
Although testosterone gels are effective for replacement therapy, care must be taken to 
prevent the transfer of testosterone to another person. Patients must wash their hands 
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after applying the gel to a substantial surface area of the body and they must cover the 
application site with clothing once the gel has dried (Unimed Pharmaceutical Products, 
2002). Furthermore, AndroGel® required large surface area of application as the study 
conducted by Wang et al. (Wang et al., 2000a) showed that the application of the same 
gel amount at 4 sites of the body contained approximately 4 times higher testosterone 
than 1 site. Rolf et al. (Rolf et al., 2002) recently showed that newly developed 
hydroalcoholic gel was effective for replacement therapy. The advantage is the gel can 
be washed after 10 minutes application to avoid transfer to another person. 
The delivery of testosterone through buccal mucosa has also been evaluated recently. 
Baisley et al. (Baisley et al., 2002) has evaluated the buccal adhesive testosterone tablet 
(BATT) which is under development by Abbott Laboratories, USA. BATT was applied 
to the gingival, in the region of infranasal fossa. The results have showed that the three 
dosages of BATT were effective in maintaining the testosterone level within the normal 
range in healthy males at least 24 hours after application. The steady state of 
testosterone was reached at day 5 from the ten application days. 
None of the currently available testosterone replacement therapy has achieved the goal 
due to some disadvantages as discussed above. Ideal testosterone replacement therapy 
should in theory, produce and maintain physiologic serum concentrations of the 
hormone and its active metabolites without significant side effects or safety concerns 
(Hellstrom, 2004). An in vivo pilot study has been conducted earlier, to investigate the 
effectiveness of a novel TDS® - Testosterone to deliver testosterone systemically in 
rodents (Alam and Willoughby, 1999). The application of TDS®- Testosterone to the 
dorsal surface of rodents facilitates transport of quantifiable levels of testosterone in the 
systemic circulation. An increase 3 to 6 fold in the level of serum testosterone was seen 
in all animals treated with TDS®- Testosterone. In this study, TDS®- Testosterone has 
been evaluated in healthy males through two parts of the study. 
A preliminary study to look at the ability of TDS®-Testosterone to deliver a therapeutic 
amount of testosterone systemically has been conducted in five healthy males receiving 
five different dosages. The suitable dosage concluded in this study was used in the 
pharmacokinetic study of the TDS®-Testosterone conducted in twelve healthy males in 
comparison with a TDS®- Placebo and AndroGel®. 
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3.2 Objectives 
The main objective of preliminary pharmacokinetic study in 5 healthy males was to 
assess the ability of TDS® system to deliver a therapeutically acceptable serum 
testosterone concentration and to identify a therapeutically acceptable dose of 
testosterone. 
The main objective of pharmacokinetic and bioequivalence study in 12 healthy males 
was to measure the pharmacokinetic profiles and bioavailability of a new TDS®- 
Testosterone compared to Androgel®1% and TDS®-placebo in healthy males. 
The second objective of the above two studies was to assess a safety and tolerability of 
TDS®-Testosterone in healthy males subject. 
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3.3 An open label, single dose study of 5 different doses of 
TDS®- Testosterone (Preliminary study) 
3.3.1 Study Approval 
The study was approved by the East London and The City Health Authority Research 
Ethics Committee. Reference no. RS/SB/P03180, dated 9ý'' October 2003. 
3.3.2 Materials and methods 
3.3.2.1 Study treatment 
The study treatment was a topical application of the TDS®-Testosterone system (batch 
number MBR-BFLIQ84) containing 10,20,30,40, or 50mg of testosterone. The 
treatment application was via a metered-pump dispenser, each spray delivering 0.2mL 
containing 10mg of testosterone. 
3.3.2.2 Study Design 
This study was an open label and single dose of five different doses of TDS®- 
Testosterone involving five healthy males. 
3.3.2.3 Subject recruitment 
Five healthy male volunteers were recruited in response to an advertisement. Written 
informed consent was obtained from all volunteers prior to participation. A medical 
history was taken, including past illness, allergies, tobacco and alcohol consumption, 
and current use of other medically active substances. Blood samples were collected for 
clinical biochemistry, haematology and hormone levels such as testosterone, LH, and 
FSH. In addition, routine urinalysis and a screen for drugs of abuse were performed. 
Entry to the study was gained following review of pathology reports, medical history 
and the hormone level within the normal range. 
3.3.2.4 Admission and procedures 
The subjects were admitted to the Clinical Microvascular Unit, St Bartholomew's 
Hospital on the morning of each study day. Blood pressure and heart rate were 
measured after subjects had rested for 10 minutes. A 20G cannula was placed in a large 
antecubital vein for blood collection. Subjects were randomised (Table 3.1) to one of 
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five TDS®-Testosterone doses (10,20,30,40 or 50mg), and the dose applied to the left 
arm via metered dose spray and gently rubbed onto the skin. Regular meals and 
beverages were provided throughout the study day. After dosing subjects were 
permitted to engage in normal daily activities, but excluding significant physical 
exertion or activities likely to stimulate endogenous testosterone production. 
Table 3.1 Randomisation table for the five TDS®-Testosterone doses 
Subject TDS -Testosterone doses 
no. (mg) 
1 20 
2 50 
3 30 
4 40 
5 10 
3.3.2.5 Blood samplings 
On the study day, intravenous in-dwelling cannulae were maintained for 8 hours 
following the TDS®-Testosterone application. A 4mL blood sample was collected at 0 
hours (prior to dosing) to establish a baseline measurement of serum testosterone 
concentration. Subsequently, serial 4mL blood samples were collected at 0.5,1,2,3,4, 
6, and 8 hours post dose. The integrity of the cannulae was maintained using a 2mL 
saline flush after each collection. 
After the collection of a blood sample at each time point, the sample was allowed to clot 
for approximately 20 minutes and then centrifuged at 1800g for 10 minutes. The serum 
was transferred to labelled tubes (cryo-vials) and stored at 4°C. At the end of the study 
day the serum samples were transported and stored at -20°C until analysis. 
3.3.2.6 Analytical Method 
Testosterone concentrations were measured in serum using an Enzyme Link 
Immunosorbent Assay (ELISA) method. The ELISA came as a kit, complete with all of 
the reagents to perform the analysis on a 96 well plate. The testosterone Elisa kit was 
obtained from DRG Instruments GmBH, Germany, lot number 29K064. The kit has 
already been validated to demonstrate adequate sensitivity, specificity, inaccuracy and 
imprecision (within and between assays). For the accuracy of measurements and the 
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GCP requirements, all the samples were analysed together with quality control samples 
containing three different concentrations. The three level testosterone control standards 
were obtained from Bio-Rad Laboratories, USA (lot no. 40631,40632, and 40633 for 
level 1,2, and 3, respectively). The plate reader used was a GENios, computer 
controlled spectrophotometer from TECAN Company, Austria. ). The limit of 
quantification was 0.2ng/mL. All of the standards, samples and controls were analysed 
in duplicate. 
3.3.2.6.1 ELISA Principles 
ELISA is an Enzyme immunoassay (EIA) used to measure an antigen or antibody. It is a 
heterogeneous, solid phase assay that requires the separation of reagents. ELISA is 
based on the fact that an antigen or antibody can be attached to a solid phase support yet 
retains immunological activity, and either antigen or antibody can be linked to an 
enzyme while the complex retains immunological and enzymatic activity. It has two 
available techniques, the sandwich and the competitive techniques. The ELISA used in 
this study was a sandwich technique. In this technique, the polystyrene plate comes with 
an antibody bound in the well. When adding the antigen to be measured in the well, it 
will form an antigen-antibody immune complex. An enzyme conjugate is then added to 
the well and binds with the immune complex. The substrate is added to the enzyme 
conjugate which is bound onto the complex and if any enzyme conjugate complex 
exists, a colour change will occur. The intensity of the colour will depend on the amount 
of complex inexistance. Normally the colour will change to blue. The more complexes 
that exist, the more intense the colour. Stop solution is added to stop the reaction 
between substrate and enzyme conjugate and the blue colour will turn to yellow. The 
darker blue colour will change to the darker yellow, and the colour intensity can be 
observed by using spectrophotometer. 
3.3.2.6.2 Experimental procedures 
All the reagents and sample specimens were allowed to come to room temperature 
before starting the assay. The desired number of coated wells on the plate was labelled 
for blank, standards, controls, and samples. 25µL of testosterone standards, controls and 
samples were dispensed into the appropriate wells, and 200µL of enzyme-conjugate was 
added to each well. The contents of the wells were thoroughly mixed for 10 seconds by 
shaking the plate by hand. The plate was incubated for 60 minutes at room temperature 
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without covering the plate. After 60 minutes incubation, the contents of the wells were 
removed and each well was thoroughly rinsed three times with diluted wash solution (ý 
400µL per well). The wells were struck on absorbent paper to remove residual droplets. 
200µL of substrate solution was added into each well and then the plate was incubated 
again for 15 minutes at room temperature. 100µL of stop solution was added to each 
well to stop the enzymatic reaction. The intensity of the colour change was measured by 
the determination of absorbance at a wavelength of 450±10nm by spectrophotometer. 
3.3.2.6.3 Data analysis 
From the raw absorbance data obtained from the plate reader at 450 nm, the four 
parameters logistic calibration curves absorbance versus concentration (ng/mL) was 
plotted using Microsoft Excel Worksheet 2003. The four parameters logistic curve was 
plotted based on the equation 1, below: 
A= NSB + 
Top - NSB) 
S`o Equation 1 -pe 
1+ 
EC50 
[Testosterone 
A= Absorption value 
NSB = The lower value of the curve - non specific binding 
Top = The upper value of the curve - maximal binding 
EC, 50 = The midpoint value of the curve 
Slope = The slope of the curve 
The serum concentration of samples and controls were obtained from the calibration 
curve and calculated using the above formula. The mean serum concentration of 
testosterone was plotted against the sampling time for every subject to obtained the 
concentrations profile of testosterone from 0 to 8 hours. Mean serum concentration of 
testosterone change from baseline (0 hour) against the sampling time has also been 
plotted to compare the different profiles of drug concentration between the five doses 
given. 
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3.3.3 Results and discussion 
Five healthy subjects were successfully recruited in this study. All the serum samples 
were analaysed for testosterone concentration by using ELISA technique as described 
above. Figure 3.1 shows the calibration curve plotted for the mean absorbance versus 
testosterone concentration (ng/mL). The testosterone serum concentration in all the 
study samples and QC samples were obtained by extrapolating the absorbance value 
from the calibration curve. 
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Figure 3.1 Calibration curve for the Absorbance versus concentration (ng/mL) 
Table 3.2 summarises the QC samples result obtained during the analysis of testosterone 
by ELISA. From the concentrations obtained, the mean, standard deviation and the 
coefficient of variation (CV%) were calculated. The CV for imprecision were all below 
15%. 
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Table 3.2 Coefficient of Variation (CV) for all the Quality Control (QC) samples 
achieved during the assay 
Control 
no. QCl QC2 
(ng/mL) 
QC3 
1 0.79 3.98 9.25 
2 0.88 3.88 11.12 
3 0.82 4.21 8.22 
4 0.92 3.65 9.35 
5 0.85 3.77 9.78 
6 0.9 3.55 9.21 
7 0.98 3.46 8.1 
8 0.72 4.1 11.21 
9 0.73 3.98 9.36 
10 0.94 3.25 7.21 
Mean 0.85 3.78 9.28 
SD 0.09 0.30 1.26 
CV (%) 10.27 8.03 13.52 
Figure 3.2 and Figure 3.3, show the plot of mean serum concentrations of testosterone 
(ng/mL) versus time (h) and mean serum concentration of testosterone changed from 
baseline (0 hour) from 0 to 8 hours for five subjects and five different dosages, 
respectively. 
The plot of plasma concentration changed from baseline for five different doses showed 
that 40 and 50mg doses have a reasonable higher absorption profile compared to 10,20, 
and 30mg with 50mg is slightly higher than 40mg. The testosterone profiles also show a 
slight fluctuation in all the subjects within the sampling period, obviously at three hours 
post dose. All the subjects were well tolerated the dosages well. No serious or 
unexpected adverse events were reported or observed during the study day. 
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Figure 3.2 Serum concentration versus time for five different doses (10 -50mg) 
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Figure 3.3 Serum concentration (change from baseline) versus time for five 
different doses (10 - 50mg) 
3.3.4 Conclusion 
This was a pilot study for dose ranging. The dose that has been chosen for the main 
pharmacokinetic study of testosterone was the minimum that could be shown different 
from the lowest dose. The lowest dose was effectively a "placebo" dose. The result from 
this study showed that TDS®-Testosterone was effective in delivering testosterone 
systemically through the skin and a 50mg dose was found to be the most effective dose 
with a maximum of a4 fold increases in the concentration of testosterone without any 
adverse event to the subject. Therefore, 50mg dose of TDS®-Testosterone was an 
-1-- -Y 
-3 
--------------------- 
\/------------- 
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effective dosage that can be used in the three way comparative bioequivalence study of 
TDS®-Testosterone, AndroGel® and the TDS®-Placebo. 
3.4 Pharmacokinetic and bioequivalence study of 50mg 
TDS®-Testosterone in 12 healthy males 
3.4.1 Study approval 
The study was approved by the East London and The City Health Authority Research 
Ethics Committee. Reference no. DAUSB/P03180, dated 6th. April 2004. 
3.4.2 Materials and methods 
3.4.2.1 Study Materials 
The TDS®-Testosterone system, 50mg (batch number MBR-BFLIQ84), TDS®-Placebo 
and AndroGel® 1% (50mg) (batch number 20293 LC) were supplied by TransDermal 
Technologies, Inc., Florida, USA. The TDS®-Testosterone and TDS®-Placebo were 
supplied as a liquid formulation, delivered by metered pump, with each spray containing 
10mg of testosterone. AndroGel® was supplied as a gel in unit-dose aluminium foil 
packets of 5g each containing 50mg testosterone. 
3.4.2.2 Study design 
This was a single dose, randomised (Table 3.3), three-way crossover study (with 3 
treatments, 3 periods, and 6 sequences) with a minimum of one week washout period 
between each treatment. 
Table 3.3 Randomisation table for the three treatments given in 12 healthy males 
Subject 1 2 3 4 5 6 7 8 9 10 11 12 
Period 1 A B C B C A A B C B C A 
Period 2 B C A A B C B C A A B C 
Period 3 C A B C A B C A B C A B 
A= TDS'°'-Testosterone; B= TDS'"-Placebo; C= AndroGe1' 
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3.4.2.3 Subject recruitment 
Recruitment procedures are the same as mentioned in 3.3.2.3, but involving 12 healthy 
males. 
3.4.2.4 Admission and procedures 
On the morning of the study day, blood pressure and heart rate were measured after 
subjects had rested for 10 minutes. A 20G cannula was placed in a large antecubital vein 
for blood collection. The drug formulation was then applied to the left arm and gently 
rubbed into the skin. Regular meals and beverages were provided throughout the study 
day. After dosing, subjects were permitted to engage in normal daily activities, but 
excluded from significant physical exertion or activities likely to stimulate endogenous 
testosterone production. 
3.4.2.4.1 Blood sampling 
Intravenous in-dwelling cannulae were maintained for 12h following the treatment 
application. Approximately 4mL of blood was collected at -0.5 (30 minutes before 
dosing) and 0 hour (immediately prior to dosing), to establish a baseline measurement 
of serum testosterone concentration. Subsequently, serial blood samples were collected 
at 0.5,1,1.5,2,2.5,3,3.5,4,5,6,7,8,10,12, and 24 hours post-dose. Samples were 
allowed to clot for approximately 20 minutes at room temperature (26°C) and were then 
centrifuged at 1800g for 10 minutes. The serum was transferred to labelled tubes and 
stored at -20°C until analysis. 
3.4.2.5 Testosterone analysis 
Testosterone concentrations were measured in the serum using an Enzyme Link 
Immunosorbent Assay (ELISA) method as described previously. 
3.4.2.6 Data analysis 
Pharmacokinetic parameters and the statistical analysis were performed using Kinetica 
Version 4.2 software. Cm. and tma,, were determined directly from the individual serum 
concentration-time curves. The AUC was calculated using the linear trapezoidal 
method. The difference between treatments for AUCO_12 and Cm. were analysed after 
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logarithmic transformation using the analysis of variance (ANOVA) for cross over 
studies that accounts for variation due to sequence, subject, formulation, and period. 
Bioequivalence testing was based upon the 90% confidence interval (CI) for the ratio of 
population mean between two treatments. This method is equivalent to the 
corresponding two one-sided test procedure, with the null hypothesis of bioequivalence 
at the 5% significance level. Formulations were considered bioequivalent if the 90% CI 
of the ratio, test to reference, was contained within 80 to 125% (EMEA, 2001; FDA, 
2003; Pabst and Jaeger, 1990). 
3.4.3 Results 
Twelve healthy males successfully completed the protocol. Figure 3.4 and Figure 3.5 
show the plots of mean serum concentration of testosterone (ng/mL) versus time (h), 
and mean serum concentration changes from baseline (0 hour) (ng/mL). Testosterone 
concentrations fluctuated slightly in most of the subjects during all of the treatments. 
Most of the subjects treated with AndroGel® and TDS®-Testosterone showed the higher 
value compared to placebo at 24 hours post dose. 
The pharmacokinetic parameters, AUC and Cm are summarised in Table 3.4, Table 
3.5, and Table 3.6 for TDS®-Testosterone, Androgel® and TDS®-Placebo, respectively. 
The AUC and Cm. values were calculated for both 0-12 and 0-24 hour. The mean 
AUCo. 12 was higher following application of TDS®-Testosterone compared to 
AndroGel® and TDS®-Placebo. However, the mean AUCO-24 for AndroGel® was 
higher than TDS®-Testosterone and TDS®-Placebo. The mean Cmax (0-12) was similar 
for TDS®-Testosterone and AndroGel® and these values were higher than that obtained 
for TDS®-Placebo. Owing to the higher concentrations of testosterone at 24 hours in 
some subjects, the mean Cm. (0 - 24) value for AndroGel® was higher than those for 
TDS®-Testosterone and TDS®-Placebo. Due to no samples taken between 12 to 24 
hours and the higher testosterone concentration at 24 hours for most of the subjects in 
the active treatments, only the 0-12 hour data was used for the determination of 
bioequivalence. The tm. values including the median and the interquartile range (IQR) 
for all the treatments are summarise in Table 3.7. 
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Figure 3.4 Plots of mean serum testosterone concentration (ng/mL) versus time (h) 
for each treatment from 0-12 hours 
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Figure 3.5 Plots of mean serum testosterone concentration change from baseline 
(ng/mL) versus time (h) for each treatment from 0-12 hours. 
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Figure 3.7 Plots of mean serum testosterone concentration change from baseline 
(ng/mL) versus time (h) for each treatment from 0-24 hours. 
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Table 3.4 Cn,. and AUC values with mean, SD and CV% for TDS®-Testosterone 
Subject C, (0-12) AUCO-12 Cmax (0-24) AUCO-24 
(ng/mL) (h. ng/mL) (ng/mL) (h. ng/mL) 
1 6.45 65.21 8.46 142.43 
2 4.02 38.57 4.02 76.25 
3 8.79 77.42 8.79 162.09 
4 5.60 46.56 5.60 88.68 
5 9.23 96.81 19.23 259.71 
6 7.59 72.18 7.59 141.66 
7 6.28 57.73 7.04 123.85 
8 5.16 53.31 5.16 104.19 
9 6.91 59.32 6.97 127.06 
10 6.65 58.26 6.65 120.84 
11 5.59 52.20 13.59 150.96 
12 7.45 64.58 7.45 131.48 
Mean 6.64 61.85 8.38 135.77 
SD 1.49 15.28 4.16 46.30 
CV % 22.40 24.70 49.65 34.10 
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Table 3.5 Cm.,, and AUC values with mean, SD and CV% for Androgel® 
Subject Cm. (0-12) AUCo-12 Cm. (0-24) AUCo-24 
(ng/mL) (ng/mL. h) (ng/mL) (ng/mL. h) 
1 5.78 54.06 5.90 110.04 
2 5.63 44.30 5.63 87.26 
3 8.25 64.39 12.77 166.21 
4 6.49 56.41 6.49 114.55 
5 8.27 74.66 49.35 399.62 
6 9.16 76.89 25.67 261.45 
7 5.60 55.30 9.32 130.78 
8 4.67 49.90 5.12 100.48 
9 4.71 45.85 4.91 94.93 
10 8.51 69.83 8.51 143.93 
11 5.81 51.66 18.82 181.68 
12 5.55 48.76 5.55 98.02 
Mean 6.54 57.67 13.17 157.41 
SD 1.58 11.14 13.07 90.82 
CV % 24.11 19.32 99.25 57.69 
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Table 3.6 Cm, and AUC values with mean, SD and CV% for TDS®-Placebo. 
Subject Cm (0-12) AUCo_12 Cnax (0-24) AUCo-24 
(ng/mL) (ng/mL. h) (ng/mL) (ng/mL. h) 
1 5.95 50.94 5.95 104.88 
2 4.13 32.48 4.13 60.44 
3 5.22 42.03 6.85 105.03 
4 6.33 51.95 6.33 110.81 
5 8.32 75.81 8.66 160.59 
6 5.45 45.38 5.45 97.34 
7 5.90 60.40 5.90 110.80 
8 3.98 36.97 3.98 67.83 
9 4.44 42.54 4.44 83.39 
10 5.83 56.37 6.61 120.33 
11 6.60 61.64 6.60 108.62 
12 6.45 51.45 6.45 89.97 
Mean 5.72 50.66 5.95 101.67 
SD 1.21 11.94 1.32 25.92 
CV % 21.13 23.57 22.18 25.50 
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The 90% confidence intervals (CI) on the relative difference of the ratio for the AUCo_12 
and the Cma, (0-12) between TDS®-Testosterone and AndroGel® were contained within 
the bioequivalence limit (80 - 125%), (Cn, a, (0-12): 87.0 to 119.1% and AUCO_12: 91.0 to 
123.8%). Serum testosterone concentrations were lower following TDS®-Placebo and 
were not bioequivalent either to the gel or the spray. The CI values obtained for all the 
treatments' comparison are summarised in Table 3.8. Table 3.9 summarises the QC 
sample results obtained during the analysis of testosterone by ELISA. From the 
concentrations obtained, the mean, standard deviation and the coefficient of variation 
(CV%) were calculated. The CV for imprecision and inaccuracy were all below 15%. 
No serious or unexpected adverse events were reported or observed during the study 
day. The applied dosages and protocol requirements were well tolerated by all subjects. 
Table 3.8 Confidence interval (CI) for all the treatments' comparison 
Comparison 90 % CI 
AUCp. 12 Cmax (0-12) 
TDS -Testosterone vs. Androgel 91.0-123.8 87.0-119.1 
TDS®-Testosterone vs. TDS®-Placebo 105.0 - 142.1 99.0 -135.4 
Androgel® vs. TDS®-Placebo 98.5 -134.0 97.2 -133.0 
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Table 3.9 Coefficient of Variation (CV) for all the Quality Control (QC) samples 
achieved during the assay 
No of Cl C2 C3 
control ng/mL 
1 0.83 4.28 8.63 
2 0.96 3.91 10.25 
3 0.84 3.26 8.99 
4 0.93 3.66 9.45 
5 0.80 3.14 8.87 
6 0.99 3.47 9.64 
7 0.70 3.23 11.89 
8 0.63 3.49 10.01 
9 0.94 3.15 6.82 
10 0.99 2.86 8.50 
11 0.70 3.18 8.88 
12 0.60 2.99 8.34 
13 0.77 3.12 8.24 
14 0.76 2.68 10.31 
15 0.92 3.69 10.47 
16 0.73 3.47 7.56 
17 0.78 3.28 7.75 
18 0.92 2.64 9.88 
19 0.71 2.60 6.44 
20 0.85 3.24 8.89 
21 0.81 3.82 7.81 
22 0.91 3.34 10.50 
23 0.96 3.49 9.32 
24 0.92 3.40 10.37 
25 0.82 3.82 8.38 
26 0.82 3.15 7.96 
27 0.70 3.56 10.10 
28 0.85 2.78 8.97 
29 0.89 3.28 8.56 
Mean 0.83 3.31 9.03 
SD 0.11 0.39 1.21 
CV 12.96 11.92 13.42 
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3.4.4 Discussion and conclusion 
The systemic delivery of testosterone has been successfully achieved by using the TDS® 
system in this study. The 50 mg dose applied was well tolerated in all the twelve 
subjects tested. However, the real amount of TDS®-Testosterone and AndroGel® applied 
on the skin surface cannot be confirmed as the glove has been used to rub both of the 
treatments on the skin. Some of the testosterone from the solution or the gel may stick 
to the glove. This would contribute to the inter subjects variability. This factor of 
variability has been minimised by using the same application method into all the 
subjects. Although we have assumed that the amount stuck to the glove is very little 
and has only a small contribution to the exact dosage amount, it would be ideal if the 
drug content in the glove could be analysed so that the exact amount applied can be 
confirmed. Therefore, the future study on the development of TDS®-Testosterone needs 
to include this analysis. 
In conclusion, the TDS®-Testosterone preparation was shown to be able to deliver 
testosterone systemically in humans. The concentrations of hormone in the first 12 
hours following TDS® administration were found to be bioequivalent to an existing 
topical delivery gel. However higher pharmacokinetic profiles such as AUC and Cm. 
were observed for TDS®-Testosterone compared to AndroGel®. Both TDS-Testosterone 
and AndroGel® were not bioequivalent to TDS® - Placebo. 
This conclusion is based on the direct analysis of serum testosterone profile from 0 to 
12 hours for the three treatments given. However, circulating endogenous testosterone 
may influence the bioequivalence assessment of exogenously administered testosterone. 
The following section will explain the detail of the endogenous correction method that 
can be applied for more accurate bioequivalence assessment of testosterone. 
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3.5 Methods of correction for endogenous concentration 
for bioequivalence assessments of testosterone. 
3.5.1 Introduction 
In the evaluation of new drug preparations, a bioequivalence (BE) study in healthy 
volunteers normally has to be conducted in order to show that the new preparation is as 
effective as current preparations. Guidelines for the determination of bioequivalence of 
pharmaceutically active formulations are fully documented by Food and Drug 
Administration (FDA) in the USA (FDA, 2003) and by the Committee for Proprietary 
Medicinal Products (CPMP) for the European Union (EMEA, 2001). Bioequivalence 
studies compare the rate and extent of absorption for a new treatment against that of the 
reference product using the parameters of maximum serum concentration (Cm) and 
area under the curve (AUC). For exogenously administered endogenous compounds, 
like testosterone, the comparison needs to allow for the normal circulating 
concentrations of the compound. However, the circulating concentrations of 
testosterone, complicate the analysis of pharmacokinetic parameters when these 
compound is administered exogenously. Therefore, correction of the data to remove the 
influence of endogenous testosterone is necessary to obtain the concentration of 
testosterone that is attributable to the exogenous source. 
Except levothyroxine sodium (FDA, 2001c) and potassium chloride (FDA, 1994), the 
current BE guidelines offer no guidance on the correction for the endogenous 
concentrations. The four endogenous correction methods have been evaluated in this 
study for the proper determination of bioequivalence of testosterone. 
3.5.2 Correction Methods 
Three methods of data correction were used to subtract the influence of endogenous 
concentrations of testosterone from the total concentration measurements. The AUC and 
the Cma., were then calculated from the data generated in corrections 1,2 and 3. 
Correction 4 was carried out on the AUC and Cm. values obtained from uncorrected 
data. 
" Correction Method 1 
The mean pre-dose testosterone concentration (-0.5 and 0 hour) was subtracted from 
each testosterone concentration after dosing for each subject and treatment. 
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" Correction Method 2 
The endogenous data was modelled from the placebo data using a polynomial 
equation and then subtracted from the measured treatment values. The endogenous 
concentration obtained for each time point was then subtracted from the analogous 
time point for active treatments. 
" Correction Method 3 
The concentrations on the placebo day were subtracted from the active treatment 
concentrations at the analogous time point for each subject. 
" Correction Method 4 
The testosterone Cm and AUC values calculated without data correction on the 
placebo day were subtracted from the parameters calculated from the two active 
treatment days. 
Some of the negative values were generated after subtractions. These values are due 
to the variability in the endogenous testosterone level without any increased from 
exogenously administered testosterone. Therefore, all the negative values can be 
considered zero for more reliable statistical analysis. The corrected serum 
testosterone concentrations (ng/mL) were then plotted versus times (h) along with 
corrections 1,2, and 3. 
3.5.3 Pharmacokinetic and statistical analysis 
Cmax was determined by observation and AUC was calculated using the linear 
trapezoidal method. The AUC and Cm. for the uncorrected and corrected data were 
determined from 0-12 hour data for each treatment. Analysis of variance (ANOVA) 
were carried out on the log transformed AUC and Cma,, to determine the bioequivalence 
between TDS®-Testosterone and AndroGel®. All the statistical analyses were carried 
out using Kinetica version 4.2 Software (Kinetica, 2006). 
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3.5.4 Results 
3.5.4.1 Serum testosterone profiles 
3.5.4.1.1 Uncorrected serum testosterone data 
The plot of mean testosterone serum concentration for TDS®-Testosterone, TDS®- 
Placebo and AndroGel® was shown in Figure 3.4. Higher testosterone concentration 
profiles were observed for both of the active treatments compared to placebo. Serum 
testosterone profiles for TDS®-Testosterone and AndroGel® were lower at the pre dose, 
and increased after the treatments application. Both the active treatments achieved the 
highest concentration after 3 to 4 hours post dose and declined following a period of 12 
hours. However, the TDS®-Placebo showed a decreased in serum testosterone profile 
from pre dose until the 12 hours post dose. 
3.5.4.1.2 Correction Method 1 
Following the 12 hours sampling period, the TDS®-Testosterone showed a higher 
profile of testosterone concentration compared to AndroGel® and the TDS®-Placebo ( 
Figure 3.8). AndroGel® also showed the small increase from 0 up to 2.5 hours and 
decrease through out the day to the same level as the placebo. The TDS®-Placebo 
treatment remains constant and slightly fluctuated for the whole sampling period. 
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Figure 3.8 Plot of mean serum testosterone concentration (ng/mL) versus time (h) 
for each treatment based on Correction Method 1. 
3.5.4.1.3 Correction Method 2 
Figure 3.9 shows the testosterone profile for the placebo treatments for 12 subjects with 
the examples of polynomial regression and equation on selected subjects. Figure 3.10 
shows the plot of testosterone concentration versus time for TDS®-Testosterone and 
AndroGel® based on Correction Method 2. The plots for TDS®-Testosterone and 
AndroGel® were quite a similar with the concentration peaks at 3.5 hours and 3 hours, 
respectively. However, the testosterone concentrations were higher for the TDS®- 
Testosterone compared to AndroGel® for most other sampling times. 
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Figure 3.9 Plots of concentration vs. time for TDS®-Placebo in 12 subjects with 
examples of polynomial regression on selected lines. 
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Figure 3.10 Plots of mean serum testosterone concentration (ng/mL) versus time (h) 
for TDS®-Testosterone and AndroGel® based on Correction Method 2. 
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3.5.4.1.4 Correction Method 3 
The mean serum testosterone concentrations for AndroGel® were higher than for the 
TDS®-Testosterone after application up to 3 hours, but decreased dramatically to lower 
than the pre dose value, especially at 12 hours post dose. The serum testosterone 
concentration profile for the TDS®-Testosterone were increased after application and 
peaked at 4 hours, before decreased constantly through out the day (Figure 3.11) 
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Figure 3.11 Plots of mean serum testosterone concentration (ng/mL) versus time (h) 
for TDS®-Testosterone and Androgel® based on Correction Method 3. 
All the plots for serum testosterone concentration (ng/mL) versus time (h) based on 
uncorrected and Correction Methods 1,2, and 3 showed the higher testosterone profile 
for the TDS®-Testosterone than AndroGel®. 
3.5.4.2 Bioequivalence and statistics 
The relative bioavailability comparison of the AUC and C, nax for the TDS®- 
Testosterone and AndroGel® are summarises in Table 3.10 for all uncorrected, 
Correction Methods 1,2, and 3 data. The AUC and C, for TDS®-Testosterone and 
AndroGel® were not bioequivalent with the TDS®-Placebo using the uncorrected and 
Correction Method 1 data. However, the 90% CI of the AUC and Cmax for the 
comparison between the TDS®-Testosterone and AndroGel® gave a different results 
between uncorrected and Correction Methods 1,2, and 3. The TDS®-Testosterone and 
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AndroGel® were found to be bioequivalent based on uncorrected data, but they were not 
bioequivalent with Correction Methods 1,2, and 3. 
Table 3.10 Relative bioavailability (90% CI) for uncorrected and all corrections 
data. 
Correction Methods Bioequivalence (90% Cl) 
AUCo_12 Cmax (0-12) 
Uncorrected 91-124 87-119 
Correction 1 52-106 50-258 
Correction 2 71-655 87-286 
Correction 3 67-315 88-157 
Reference: AndroGe1 ' 
Table 3.11 summarises the percentage differences of AUC and Cmax between TDS®- 
Testosterone and AndroGel®. The differences were lower for uncorrected data 
compared to corrected data. Within the corrected data, the largest difference was seen in 
Correction Method 1. Similarly, the other correction methods showed higher AUC and 
Cm. values for the TDS®-Testosterone compared to AndroGel®. Thus, data corrected 
for endogenous serum testosterone concentrations showed increased testosterone 
profiles for the TDS®-Testosterone compared to AndroGel®, with correction AUC by 
30 to 190% and correction Cm. by 12 to 55%, depending on the method of corrections. 
ANOVA could not be performed on Correction Method 4 due to the negative values 
generated. Therefore, only the average of AUC and Cm. were reported. 
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Table 3.11 Percentage differences (%) in mean AUC and Cm. between TDS®- 
Testosterone and AndroGel®. 
Mean Values Percentage differences 
(TDS®-AndroGel®) 
AUCO-12 Cmax(0-12) AUCO-12 Cmax(0-12) 
(ng/mL. h) (ng/mL) (%) (%) 
Uncorrected 
TDS®-Testosterone 61.92 6.63 7.18 1.47 
AndroGel® 57.77 6.54 
Correction Method 1 
TDS®-Testosterone 7.47 1.69 190.15 54.90 
AndroGel® 2.57 1.09 
Correction Method 2 
TDS®-Testosterone 13.61 2.42 36.37 29.41 
AndroGel® 9.98 1.87 
Correction Method 3 
TDS®-Testosterone 13.86 2.88 30.07 16.45 
AndroGel® 10.65 2.48 
Correction Method 4 
TDS®-Testosterone 11.15 0.95 59.29 11.76 
AndroGel® 7.00 0.85 
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3.5.5 Discussion 
Currently licensed transdermal delivery systems for testosterone in UK are available as 
patches, gels and buccal tablets. However they do not fully achieved the goal for 
testosterone replacement therapy as described in Section 3.1 (Introduction). TDS®- 
Testosterone preparation appears to provide a more convenient transdermal delivery of 
testosterone with rapid drying and no skin irritation compared to some of the other 
transdermal systems. TDS®-Testosterone has proved to be more effective than 
AndroGel® in delivering testosterone systemically, in the same dosage (50mg) given. 
AndroGel® was used for the comparison due to the same mode of application, 
availability and widely used currently in UK for the treatment of hypogonadism. 
In the bioequivalence evaluation of exogenously administered endogenous compound 
such as testosterone, the circulating endogenous compound should be taken into 
account. Without proper consideration, the judgement of bioequivalent may be 
inaccurate. There are a few methods that have been published in consideration of the 
endogenous compound by using correction methods. 
Blakesley (Blakesley, 2005) has proposed several correction models in the 
bioequivalence assessment of Levotyroxine sodium (T4). Correction for endogenous T4 
has been done by three different approaches. In Method 1, the mean of three pre-dose 
values were subtracted from each concentration at post dose. In correction method 2, the 
post dose concentrations were corrected based on hypothetical decay of endogenous T4 
with a seven day half life. Corrrection Method 3 used the concentration T4 measured on 
the day prior to dosing to subtract the post dose concentrations at the analogous time 
point. This study concluded that, without endogenous correction, the bioequivalence 
conclusion showed a failure to identify differences between T4 products varying as 
much as 25%-33% in dosage strength. 
Other studies conducted on testosterone used another approach for correcting 
endogenous concentration. The pharmacokinetic study to compare the three dosage 
regimens of buccal adhesive testosterone tablets has been conducted (Baisley et al., 
2002). In this study three injections of leuprorelin acetate to compress the testosterone 
productions were administered in healthy males, followed by androgen replacement 
therapy (oral testosterone undecanoate) within the three weeks of screening phase. At 
the end of replacement therapy, whose morning serum testosterone <_ 5.38nmol/L were 
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entered the baseline and treatment phase of the study. The endogenous concentration 
was corrected by deducting the baseline AUCO_24 from the treatment AUCo. 24. This 
approach has an advantage of minimizing the fluctuation of testosterone in healthy 
males, hence contributed to less interference from endogenous testosterone. 
The similar approach in testosterone suppression method has been carried out by Rolf et 
al. (Rolf et al., 2002). In this study the testosterone production has been suppressed by a 
single intramuscular injection of 400mg norethisterone enanthate 5 days before the start 
of the study. The testosterone gel was applied daily for 10 days and the serum 
testosterone concentration was studied at pre-dose (basal level), day 1, day 5, and day 
10 of treatment's application. The plot of testosterone basal level after injection of 
norethisterone had really shown a complete suppression without any diurnal variation in 
the testosterone level within the 24 hours observed. The testosterone plot showed a 
higher level at day 1,5 and 10 compared to the basal level. 
Based on the above described correction methods, four correction methods on 
endogenous testosterone have been carried out in this study. The outcomes from the 
correction methods that have been carried out can be considered as an interesting 
finding in which the results showed the different outcomes between corrected and 
uncorrected data. Although all the correction methods gave the same conclusion in the 
bioequivalent of TDS®-Testosterone and AndroGel®, there are potential advantages and 
disadvantages existed, which may influence the accuracy of each correction method 
used. 
The first correction method (Correction Method 1) was based on the assumption that the 
endogenous testosterone level remained constant at all times. Therefore, the mean pre 
dose (-0.5 and 0 hour) concentration value can be used to subtract the post dose values 
to obtain the correct amount attributable exogenous administration. The advantage of 
this method is that the pre dose values were obtained exactly before the administration 
of testosterone, which minimised the period error. However, this method also offers 
some disadvantages, as it is known that testosterone secretion is likewise pulsatile and 
diurnal. In healthy males, recorded plasma testosterone concentration is normally higher 
in the morning, at about 8 am and lowest in the evening (-. 8 pm) (Snyder, 2001). This 
condition can be seen in the pattern of mean testosterone concentration from the placebo 
treatment in Figure 3.6, which were higher at the beginning and lower throughout the 
day (up to 12 hours) and increased again to the same level as 08: 00 at 24 hours post 
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dose. Our placebo data also correlated well with the literature values of an observed and 
predicted testosterone level in healthy young males as published by Gupta et al. (Gupta 
et al., 2000) 
The second correction (Correction Method 2) was based on the inhibition of the gonad 
regulating cycle, which can cause the body to reduce production of testosterone when its 
level is too high. During exogenous administration of testosterone, endogenous 
testosterone release may be inhibited through feedback inhibition of pituitary luteinizing 
hormone (LH), resulting in declining levels of testosterone. Correction Method 2 may 
offer a slight advantage over Correction Method 1, as the average level of testosterone 
production can be estimated through the best fit of a polynomial regression for the 
placebo modelled data. This data can therefore be accepted as an average endogenous 
level of testosterone on that individual subject. However, the inhibition of endogenous 
testosterone productions may only happen with large doses of exogenously administered 
testosterone. No data was available to date to suggest the exact amount of testosterone 
that may inhibit the production of testosterone. Assuming the diurnal variation of 
testosterone as explained previously, Correction Methods 1 and 2 have similar 
disadvantages. 
Correction Method 3 and 4 were based on the analogous placebo data can be assumed 
as the endogenous level of testosterone. Therefore by subtracting the placebo's 
testosterone concentration values at the analogous time points and AUC and Cmax for 
each subject and treatment in Method 3 and 4, respectively, the amount from exogenous 
administration can be obtained. These methods may offer further advantages over 
Correction Methods 1 and 2, as these methods can overcome the diurnal variation of 
testosterone in healthy males. However, this method may have a disadvantage as the 
analogous placebo values, which were obtained at different periods may not represent 
the endogenous testosterone level on the day the active treatments were administered. 
This can be explained by the high variability in pre-dose testosterone concentration 
values (0 hour). As manifest by the within subject coefficient of variation (CV) of the 
mean CO values which ranged from 1.4 to 28.2%. The study by Andersson and co- 
workers (Andersson et al., 2003) also suggested that there was variability in the 
testosterone levels from month to month. To minimise this error, a placebo treatment 
may need to be conducted in the days immediately before the active treatment is given. 
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The conclusions about bioequivalence in the uncorrected and corrected data in this 
study are based on the 90% CI values from the ANOVA. It can be seen that the 90% CI 
for all the correction methods performed were not only outside the bioequivalence limit 
(80-125%), but contained a wider range of intervals. This condition resulted from the 
variability in the results obtained after endogenous subtractions. Most of the plasma 
levels obtained after subtractions are fluctuated closed to zero, especially for 
AndroGel®. Twelve subjects used in this study were not enough to overcome the 
variability arose from the testosterone level after endogenous corrections. Therefore, to 
obtain a more accurate bioequivalence assessment with endogenous corrections, the 
sample size needs to be increased, such as using 24 subjects instead of using 12 subjects 
in this study. 
3.5.6 Conclusions 
TDS®-Testosterone is found to be more effective in delivering testosterone systemically 
in much smaller volume and more convenient to use than AndroGel®. Hence, TDS®- 
Testosterone has the potential to be an alternative treatment for hypogonadism. The 
phase II study in a bigger number of hypogonadal patients has to be carried out for this 
purpose. 
Different results obtained in the relative bioavailability between the TDS®-Testosterone 
and AndroGel® for uncorrected and corrected data, suggest that correcting endogenous 
concentrations is important for the proper determination of bioequivalence for 
endogenous compound such as testosterone. Without endogenous data correction, an 
incorrect conclusion about bioequivalence may result with products being declared 
bioequivalent when they are actually not bioequivalent or vice versa. 
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Chapter 4 Comparative pharmacokinetic 
assessments of topical drugs: Evaluation by 
dermatopharmacokinetics, microdialysis, and systemic 
measurement. 
4.1 Introduction 
The conventional pharmacokinetic profiles of drugs are mainly described through the 
plasma concentration versus time profiles. This is vital for most orally administered 
drugs which undergo systemic absorption before the drug can be distributed to the site 
of action. However some drugs such as local anaesthetics, antifungal agents, topical 
corticosteroids, etc. are designed to target the local tissue where the drugs are applied 
and, as such, have limited systemic absorption. The distribution and the action of these 
drugs are more appropriately measured in the local tissue rather than systemically. Thus, 
conventional drug measurement using systemic blood samples is inappropriate. The 
concentrations of a drug in systemic circulation may be too low to detect, hence 
hampering the pharmacokinetic profiling of the drug. Although the concentration of the 
drug can be detected, it may not directly relate to the amount of drug in the local tissue 
in which they are producing the therapeutic effects. Some of the topically administered 
drugs such as local anaesthetics are retained in the local tissue rather than absorbed into 
the the systemic circulation. Hence the direct measurement of these drugs in the local 
tissue tends to be more appropriate for a pharmacokinetic assessment. To date, a 
number of in vitro and in vivo techniques are available for direct measurement of 
pharmacokinetic or clinical relevance information about the drug contents in the target 
tissue and skin. 
In vitro experimentation tends to be a simple method to study drug permeation through 
the skin, especially in the early development of drugs. Animal skin or excised human 
skin obtained from a skin bank or by donations from a patient undergoing a surgical 
procedure are always used in in vitro experiments. These excised human or animal skin 
samples are used as a membrane and normally fixed to a diffusion cell where a 
membrane is clipped between two compartments, termed as donor and receptor. Drug 
applied on the membrane on the donor side will diffuse through the membrane to the 
receptor side where the concentration can be analysed. There are a few types of 
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diffusion cell with different designs but similar in their functioning. The well known 
and commonly used diffusion cell is the Franz type diffusion cell (Franz, 1975). 
However, it should always be kept in mind that the data obtained from excised skin may 
not translate directly to the in vivo situation. The barrier properties of the skin may be 
disrupted when the skin undergoes the excision process and the most important 
properties, the integrity of the skin in terms of water retention, blood supply and skin 
metabolism may be lost. Furthermore, it is impossible to obtain a large quantity of 
human skin therefore animal skin and artificial membranes are frequently used in in 
vitro experimentation. Although it is possible to get a large amount of animal skin, the 
structure and the function of animal skin is different to that of human skin and different 
between species. 
In order to obtain clinically relevant information about a drug's action in the skin, 
especially for pharmacokinetic study, in vivo techniques must be applied. There are a 
few techniques currently available to obtain drug information in the skin and also a 
pharmacokinetic profile, techniques include dermal microdialysis (DMD) (Anderson et 
al., 1992; Benfeldt, 1999; Hegemann et al., 1995), tape stripping - 
dermatopharmacokinetic (DPK) (Pershing et al., 2003), skin blister fluid method 
(Nowak and Klimowicz, 1990), magnetic resonance imaging (Jynge et al., 1990), and 
biopsy followed by tissue homogenisation (Roos and Brorson, 1990). Among the 
various techniques mentioned above, microdialysis and tape stripping are widely used in 
the skin pharmacokinetics compared to the other methods due to their reliability and 
reproducibility. Due to higher costs, ethical problems, invasive procedures, and lack of 
reproducibility, some of the other methods mentioned above are not practicable to use in 
drug development. 
Since both DMD and DPK are still under investigation by many researchers, they have 
not yet been accepted as the valid techniques for the pharmacokinetic study, especially 
for bioequivalence. But these techniques are useful for determining the pharmacokinetic 
profile of drugs especially for transdermal application. The future challenge for 
assessment of these techniques lies in the sampling of lipophilic compounds, which 
constitute the majority of novel drugs targeted to the skin. Lidocaine is a good lipophilic 
model drug for this purpose as it possesses local activity and is widely used as a topical 
local anaesthetic. 
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4.2 Microdialysis 
Microdialysis has been shown in the previous publications (Benfeldt et al., 
1999; Benfeldt, 1999; Benfeldt and Groth, 1998; Hegemann et al., 1995; Murakami et al., 
1998; Okahara et al., 1995) to provide reliable estimates of the drug content in the skin 
after topical administration. It enables the measurement of the quantity of the drug 
compound directly in the target organ, i. e., the dermis or subcutaneous layers of the skin 
after topical administration. Microdialysis is a sampling technique where a 
semipermeable membrane probe is placed in an extracellular compartment and perfused 
by perfusion fluid with a similar ionic strength and pH as the tissue fluid. It can be used 
for measuring endogenous and exogenous compounds in extracellular spaces. The 
technique was originally developed in neuroscience to monitor the relationship between 
neurochemistry and behaviour (Groth, 1996). Bito et al. (Bito et al., 1966) first 
described the idea to sample extracellular by dialysis and was followed by Delgado et 
al. (Delgado et al., 1972). The technique was evolved and after further refinements, 
microdialysis has become the major bioanalytical sampling tool in brain research 
(Groth, 1996). Nowadays, microdialysis has been widely used in clinical drug studies in 
several compartments such as adipose tissue. Microdialysis offers several advantages 
over traditional methods of measuring tissue drug concentrations such as skin biopsy 
and suction blister. Although biopsy and blister samples can give information about 
drug concentrations, the number of samples is limited and frequent sampling is not 
possible due to the invasive nature of the procedure and ethical considerations. Time 
courses of drug concentrations are therefore difficult to obtain. More sophisticated and 
non-invasive techniques, such as magnetic resonance imaging, are expensive and 
require specialised equipment and expertise. 
In contrast, microdialysis technique allows simultaneous sampling at the same site or 
multiple sites. By placing the microdilaysis probe in the dermis or any other tissues, 
continuous sampling can be done by continuously perfusing the sampling site with 
buffer solution. It is also be able to monitor topical drug penetration continuously for a 
certain period of time with detailed real-time chronology. In one animal experiment, a 
microdialysis probe was implanted in rat tissue with the other end connected to liquid 
chromatography (LC) or capillary electrophoresis (CE), (Wang et al., 2005; Zhang et al., 
2006) for real-time analysis. The technique also allowed multiple site drug 
administration with each site of application having no effect on the other sites, therefore 
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allowing different dosages to be applied to one subject for a topical drug study. This 
method can significantly reduce the number of subjects required. Furthermore, 
microdialysis causes only moderate pain, when compared to intramuscular and 
subcutaneous injection and is also easy to perform. 
4.2.1 Principles of microdialysis 
Microdialysis involves the insertion of a microdialysis probe into a tissue or (body) 
fluid to monitor the chemistry of the extracellular space in the living tissue. The probe 
consists of a semipermeable fibre membrane forming a thin hollow `tube' (typically 
0.2-0.5 mm diameter). The probe also connects to the impermeable tube which further 
connects to a micropump at one side and sampling vial at another side. The probe is 
continuously perfused with Ringer solution which has the same ionic strength as the 
extravascular fluid. When this physiological salt solution is slowly pumped through the 
microdialysis probe, the solution equilibrates with the surrounding extracellular tissue 
fluid. Any molecule which smaller than the membrane pore size may pass through the 
membrane and permeate into the perfusion medium across the concentration gradient 
and will be collected in the sampling vial for further analysis. The movements of the 
molecules follow the law of simple diffusion (Benveniste and Huttemeier, 1990). 
However bigger molecules, larger than the membrane cut-off (e. g. proteins and 
enzymes), will be excluded (Benfeldt et al., 1999). There are a few types of probe that 
are available for these purposes such as; linear, concentric, flexible, and shunt (Davies 
et al., 2000). Concentric, linear, and flexible probes are the most commonly used and 
are commercially available. A concentric probe is commonly used in animal studies 
such as rat and rabbit and is normally inserted into the brain. A linear probe and flexible 
probe are widely used in human studies and can be inserted intravenously or into the 
dermis for transdermal delivery studies. Figure 4.1 shows a diagram of a flexible probe 
and how it can be connected to the microdialysis pump and microvial. 
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Figure 4.1 A diagram of flexible probe (in circle) with connections to the pump and 
microvial (Courtesy of CMA Microdialysis AB) 
For cutaneous microdialysis, the probe is implanted in the dermis of the skin via a guide 
cannula. The probe is slowly perfused (typically 0.1-5 µL/min) with a Ringer solution, 
which equilibrates with the extracellular fluid of the surrounding tissue. Any drug 
concentrations occuring in surrounding tissue will enter the probe and diffuse into the 
perfusion fluid. Perfusion fluid entering the probe is known as perfusate and that exiting 
the probe is known as dialysate. 
4.3 Tape stripping - Dermatopharmacokinetic (DPK) 
Many in vivo methods for measuring dermal absorption of chemicals are invasive such 
as the need to cannulate a vein for blood sampling, skin blister, and probe insertion in 
microdialysis studies, etc. Tape stripping of the outermost skin layer, the stratum 
corneum (SC), is a simple and relatively noninvasive technique used to measure the 
drug content in the skin (Pershing et al., 2003; Stinchcomb et al., 1999). This approach is 
based upon the theory that the stratum corneum is a rate limiting barrier for any 
substance entering the body through the skin. In order for a drug to enter the site of 
action in the skin, it must first penetrate the stratum corneum. A drug is normally 
retained in the stratum corneum before slowly diffusing to a viable epidermis and the 
dermis. By sampling the stratum corneum it is possible to measure the drug quantities 
that penetrate the skin per unit time. 
In DPK experiments, a certain area is marked on the skin and exposed to a drug for a set 
period of time and then cleaned. A number of adhesive tapes are applied to and removed 
from the exposed area in sequence so that sufficient quantities of stratum corneum can 
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be sampled. Many studies reported the mass of absorbing chemical as a function of tape 
strip numbers. However, the amount of stratum corneum removed by each tape strip 
generally decreases with increasing depth (Bashir et al., 2001; Islam et al., 1999). The 
numbers of tape stripped in the previous studies were variable, ranging from 5 to 100. 
However most published methods used 10 tape strips to assess the drug content in the 
stratum corneum. It has been shown that about 90% of drug content in the stratum 
corneum are found in the first 10 strips (Benfeldt et al., 2006). The next 10 strips 
contained less than 5% of the drug content (Caron et al., 1990). The study by Franz and 
co-workers compared the drug contents in 10 and 20 tape strips and also found no 
difference between 10 and 20 strips (Shah, 2005). 
The drug contents in the tape can be analysed by a validated bioanalytical assay such as 
liquid chromatography and capillary electrophoresis methods (Shah et al., 1991). The 
DPK method has been shown to demonstrate reproducibility in its application to 
antifungal drugs (Pershing et al., 2002b), and dermatologic corticosteroid products 
(Pershing et al., 2002a), using the human volar forearm. 
4.4 EMLA (Eutectic Mixture Local Anaesthetic) 
The term eutectic mixture refers to the phenomenon where the melting point of a 
mixture of two local anaesthetics is lower than the melting points of each, alone 
(Buckley and Benfield, 1993). At room temperature, both lidocaine and prilocaine exist 
as liquid oil rather than as crystal in a ratio of 1: 1. Each gram of 5% EMLA cream 
contains 25 mg lidocaine and 25 mg prilocaine in the mixture with other compounds as 
an excipient and purified water as a medium. These mixtures form an oil-in water 
emulsion with the mixture of local anaesthetics as the disperse phase and water as the 
continuous phase (Brodin et al., 1984; Nygvist-Mayer et al., 1985). Lidocaine, an amide 
type is widely used as local anaesthetic since it was discovered in 1948. Besides local 
anaesthetic effects, lidocaine is also used as an antiarrythmic, anti thrombic drug, etc. 
Prilocaine (Figure 4.2) is also an amide type local anaesthetic which has an action and 
potency similar to lidocaine. Hence, by combining these two local anaesthetics for 
topical application, and using it prior to cannulation or injection, it was hoped that 
needle phobia, which affects many people especially children would be reduced. 
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Figure 4.2 Prilocaine chemical structure 
4.4.1 Mechanism of action and pharmacokinetics of EMLAT"" 
EMLATM cream when applied on the skin under occlusive dressing provides dermal 
analgesia approximately 1 hour after application. Low level of lidocaine and prilocaine 
can be detected in plasma after topical applications of EMLA. The plasma 
concentrations of lidocaine and prilocaine after EMLATM applications have been studied 
by a few researchers. Plasma concentrations of prilocaine tend to be lower than those of 
lidocaine (Buckley and Benfield, 1993). In a healthy volunteer study by Evers et al. 
(Evers et al., 1985), 20g of EMLATM cream was applied to a 300cm2 area of the thigh 
for 60 minutes. The maximum plasma concentration of lidocaine and prilocaine were 
74.5 and 24.7ng/mL, respectively. The maximum concentration was achieved 
approximately 3 hours after application. In another study in infants (Engberg et al., 
1987), 2mL of EMLATM cream was applied to a 16cm2 are of skin for 4 hours. The 
maximum concentrations achieved were 410ng/mL for lidocaine and 130ng/mL for 
prilocaine. The amount of lidocaine and prilocaine absorbed systemically are related to 
the duration of application and the application area. Buccal mucosa showed higher 
absorption compared to normal skin. The maximum concentration measured was 
418ng/mL for lidocaine and 223ng/mL for prilocaine when 8g of EMLATM was 
occluded to 18cm2 of buccal mucosa for 30 minutes (Vickers et al., 1997). 
4.5 Objective 
The objective of this study was to investigate the outcome of the three techniques, 
DMD, DPK, and systemic blood measurements in the pharmacokinetic evaluation of 
topically applied drugs. The results obtained from these three methods have been 
compared to show the reliability and integrity of each method in pharmacokinetic 
evaluation. For the above purposes, the analyses of lidocaine content in all of the 
parameters of evaluations are the main outcome measures. 
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4.6 Study Approval 
The study was approved by the East London and The City Health Authority Research 
Ethics Committee. Reference no. 05/Q0605/98, dated 9`h- September 2005. 
4.7 Study Material 
4.7.1 Treatment 
EMLATM cream (Astra Zenecca, UK) containing 2.5% lidocaine and 2.5% prilocaine 
4.7.2 Apparatus 
CMA 60 microdialysis catheter was used together with CMA 106 microdialysis pump 
supplied by CMA Microdialysis Ltd. Sweden for DMD study. Adhesive tape for DPK 
study was a TESA 4204 PV5 supplied by TESA UK Ltd. 
4.8 Subjects 
The study involved twelve healthy subjects. 
4.9 Study Methods 
4.9.1 Study Design 
The study was an open label, involving two visits with a minimum of a one-week 
washout period in between. DMD and systemic drug measurements were performed on 
one occasion and DPK alone on the other. 
4.9.2 Study Protocol 
Prospective subjects attending the study had the nature of the study fully explained to 
them, the procedures and the risks. Before any screening procedures occured they had 
signed an Informed Consent Form in which they acknowledged that they were willing 
to take part and follow all of the study protocols. In the screening evaluations, subjects 
were checked for the inclusion/exclusion criteria, physical examinations (blood pressure 
and heart rate), health questionnaires, concomittant medications, drugs of abuse and 
they also provided urine samples for urinalysis and a pregnancy test for females. 
Subjects were permitted to participate in the study soon after they had passed the 
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screening. The arms were checked for cuts or abrasions which would invalidate the 
study. The subject was asked to lay supine on a bed and one arm was cannulated with a 
20G cannula for serial blood samples collection. A 5mL blood sample was drawn 
immediately after cannulation for baseline sampling. On the contralateral arm of the 
venous sampling, a circular area of 10cm2 was marked with a pen in the centre of the 
left volar forearm using a template for the treatment applications. 
DMD probe implantation 
The DMD guide cannula was inserted subcutaneously at about 1 cm below the marked 
(treatment) area so that the probe lies horizontally below the treatment area. Probe 
implantation was performed without anaesthesia under sterile conditions. The DMD 
probe was inserted through the tip of the cannula and the needle then retracted, leaving 
the 3cm long probe implated in subcutaneous tissue below the marked area. The inlet 
and outlet tubing were attached to the skin using the adhesive mefix. The inlet tubing 
was then connected to the DMD pump and the outlet tubing connected to the microvial. 
Upon successful DMD probe implantation, the subject was allowed to recover for 60 
minutes to diminish skin reactions (i. e. increased skin blood flow and histamine release) 
(Anderson et al., 1994; Rougier et al., 1985) before onset of the experiment. The 
perfusion fluid (Ringer solution) was perfused for 20 minutes at the flow rate of 
1. ORL/min before the treatment applications for baseline sampling. 
The treatment, 1g of EMLATM cream (2.5% lidocaine / 2.5% prilocaine, AstraZeneca, 
UK) was applied to the skin at the marked area and occluded with a dressing. The DMD 
microvial was replaced for the 20 minute sampling and the vial was continuously 
replaced every 20 minutes for up to 4 hours. The residual drug was removed from the 
treated area after 1 hour of application. Venous samples were further collected at 20,40 
minutes, 1 hour, 1.5,2,2.5,3,3.5, and 4 hours post dose. Both venous and DMD 
samples were stored at -20°C until further analysis. After completing all of the above 
procedures, both the DMD and intravenous catheter were removed and the subjects 
discharged. After a minimum of a one week washout period, subjects returned for the 
DPK study. 
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Figure 4.3 A photo taken of a study subject showing a DMD procedure 
4.9.3 Tape stripping procedure 
A total of 9 rectangular sites (site 1-9), each 6cm2 (2 cm x3 cm) of skin surface area 
were demarcated on the ventral forearm using a template (Figure 4.4). The treated areas 
(sites 2-8) were on the central volar forearm which was 3cm above the wrist and 3cm 
below the antecubital fossa. Site 1, a minimum of 3cm above the antecubital fossa 
served as a control (0 hour sampling). The treatment, Ig of EMLATM cream was applied 
on each of the 8 application sites by using a syringe. The cream was distributed to cover 
the whole treatment area by a metal spatula. The subject was asked to maintain their 
hand in a horizontal position during the treatment period. All 9 of the sites were 
represented in the uptake and the elimination phase. DPK was performed at 0,15,30, 
45 minutes and 1 hour for the uptake phase (site 1,2,3,4, and 5) and 1.5,2,3, and 4 
hours for the elimination phase (site 6,7,8, and 9). 
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Figure 4.4 The treatment application areas on the volar forearm 
4.9.3.1 Residual product removal and stratum corneum harvesting 
The stratum corneum harvesting was performed directly on site 1 before the treatment 
application. Before stratum corneum harvesting from the treated skin site, the residual 
product was removed from the skin surface using a metal spatula and 3 independent dry 
cotton tips. The residual product was removed at 15,30,45 minutes from site 2,3, and 
4. For sites 5 to 9, the residual product was removed at 1 hour. After product removal 
from the skin, the first adhesive tape was applied and briskly rubbed with the blunt 
ended forceps to harvest the stratum corneum. The tape was removed using the forceps. 
The first adhesive tape was discarded as a result of the potential contamination from the 
residual product not removed with dry cotton wool. The remaining 9 adhesive tapes 
were applied sequentially using the same procedure described above. All the tapes were 
placed in a polypropylene tube and kept frozen at -20°C until further analysis for the 
lidocaine content. The product application and stratum corneum harvesting were 
performed by a single person. The forcep used for the application and removal of the 
tape was washed with water and wiped with 70% isopropyl alcohol between skin sites 
to avoid contamination. Pin prick testing was carried out at the stripping site to measure 
the degree of anaesthesia. 
4.9.4 Pin prick procedure 
Pin prick testing was performed by using a safety pin which was inserted through a 
rubber stopper with a mass of 30g. The apparatus was lowered down perpendicularly 
onto the skin and rested gently on the skin surface. The 30g stimuli was to ensure the 
pressure was always the same for every pin-prick and the needle did not penetrate the 
skin (Dreher et al., 1998). The pin prick was performed at an adjacent untreated site, 
first followed by the treatment site. Pain scores after the pin prick test were recorded 
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using a Likert verbal rating score (VRS) and visual analogue score (VAS) (Tucker et al., 
2006). In the VRS assessment, the subject was asked the following question: What did 
the pin prick feel like?, compared to an adjacent untreated site. The prick at the 
untreated site was considered sharp pain (category 4 and 100mm). The subject was 
provided with a choice of four categories: 1, no pain; 2, minimal sensation; 3, moderate 
pain; 4, sharp pain. The subject selected one answer for each time point by circling the 
relevant number. In the VAS assessment, a 100mm horizontal line with endpoints that 
are anchored by descriptors `no pain' for 0mm and `sharp pain' for 100mm was made. 
For each time point, the subject was asked the same question as above and then 
requested to make a vertical line across the tramline which represented the intensity or 
unpleasantness of their pain caused by the procedure. Values were measured in 
millimeters from the left of the tramline. 
4.10 Analytical 
Lidocaine concentration from plasma and DMD samples were analysed by the validated 
LC-MS-MS method due to expected low concentration of lidocaine in plasma and the 
small volume of DMD samples (20µL). Therefore a highly sensitive analytical method 
such as LC-MS-MS is required for the above purposes. As the LCMS-MS method for 
analysis of lidocaine in plasma has been validated previously (Chapter 2), the re- 
validation procedures were performed on the assay by using Ringer solution as a matrix 
for the DMD samples. 
On the- other hand, tape samples contained an expectedly high concentration of 
lidocaine, for which analysis can be performed by various chromatography techniques 
with UV detection. For analysing the tape samples, we have developed a fast and simple 
capillary electrophoresis (CE) with UV detection method. 
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4.11 LC-MS-MS validation for analysis of DMD samples. 
4.11.1 Experimentals 
All of the chemicals, and the chromatographic systems used are similar as explained in 
the validation of LC-MS-MS method for the analysis of lidocaine in Chapter 2. 
4.11.2 Assay Procedures 
4.11.2.1 Preparation of stock solutions 
4.11.2.1.1 Lidocaine Calibrator 
A stock solution of lidocaine was prepared by dissolving 5.8mg of lidocaine 
hydrochloride in 100mL of 50% methanol. The concentration of the stock solution was 
(after correcting for the salt and assuming purity 100%) 50pg/mL. 
4.11.2.1.2 Lidocaine Quality Control (QC) 
A stock solution of lidocaine was prepared by dissolving 5.8mg lidocaine hydrochloride 
in 100mL 50% methanol. The concentration of the stock solution was (after correcting 
for the salt and assuming purity 100.0%) 50µg/mL. 
4.11.2.1.3 Bupivacaine (Internal Standard) 
A stock solution of bupivacaine was prepared by dissolving 5.8mg of bupivacaine 
hydrochloride in lOOmL of 50% methanol. The concentration of the stock solution was 
(after correcting for the salt and assuming purity 99.9%) 50µg/mL. A working strength 
solution was prepared by diluting 0.2mL of the stock to 100mL with de-ionised water 
giving a final concentration of 100ng/mL. 
All the above stock solutions were stored at approximately -20°C. 
4.11.2.2 Ringer solution aliquots 
4.11.2.2.1 Calibrator 
0.5mL of lidocaine stock solution was pipetted into a 50mL volumetric flask and made 
up to the mark with ringer solution to produce a sub-stock (Cal. 1). Working calibration 
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solutions were prepared by diluting the sub stock with Ringer solution as tabulated in 
Table 4.1 
Table 4.1 Working calibration concentrations with related dilution in Ringer 
solution 
Volume of Volume Total Nominal Measured Inaccuracy Cal. 
sub stock of ringer volume concentration concentration No. 
(Ringer) added (Ringer) 
(mL) (mL) (mL) (ng/mL) (ng/mL) % 
0.02 19.98 20.0 0.5 0.5 0.0 8 
0.04 19.96 20.0 1 1 0.0 7 
0.4 19.6 20.0 10 10 0.0 6 
1.0 19.0 20.0 25 25 0.0 5 
2.0 18.0 20.0 50 50 0.0 4 
4.0 16.0 20.0 250 250 0.0 3 
10.0 10.0 20.0 500 500 0.0 2 
0.5mL 49.5 50.0 500 500 0.0 1 
stock (Sub 
solution stock) 
Calibrator 1 and calibrator 8 were used as upper limit of quantitation (ULOQ) and lower 
limit of quantitation (LLOQ), respectively. 
4.11.2.2.2 Quality Control (QC) samples 
O. 5mL of the lidocaine stock for control was pipetted into a 25mL volumetric flask and 
made up to the mark with ringer solution to produce a sub-stock (QC 4, 
1000ng/mL). Working controls were prepared by diluting the sub stock with Ringer 
solution as tabulated in Table 4.2. 
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Table 4.2 Working control concentrations with related dilution in ringer solution 
Volume of Volume Total Nominal Measured Inaccuracy Cal No. 
sub stock of ringer volume concen- concen- 
(Ringer) solution (Ringer) tration tration 
(mL) (mL) (mL) (ng/mL) (ng/mL) % 
0.015 9.985 10.0 1.5 1.5 0.0 1 
(low) 
2.00 8.0 10.0 200.0 200.0 0.0 2 
(medium) 
4.50 5.5 10.0 450.0 450.0 0.0 3 
(high) 
0.5mL 24.5 25 1000 1000 0.0 4 
stock (Sub 
solution stock) 
4.11.2.3 Extraction 
The same liquid-liquid extraction procedure as described in Chapter 2 was used to 
extract lidocaine from dialysate. However, the amount of sample used was only 10µL 
and the concentration of the internal standard used was I OOng/mL. 
4.11.3 Validation procedures and results 
4.11.3.1 Specificity 
Six samples of blank ringer solution and six samples of ringer solution spiked with 
lidocaine and the internal standard were prepared and the extraction carried out. The 
concentration of lidocaine used was O. 5ng/mL (LLOQ) and the internal standard was 
100ng/mL. No significant interfering peaks were found at the retention time of lidocaine 
and the internal standard. The signal to noise ratio for both lidocaine and the internal 
standard were both greater than 5. Figure 4.5 shows the chromatogram obtained from 
blank ringer solution spiked with 0.5ng/mL lidocaine and IOOng/mL bupivacaine. 
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Figure 4.5 Chromatograms obtained from extracted blank ringer solution spiked 
with 0.5ng/mL lidocaine, and blank ringer spiked with 100ng/mL 
bupivacaine. 
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4.11.3.2 Calibrations 
A calibration curve consists of eight non zero, calibrators assayed in duplicate (nominal 
values 0.5,1.0,10,25,50,100,250 and 500ng/mL). All of the results were calculated 
using a 1/x2 weighted quadratic regression. The peak area ratio, regression coefficient 
and the slope of the calibration line etc. were calculated from the peak area data by the 
Analyst program. The regression coefficient for all the calibration curves were greater 
than 0.99. Mean results obtained from five curves are summarised in Table 4.3. 
Table 4.3 Regression parameters for five calibration curves during validation 
Batch Curvature 
(C) 
Slope 
(A) 
Intercept 
(B) 
1 7.18 E-7 0.00200 0.00160 0.9912 
2 7.81 E-7 0.00152 0.00164 0.9910 
3 9.00 E-7 0.00210 0.00330 0.9988 
4 2.79 E-6 0.00234 0.00237 0.9991 
5 6.63 E-7 0.00179 0.00139 0.9948 
Second-order equation: y= Cx2 + Ax +B 
4.11.3.3 Inaccuracy and Imprecision, 
Inaccuracy and imprecision were carried out as mentioned in Chapter 2. The 
concentrations of the quality control used were 1.5,200, and 450ng/mL for QC1, QC2, 
and QC3, respectively. The concentrations for LLOQ and ULOQ were 0.5ng/mL and 
500ng/mL, respectively. 
4.11.3.3.1 Within-assay reproducibility 
The CV % and the percentage for within assay imprecision and inaccuracy including 
LLOQ and ULOQ were all within the accepted range with ranging from 1.5 to 13.5% 
and 0 to 10 %, respectively (Table 4.4). 
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4.11.3.3.2 Between assay repeatability 
The CV% and the percentage for between assay imprecision and inaccuracy including 
LLOQ and ULOQ were all within the accepted range with ranging from 1.6 to 10.7% 
and 0 to 3%, respectively (Table 4.5). 
4.11.3.3.3 Nested ANOVA 
From the nested Analysis of Variance, the within and between-batch and the total 
variability for all the QC samples including ULOQ and LLOQ were all below than 12 
% (Table 4.6). 
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Table 4.4 Within assay imprecision and inaccuracy in ringer solution 
No. of 
batches 
Nominal 
conc. 
Mean SD CV Mean 
inaccuracy 
(ng/mL) N=6 (%) (%) 
0.5 0.50 0.06 12.00 0 
1.5 1.55 0.10 6.45 3 
200 186.54 10.56 5.66 -7 
450 460.35 26.49 5.75 2 
500 519.85 9.04 1.74 4 
0.5 0.52 0.05 9.62 4 
1.5 1.35 0.12 8.89 -10 
200 197.75 7.41 3.75 -1 
450 449.07 12.09 2.69 0 
500 529.35 7.08 1.34 6 
0.5 0.52 0.07 13.50 4 
1.5 1.45 0.10 6.90 -3 
200 199.58 5.56 2.79 0 
450 478.63 10.74 2.24 6 
500 515.50 7.83 1.52 3 
Table 4.5 Between assay imprecision and inaccuracy in ringer solution 
Nominal 
concentrations 
Mean SD CV% Mean 
accuracy 
(ng/mL) n=18 (%) (%) 
0.5 0.51 0.05 10.66 3 
1.5 1.45 0.13 8.97 -3 
200 194.62 9.66 4.96 -3 
450 462.68 20.99 4.54 3 
500 500.66 7.86 1.57 0 
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Table 4.6 Within and between batch variability from the nested analysis of variance 
(ANOVA). 
LLOQ QC1 QC2 QC3 ULOQ 
Nominal concentration 
(ng/mL) 0.5 1.5 200 450 500 
Mean (ng/mL); n =15 0.51 1.49 193.98 464.12 502.16 
SDw - 0.05 - 7.66 1.29 
SDb 0.06 0.09 10.40 19.04 7.68 
SDt 0.06 0.10 10.40 20.52 7.78 
CVw (%) - 3.1 - 1.7 0.3 
CVb (%) 11.3 5.9 5.4 4.1 1.5 
CVt (%) 11.3 6.6 5.4 4.4 1.5 
w- within batch; b- between batch; t- total 
4.11.3.4 Extraction recovery 
Absolute recovery of lidocaine was tested using Ringer solutions spiked with lidocaine 
at the same nominal concentration as the quality control samples. The absolute recovery 
of lidocaine and bupivacaine ranged from 81 to 91% and 94%, respectively. All of the 
values are summarised in Table 4.7. 
4.11.3.5 Microdialysis probe recovery 
Three DMD probes (probe 1,2, and 3) were placed in three eppendorf tubes containing 
1.5ng/mL lidocaine in ringer solution. Using the DMD pump, the blank ringer solution 
was perfused through the probe and the dialysate was collected every 20 minutes for 80 
minutes and labelled sample 0,1,2, and 3. The first 20 minute sample (sample 0) was 
not used in the analysis. The probes were then transferred into another eppendorf tube 
containing 200ng/mL lidocaine and the above procedures were repeated and finally with 
450ng/mL lidocaine. The samples were analysed for their lidocaine concentration. 
Relative Recovery (RR) was calculated by the following formula: 
Cout 
RR= x100% Cm 
Cout = Drug concentration in the dialysate 
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Cm = Drug concentration in the medium 
The mean percentage probe recovery for low concentration (1.5ng/mL) is higher 
compared to medium (200ng/mL), and high concentrations (450ng/mL) with the values 
of 94,83, and 74%, respectively. The percentage recoveries were found to decrease 
when the concentration increased. All of the values are summarised in Table 4.8. The 
analysis of variance for the within, between and total probe variabilities found there to 
be higher variability for low concentrations compared to medium and high. Table 4.9 
summarises the within, between and the total probe variability obtained from the nested 
analysis of variance (ANOVA). 
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Table 4.9 Within and between probe variability from the nested analysis of 
variance (ANOVA) 
Low 
concentration 
Medium 
concentration 
High 
concentration 
Nominal concentration (ng/mL) 1.5 200 450 
Mean observed concentration 1.41 166.72 332.91 
(ng/mL) 
SDw - 18.34 - 
SDb 0.30 11.98 29.20 
SDt 0.30 21.90 29.20 
CVw (%) - 11.0 - 
CVb (%) 21.5 7.2 8.8 
CVt (%) 21.5 13.1 8.8 
w=within probe; b=between probe; t=total 
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4.12 Validation and application of capillary electrophoresis 
for the analysis of lidocaine in DPK study. 
4.12.1 Introduction 
Various techniques are available to measure lidocaine in plasma such as HPLC with UV 
detection, LC-MS-MS, and GCMS, as explained in Chapter 2. Most of the analysis of 
lidocaine (Padula et al., 2003) and other compounds (Pershing et al., 2003; Weigmann et 
al., 1999) from tape samples has been done by using HPLC with UV detection. The 
drug contents in the tape obtained from a DPK study is normally higher than in plasma 
especially for local anaesthetic studies. Therefore, the high sensitivity techniques such 
as LC-MS-MS or GCMS are not required since UV detection is sufficiently sensitive to 
detect such levels of a drug. Moreover, the cost of running analysis by UV detection is 
less compared to MS detection. 
On the other hand, capillary electrophoresis (CE) is an alternative to the 
chromatography techniques used in drug analysis which can separate a variety of 
compounds by using an electric field. The separation of the compounds by 
electrophoresis in CE is based on the differences in electrophoretic mobility and the 
voltage applied. Like HPLC, CE also can be coupled with a UV detector (CE-UV) and 
MS (CE-MS) forming a powerful analytical method for drug analysis. Capillary 
electrophoresis with UV and MS detection for the analysis of lidocaine in 
pharmaceutical formulations have been reported previously (Geiser et al., 2003; Geiser 
et al., 2005; Wang et al., 2001). In this study, we have performed a method validation 
and CE analysis of lidocaine in tape samples obtained from a DPK study in healthy 
subjects. 
4.12.2 Experimentals 
4.12.2.1 Chemicals 
Lidocaine Hydrochloride (99.9% purity) and Procaine Hydrochloride (99.9% purity) 
(internal standard) were obtained from Sigma-Aldrich Company, Poole, UK. The 
chemical structure of lidocaine and procaine are shown in Figure 4.6. All HPLC grade 
solvents were obtained from Rathburn Chemicals Limited, Walkerburn, Scotland. All 
AnalaR grade reagents were obtained from Merck (BDH) Limited, Poole, Dorset, 
England. 
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0 (CH3 
\ 0V -N 
,ý 
CH3 
H2N 
Figure 4.6 Chemical structure of procaine 
4.12.2.2 Adhesive tape 
Tesa 4204 PV5, Beiersdorf, Hamburg Germany supplied by TESA UK ltd. Tape 
dimension was 19mm widths, and the backing material is polypropylene. 
4.12.2.3 Background electrolyte 
The aqueous background electrolyte used in this analysis was 100mM Tris-phosphate 
buffer at pH 2.5. To prepare this solution, 20mL phosphoric acid (0.5M) was diluted 
with 80mL water and l5mL Tris (0.5M) was added to obtain a solution at pH 2.5. The 
solution was topped up to 100mL with deionised water. 
4.12.2.4 CE instrumentation and capillaries 
Separations were carried out on an Agilent 3DCE G1600AX capillary electropherograph 
(Agilent, West Lothian, UK) controlled by Chemstation B. 02.01 (Agilent, West 
Lothian, UK). 350mm (265mm to window) x 50µm i. d., fused silica capillaries 
(Composite Metal Services, Ilkley, UK) were conditioned on first use by flushing with 
1M NaOH (BDH, Poole, UK) at >950 mbar, 40°C for 20 minutes. Pre-conditioning on 
injection was 3 minutes flush with 0.1M HCl (BDH, Poole, UK), then a2 minute flush 
with background electrolyte (BGE). Separation was at a potential difference of 
+25.0kV. The capillary was thermostated at 25.0°C. Detection was by photodiode-array 
over 195 - 300nm, but 200nm with bandwidth 6nm, was used for quantitation. Run time 
was 4 min. Both BGE vials were replenished every 12 injections. All samples and 
standards in the autosampler were kept at ambient temperature. The injections of the 
samples into the system were carried out hydrodynamically for 12 seconds at 50mBar. 
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4.12.2.5 Assay Procedures 
4.12.2.5.1 Preparation of stock solutions 
A stock solution of lidocaine and procaine was prepared in 50% methanol. All of the 
sub-stock solutions were stored at -20°C. All the calibrators and QC sample 
concentrations were prepared by appropriate dilution of the sub-stock. 
Lidocaine Calibrator 
A stock solution of lidocaine was prepared by dissolving 2900mg of lidocaine 
hydrochloride in 50mL of 50% methanol. The concentration of the stock solution was 
(after correcting for the salt and assuming a purity of 100%) 50mg/mL. 
Lidocaine Quality Control (QC) 
A stock solution of lidocaine was prepared by dissolving 1450mg of lidocaine 
hydrochloride in 25mL of 50% methanol. The concentration of the stock solution was 
(after correcting for the salt and assuming a purity of 100.0%) 50.0mg/mL. 
Procaine (Internal Standard) 
A stock solution of procaine was prepared by dissolving 139.2mg procaine 
hydrochloride in 1L deionised water. The concentration of the stock solution was (after 
correcting for the salt and assuming purity 99.9%) 120pg/mL. 
The stock solutions for lidocaine calibrator and quality control were stored at 
approximately -20°C. 
Working standard solutions 
Calibrator 
20mL of the lidocaine stock solution was pipetted into a lOOmL volumetric flask and 
made up to the mark with 50% methanol to produce a sub-stock (Cal 1). Working 
calibration solutions were prepared by diluting the sub stock with 50% methanol as 
tabulated in Table 4.10. 
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Table 4.10 Working calibration concentrations with related dilutions in 50% 
methanol 
Volume of Volume Total Nominal Measured Inaccuracy Cal 
sub stock of 50% volume concentration concentration No. 
methanol 
(mL) (mL) (mL) (mg/mL) (mg/mL) % 
1.25 23.75 25.0 0.5 0.5 0.0 6 
2.50 22.50 25.0 1.0 1.0 0.0 5 
6.25 18.75 25.0 2.50 2.5 0.0 4 
12.50 12.50 25.0 5.0 5.0 0.0 3 
18.75 6.25 25.0 7.5 7.5 0.0 2 
20mL 80.00 100 10 10.0 0.0 1 
stock (Sub 
solution stock) 
Calibrator 1 and calibrator 6 were used as upper limit of quantitation (ULOQ) and lower 
limit of quantitation (LLOQ), respectively. 
Quality Control (QC) samples 
lOmL of the lidocaine stock solution was pipetted into a 25mL volumetric flask and 
made up to the mark with 50 % methanol to produce a sub-stock (QC 4, 
20mg/mL). Working controls were prepared by diluting the sub stock with 50% 
methanol as tabulated in Table 4.11. 
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Table 4.11 Working control concentrations with related dilutions in 50% methanol 
Volume Volume Total Nominal Measured Inaccuracy Cal No. 
of sub of 50% volume concentration concentration 
stock methanol 
(mL) (mL) (mL) (mg/mL) (mg/mL) % 
0.8 19.2 20 0.8 0.8 0.0 1 
(Low) 
4.0 16.0 20 4.0 4.0 0.0 2 
(Medium) 
8.0 12.0 20 8.0 8.0 0.0 3 
(high) 
lOmL 15 25 20.0 20.0 0.0 4 
stock (sub 
solution stock) 
4.12.2.5.2 Preparation of tape samples 
For the purpose of validation and assay calibration, a length of self adhesive tape (Tesa 
4204 PV5) was cut into 10 samples so that each tape was approximately 3x 2cm. 
100µL volume of standard or quality control solution were spiked on the adhesive part 
of the tape. The solution was distributed approximately evenly on all of the tapes. The 
samples were left to dry naturally at room temperature. This required, approximately 30 
minutes. The samples were then transferred into IOmL polypropylene tubes and stored 
frozen at -20°C until analysis. Samples were obtained from patients by applying the 
tape (3 x 2cm) on the skin and stripped off by using forceps. The procedure was 
repeated 10 times to obtain 10 samples at each skin site. The samples were placed in 
IOmL polypropylene tubes and stored frozen at -20°C until analysis. 
4.12.2.5.3 Extraction procedure 
5mL of methanol was dispensed into the tube containing standard/QC tape or samples. 
The contents were mixed for 45 minutes by using a vortex mixer. 5mL of internal 
standard solution containing 120µg/mL procaine in water was added to the tube to make 
a 50% methanol solution. The contents were mixed again by a vortex mixer for another 
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15 minutes. A 200µL quantity of the solution was transferred into 250µL auto injector 
vial for CE analysis. 
4.12.3 Validation procedures and results 
4.12.3.1 Specificity 
Six samples of blank tape and six samples of tape spiked with lidocaine were prepared 
and the extraction was carried out. The amount of lidocaine spike was 50µg (LLOQ) 
and the internal standard added was 600µg. No significant interfering peaks were found 
at the retention time of lidocaine or procaine. The signal to noise ratio for both drugs 
were greater than 10. 
Figure 4.7 shows the electropherogram obtained from blank tape spiked with 50µg 
lidocaine and added IS of 600µg procaine. Whilst 
Figure 4.8 and Figure 4.9 shows the electropherograms of EMLA cream solution and 
one of the tape samples, respectively. 
160- 
140- 
120- 
100 
< 80 
60 
40 
20 
0 
0 
Figure 4.7 Electropherogram obtained from extracted tape sample spiked with 50µg 
lidocaine and added IS of 600µg procaine. 
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Figure 4.8 Electropherogram obtained from EMLA cream solution containing 50µg 
lidocaine and prilocaine and added IS of 600µg procaine. 
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Figure 4.9 Electropherogram obtained from tape sample at 4 hours post dose with 
added IS of 600µg procaine. 
0 Page 137 of 249 
0.5 1 1.5 2 2.5 3 3.5 4 
min 
0.5 1 1.5 2 2.5 3 3.5 4 
min 
Comparison of DPI, DMD and systemic measurement 
4.12.3.2 Calibration curve/ linearity 
The calibration curve consists of six non-zero calibrators with nominal values of 50, 
100,250,500,750, and 1000µg and 600µg procaine as internal standard (IS). Five 
batches of calibration curves were prepared for validation purposes. The calibration 
curve was plotted using the area ratio of lidocaine to IS versus known concentrations of 
lidocaine. All of the results were calculated using ay= Ax +B linear regression. The 
regression coefficient for all of the calibration curves obtained were greater than 0.99. 
Regression parameters obtained from five curves are summarised in Table 4.12 
Table 4.12 Regression parameters for five calibration curves during validation. 
Batch Slope 
(A) 
Intercept 
(B) 
r 
1 0.0257 0.0867 0.9986 
2 0.0262 0.0816 0.9974 
3 0.0255 0.0995 0.9967 
4 0.0257 0.0661 0.9997 
5 0.0240 0.1232 0.9914 
Linear equation: y= Ax +B 
4.12.3.3 Inaccuracy and Imprecision 
The method for inaccuracy and imprecision were the same as mentioned in Chapter 2. 
The nominal values for low, medium, and high control samples were 80,400 and 
800µg, respectively. The concentration for LLOQ and ULOQ were 50 and 1000µg, 
respectively. 
4.12.3.3.1 Within-assay reproducibility 
The CV for imprecision and the percentage of inaccuracy for all the quality control 
samples including LLOQ and ULOQ were below than 2% and 14%, respectively (Table 
4.13). 
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4.12.3.3.2 Between-assay repeatability 
The CV for imprecision and the percentage of inaccuracy for all of the quality control 
samples including LLOQ and ULOQ were below than 2% and 11%, respectively (Table 
4.14). 
4.12.3.3.3 Nested ANOVA 
From the nested Analysis of Variance, the within and between-batch and the total 
variability for all of the QC samples including ULOQ and LLOQ were all below than 
7% (Table 4.15). 
Table 4.13 Within assay imprecision and inaccuracy in tape samples. 
No. of Nominal Mean SD CV Mean 
batches concentration n=6 inaccuracy 
(j. tg) (N-g) (%) (%) 
50 44.93 0.65 1.45 -10 
80 85.82 0.45 0.52 7 
1 400 428.04 2.46 0.58 7 
800 830.69 1.88 0.23 4 
1000 1025.33 6.44 0.63 3 
50 47.42 0.47 0.99 -5 
80 78.83 0.35 0.45 -1 
2 400 410.58 2.07 0.50 3 
800 807.11 1.95 0.24 1 
1000 970.58 2.10 0.22 -3 
50 42.85 0.74 1.74 -14 
80 81.76 0.38 0.46 2 
400 401.67 0.82 0.21 0 
3 800 827.38 1.26 0.15 3 
1000 1043.12 7.25 0.69 4 
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Table 4.14 Between assay imprecision and inaccuracy in tape samples 
Nominal 
concentration 
Mean 
n=18 
SD CV Mean 
inaccuracy 
(ig) (N$) (%) (%) 
50 44.41 0.58 1.31 -11 
80 82.01 0.49 0.59 3 
400 413.43 2.12 0.51 3 
800 821.73 1.94 0.24 3 
1000 1005.27 5.62 0.56 1 
Table 4.15 Within and between batch variability from the nested analysis of variance 
(ANOVA). 
LLOQ QC1 QC2 QC3 ULOQ 
Nominal concentration (µg) 50.0 80.0 400.0 800.0 1000.0 
Mean; n =18 (µg) 
45.1 81.9 415.0 822.4 1013.0 
SDw 
- 0.31 0.11 - 2.78 
SDb 
0.06 0.39 2.28 2.13 5.73 
SDt 
0.06 0.50 2.28 2.13 6.37 
CVw (%) 
- 3.8 0.3 - 2.7 
CVb (%) 
1.4 4.7 5.5 2.6 5.7 
CVt (%) 
1.4 6.1 5.5 2.6 6.3 
w= within batch; b=between batch; t=total 
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4.12.3.4 Recovery 
Absolute recovery of lidocaine was tested using tape samples spiked with lidocaine at 
the same nominal concentrations as the quality control samples. Peak area 
measurements obtained from the extracted samples were compared to the peak area 
measurements obtained from direct solvent injection of the test compounds. Mean and 
standard deviation were calculated from at least three measurements at each level. The 
absolute recovery of lidocaine ranged from 97 to 103%. 
4.13 Results 
Twelve healthy subjects successfully completed the study according to the protocol. All 
of the samples obtained from DPK study were successfully analysed by the validated 
CE-UV method whilst plasma and DMD samples were analysed by the validated LC- 
MS-MS method. 
4.13.1 Lidocaine concentration profile and pharmacokinetic 
parameters 
The plots of mean lidocaine concentration versus time obtained from the analyses of 
DPK, DMD and plasma, are shown in Figure 4.10, and Figure 4.12, respectively. Figure 
4.13 shows all the plots for DPK, DMD and plasma plotted on the log scale. From all of 
the plots, we can see clearly that the lidocaine profile is higher in stratum corneum by 
1000 fold compared to dialysate and 100 000 fold compared to plasma. Lidocaine was 
detected in the stratum corneum at 15 minutes after dosing but was not detected until 
1.5 hours in the plasma and at 1.3 hours post-dose in the dialysate. 
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Figure 4.10 Plot of mean lidocaine concentration (µg) versus time (h) in tape samples 
obtained from DPK study in 12 healthy subjects. 
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Figure 4.11 Plot of mean lidocaine concentration (ng/mL) versus time (h) in DMD 
samples obtained from DPK study in 12 healthy subjects. 
Page 142 of 249 
Comparison of DPK, DMD and systemic measurement 
1.9 
1.7 
1.5 
E 
äm 
S1.3 
d 
c 
1.1 
0 
a-i. 0.9 
0.7 
0.5 
------------------------------I 
012345 
Time (h) 
Figure 4.12 Plot of mean lidocaine concentration (ng/mL) versus time (h) in plasma 
samples obtained from DPK study in 12 healthy subjects. 
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Figure 4.13 Plot of mean lidocaine concentration versus time (h) in tape, dialysate, 
and plasma samples on log scales 
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The analysis of the pharmacokinetic parameters of lidocaine showed the higher AUC 
and Cm. in DPK compared to DMD and plasma (Mean AUC04: 712.3µg. h, 458 and 
4. ing/mL. h: Mean Cm (0-4), 320.8µg, 426 and 2.5ng/mL, respectively). Table 4.16 
and Table 4.17 show the AUC and Cmax values of lidocaine in 12 healthy subjects 
obtained from DPK, DMD and plasma studies. 
The lidocaine amount in stratum corneum soon achieving the maximum concentration 
compared to dialysate and plasma. The median (IQR) tm was shorter in the stratum 
corneum, 1 (0.0) hour, compared to plasma 3.5 (0.5) hours. The different was 
statistically significant (Wilcoxon's Signed Rank test; p=0.003). The tmax for dialysate 
cannot be predicted as the concentration of lidocaine was still increasing in value at the 
last sampling point (4 hours post dose) in almost all of the subjects. Therefore, the 
terminal half life (tl/2) cannot be calculated for DMD. The t1n was calculated using the 
following formula: ti12= 0.693/Kei, where Kei is the elimination rate constant that can be 
calculated from the terminal phase slope. Kei for DPK was calculated from at least 3 
terminal phase concentration points and from 2 to 4 points in plasma. The mean t1i2 
obtained from DPK were not significantly different to the mean value calculated from 
plasma with 2.5 hours and 1.9 hours, respectively (paired `t' test test; p=0.337). Table 
4.18 and Table 4.19 show the tm. and t112 values of lidocaine in 12 healthy subjects 
obtained from DPK and plasma studies. 
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Table 4.16 AUCo4 of lidocaine with mean, SD and CV% obtained from DPK, DMD 
and Plasma in 12 healthy subjects 
Subject DPK DMD Plasma 
(µg. h) (ng/mL. h) (ng/mL. h) 
1 1155.67 123.40 4.12 
2 688.24 431.48 7.03 
3 650.77 101.68 0.72 
4 431.20 2284.60 2.35 
5 575.55 174.18 4.09 
6 700.65 535.50 3.31 
7 1180.61 1298.47 7.22 
8 730.69 57.70 2.41 
9 647.93 264.02 3.25 
10 399.65 21.45 3.77 
11 911.48 62.83 3.73 
12 475.13 136.69 6.72 
Mean 712.30 457.67 4.06 
SD 255.18 675.34 2.00 
CV % 36% 148% 49% 
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Table 4.17 Cm (0-4) of lidocaine with mean, SD and CV% obtained from DPK, 
DMD and Plasma in 12 healthy subjects 
Subject DPK DMD Plasma 
(µg) (ng/mL) (ng/mL) 
1 486.88 272.60 2.69 
2 296.60 450.50 3.22 
3 281.51 123.30 0.57 
4 194.53 2006.40 1.33 
5 311.22 249.70 7.95 
6 344.92 436.80 1.72 
7 424.77 1044.80 2.99 
8 334.66 88.40 1.61 
9 359.47 239.10 1.64 
10 222.20 10.00 1.53 
11 347.43 105.80 1.78 
12 244.98 85.10 3.42 
Mean 320.76 426.04 2.54 
SD 82.58 569.55 1.91 
CV % 26% 134% 75% 
It It Page 146 of 249 
Comparison of DPK, DMD and systemic measurement 
Table 4.18 tma., of lidocaine with mean, SD and CV% obtained from DPK and 
Plasma in 12 healthy subjects 
Subject DPK Plasma 
(h) (h) 
1 1.0 2.5 
2 1.0 3.0 
3 1.5 3.5 
4 1.0 3.5 
5 1.0 3.0 
6 1.0 3.5 
7 1.0 3.0 
8 1.0 4.0 
9 1.0 3.5 
10 1.0 3.5 
11 1.0 3.5 
12 1.0 4.0 
Median 1.0 3.5 
IQR 0.0 0.5 
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Table 4.19 tl/2 of lidocaine with mean, SD and CV% obtained from DPK and Plasma 
in 12 healthy subjects 
Subject DPK Plasma 
(h) (h) 
1 1.5 2.0 
2 4.6 1.0 
3 3.1 0.8 
4 1.4 1.4 
5 1.5 4.1 
6 3.5 1.6 
7 3.6 1.7 
8 3.1 NA 
9 1.6 2.8 
10 1.8 1.2 
11 2.6 NA 
12 2.4 NA 
Mean 2.6 1.9 
SD 1.0 1.0 
CV % 40% 56% 
The AUC and Cn, values obtained from the DPK study also showed low variability 
compared to plasma and very high variability for DMD (CV%; AUC0.4,36,49, and 
148%: Cm. (0-4), 26,75 and 134%, respectively). 
Figure 4.14 and Figure 4.15 show the plot of Test for Equal Variances (Bartlett's and 
Levene's test) for the AUC and the Cma,, from all the studies. The plots clearly showed 
the wider confidence interval for the DMD compared to plasma and DPK for the AUC 
and C, nax, meaning the variability is higher in the DMD results compared to plasma and 
DPK (Bartlett's test, p=0.000). 
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Figure 4.14 Plot of Test for Equal Variance with 95% confidence interval (AUCT= 
AUC DPK, AUCP = AUC plasma, and AUCM = AUC microdialysis 
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The pain assessment by using the pin prick test in the DPK study also correlated well 
with the stratum corneum and tissue lidocaine level in DPK and DMD, respectively. 
Figure 4.16 and Figure 4.17 show the VAS and VRS for pain plots. The lower pain 
score in VRS and VAS were obtained at 1.5 hours post dose (Mean, VRS; 1.17 unit and 
VAS; 9.08mm) were correlated well with the mean tm at 1 hour obtained in DPK 
study. The lower pain scores maintained up to 4 hours (prolong analgesia) as seen in 
VAS and VRS plot are also correlated well with DMD result which shows the lidocaine 
concentration still increasing at 4 hours post dose. Figure 4.18 and Figure 4.19 and 
show the VAS and VRS for pain together with DPK and DMD plot. 
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Figure 4.16 Mean VRS pain score corresponding to the pin prick time (n=12. Error 
bars = CD 
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Figure 4.17 Mean VAS pain score corresponding to the pin prick time (n=12. Error 
bars = Cl) 
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Figure 4.18 Plot of Verbal rating score (VRS) for pain with DPK and DMD lidocaine 
profile 
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4.13.2 Correlation between methods 
All three methods show significantly dillcrent lidocaine concentration prolile. The I)PK 
method detected 1000 and 100 000 fold higher lidocaine content (AUC) compared to 
DMD and plasma, respectively. They also significantly differ in the t,,,;, \ and C,,,,, values 
obtained in all three methods. All of the pharmacokinetic parameters obtained were 
further tested to investigate if there were any correlation existed between these three 
methods by using Pearson's Correlation Coefficient. The results showed that no 
significant correlation existed between each of the methods in all of the parameters 
tested (Table 4.20). 
Table 4.20 Correlations between Plasma, DPK, and DMD method for all the 
pharmacokinetic parameters observed. 
DMD DPK 
AUC Cß1. x tiliax tin_ AUC C, ax tilla\ t1/2 
Plasma r 0.053 -0.097 - - 0.274 0.103 0.248 -0.521 
p 0.871 0.764 - - 0.388 0.750 0.489 0.150 
DPK r -0.036 -0.195 - - 
p 0.911 0.543 - - 
r= Pearson correlation coefficient 
p value > 0.05 = No significant correlation 
4.14 Discussion 
In this study, one analytical technique, IL-MS-MS has been further validated and a new 
technique, CF-UV has been developed and validated for the analysis of lidocaine in 
dialysates and tape samples, respectively. The high sensitivity of the LC'-MS-MS 
technique is advantageous for the analysis of lidocaine in dialysate and plasma samples 
due to the small volume of the samples (DMD) and the low plasma concentration. The 
analysis of lidocaine in plasma by LC-MS-MS in this PhD project has been published 
(Chik et al., 2006b) and to further use the method fur analysis of dialysate, the re- 
validation procedure has been performed due to the different matrix, sample volume and 
the concentration range of the samples. 
Analysis of the dialysate seems to be uncomplicated as the dialysate samples are 
normally free of endogenous compounds like lipids and proteins that might interfere 
with the analysis, hence the direct introduction of the dialysate into the analytical 
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system is possible (Bagger and Bechgaard, 2004; Davies et al., 2000; de Lange et al., 
2000). However, high ionic strengths due to the proportion of salts in the dialysate, 
present a challenge when analysed by MS. The salt content in the dialysate can clog the 
ionization source and create high background noise (Davies et al., 2000). The existence 
of salts also deteriorated the shape of the analyte peak in our observations. There are 
several methods that can be used to alleviate this problem, such as the use of off line 
solid phase extraction prior to introduction into the chromatographic system (Prokai et 
al., 1998), and desalting the sample with deionised water. Since our liquid-liquid 
extraction in our previous study was easy and simple to perform, all of the dialysate 
samples have been treated the same as plasma samples prior to analysis by LC-MS-MS. 
Further work needs to be carried out for the analysis of lidocaine in the dialysate, so that 
the sample can be directly introduced into the chromatographic system without off or 
on-line treatments. 
On the other hand, tape samples obtained from the DPK study contained a huge amount 
of lidocaine. Therefore LC-MS-MS was not suitable to analyse all of the DPK samples 
as the detector was almost saturated with a high concentration of lidocaine. CE with UV 
detection was found to be a suitable method for this task due to its simplicity and 
reliability. In the development of this CE method we have attempted to reduce the 
migration time by a short - end injection (Geiser et al., 2005) and this resulted in the 
migration time of procaine at about 1 minute and lidocaine at about 1.2 minutes. 
However, prilocaine from EMLATM cream in all of the samples cannot be fully 
separated from lidocaine by using this method. 
Reducing the capillary length to 35cm from the original, 48.5cm, resulted in lidocaine 
and prilocaine being fully separated and took only about 2 minutes more than by short- 
end injection. Short migration times obtained for procaine (2.7 minutes) and lidocaine 
(3.2 minutes) is an advantage of CE compared to the 5 minute retention time for 
lidocaine using LC-MS-MS. This method has been used for the analysis of lidocaine in 
tape samples obtained from the DPK study in 12 healthy subjects. 
Analysis of lidocaine content in all of the sample matrixes have shown that the DPK 
method is the most reliable method of measuring the pharmacokinetic profile of 
lidocaine. This can be seen through all of the pharmacokinetic parameters obtained such 
as AUC, Cma,,, tmax and t112. The results showed that the amounts of lidocaine are higher 
in stratum corneum compared to the dermis layer of the skin and blood 1 hour after 
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application of EMLATM cream. From the DPK, DMD and plasma lidocaine results, we 
can prove that the local anaesthetic agents mainly absorbed, distributed and active 
within the local tissue, especially the outermost layer of the skin, epidermis and 
underneath layer, dermis and subcutaneous tissue. Within the local tissue, it shows that 
local anaesthetic is higher in the stratum corneum compared to underneath tissue, the 
dermis and the subcutaneous. The DPK result showed that the lidocaine was detected in 
stratum corneum soon after applications and higher concentration at 1 hour post 
applications. The decrease in the amount of lidocaine after 1 hour in DPK samples can 
be explained by the increased lidocaine concentration in the dialysate. This remained 
elevated even at the 4 hours sampling time. Numerous studies have demonstrated that 
EMLATM cream requires at least 45 to 60 minutes to achieve effective analgesia 
(Ehrenstrom-Reiz et at., 1983; Hallen et al., 1984) which continues to increase after 
removal of the cream (Arendt-Nielsen and Bjerring, 1988; Evers et al., 1985). The 
lowest score at 1.5 hours for VAS and VRS for pain in this study is correlated to the 
onset time of EMLATM and the continued increased of lidocaine concentration in 
dialysate is the answer of the prolong analgesia as observed in this study and as reported 
in the above literatures. 
The absorption of lidocaine into the systemic circulation is very low and took a longer 
time to achieve maximal concentration. This can be explained through the mean C,,, 
and tmax result from plasma analysis are 2.5ng/mL and 3.25 hours compared to 320.811g 
and 1 hour by the DPK methods, respectively. Although the concentration of lidocaine 
in dialysate was still increasing at 4 hours post dose, the lidocaine concentration in 
blood, however started to decreased after 3.5 hours. This condition may be due to 
elimination or metabolism of lidocaine into its major metabolites 
monoethylglycinexylidide (MEGX) and glycine xylidide (GX) by the cytochrome P- 
450 (Bargetzi et al., 1989). The lag time for the lidocaine as observed from the plasma 
result was 1.5 hours, and the tin obtained was 1.9 hours, therefore by 3.5 hours, half of 
lidocaine may already be eliminated from the body. The mean tm. value obtained from 
plasma result (3.25 hours) is very closed to the result obtained by Evers et al. (Evers et 
al., 1985) who reported the maximal concentration of lidocaine and prilocaine occcured 
180 minutes after EMLA application. The lower Cm and AUC and the longer tm. 
obtained in plasma showed that dermatological drug products such as local anaesthetic 
have a limited systemic absorption. 
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Higher variability in DMD data compared to plasma and DPK may be largely attributed 
to the probe implantation depth as the same subjects were used for all three techniques. 
Also the validation of within and between probe recovery showed a low variability in 
the three probes studied. Therefore between and within probe variability was minimal 
and did not contribute significantly to the variability seen. 
4.15 Conclusion 
The results from this study show that, DPK and DMD have been proven more reliable 
methods for the pharmacokinetic assessment of topical drugs than systemic drug 
measurements. Good reproducibility and the higher lidocaine concentration - time 
profile shown by DPK and also by the DMD method are advantageous when compared 
to the low lidocaine profiles derived from systemic measurements. Between the DPK 
and the DMD methods, good reproducibility and less variability was shown by the DPK 
method. 
However, more research and data regarding the reliability of DMD and DPK are 
necessary for the methods to be considered ideal for the pharmacokinetic assessment of 
transdermal drug delivery. A study such as to monitor the relationship of implantation 
depth of the microdialysis probe to the drug content is necessary to answer the 
variability observed in the DMD study. Once the results are confirmed that there is 
variability in the drug content related to the implantation depth, another study would 
need to be conducted investigating how to minimise the variation in the probe depth 
such as using ultrasound methodology. 
On the other hand, another study needs to be carried out to monitor the relationship 
between the pressure of the adhesive tape applied related to the tape's drug content. 
This also can help to improve and standardise the DPK method for the pharmacokinetic 
assessment of transdermal drug. 
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Chapter 5 Melanotan 
5.1 Introduction 
Over 1000 analogues of a-MSH have been synthesized and biologically evaluated by a 
group of researchers in Arizona (Hadley et al., 1998b). Several of these a-MSH 
analogues have exhibited superpotency and prolonged activity with respect to their 
melanogenic (skin tanning) properties. Among them only two a-MSH analogues, 
Melanotan I (MT-I) (Hadley et al., 1993; Levine et al., 1991) and Melanotan II (MT-II) 
(Dorr et al., 1996) have been extensively studied. Both Melanotan I and II have tanning 
capabilities, but because MT-II caused spontaneous penile erection as a side effect, it is 
now also being developed as an erectile dysfunction drug.. The tanning and penile 
erection capabilities of melanotan II have been shown in the study conducted by Dorr 
and co-workers (Dorr et al., 1996), and other studies on melanotan II have shown that 
the drug can initiate penile erection and increased sexual desire in some of the subjects 
(Hadley et al., 1998b; Wessells et al., 1998; Wessells et al., 2000). On the other hand 
MT-I has been further developed as a tanning agent (Dorr et al., 2000; Hadley and Dorr, 
2006). The delivery of MT-I is problematic as it is a peptide drug with a short half-life, 
metabolic instability, relatively high polarity, and larger molecular size which limits its 
transport via gastrointestinal absorption (Hadley et al., 1998b). Therefore to date, the 
delivery of melanotan has been studied using intravenous injection, subcutaneous 
implant, and transdermal delivery. 
Transdermal delivery of MT-I has been conducted and tested on mice (Levine et al., 
1987). MT-I was topically applied to an area of the back of the mice and within 24-48 
hours, eumelanin production was visible microscopically within hair bulb melanocytes 
in both treated and untreated areas. Thus, these results demonstrated that MT-I was 
successfully delivered through the skin and had the action of melanin production. 
However similar studies using rat skin showed poor penetration of MT-I (Dawson et al., 
1988). In another in vitro study on human skin (Dawson et al., 1990), MT-I has 
successfully delivered across human skin and was measurable using radioimmunoassay 
(RIA) to test for quantity and biologic activity, respectively. 
Preliminary clinial trials on MT-I to demonstrate tanning of skin were carried out in 
Arizona, USA by Norman Levine (Levine et al., 1991). Twenty eight healthy white men 
with history of either poor or good tanning skin were administered with 10 
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subcutaneous injection of MT-I. The results showed that a tan induced by Melanotan in 
the head and neck region, were produced in the same way as a natural tan and persisted 
for a similar time. This result has been considered the first demonstration of a stable 
drug candidate that could induce a natural tan in human beings. A study by Ugwu and 
co - workers (Ugwu et al., 1997) also showed a significant tanning of the forehead, 
arms, and neck following IV or SC dosing of MT 1 in three healthy voluteers. 
In a pharmacokinetic study (Evans AM, 2002) conducted in 12 volunteers in Australia 
of a daily subcutaneous injection of 0.16mg/kg of Melanotan for ten days demonstrated 
that Melanotan has a half-life after subcutaneous administration of about 30 minutes 
with little or no activity in the plasma after 4 hours. There appeared to be negligible 
accumulation of Melanotan in subjects (Evans AM, 2002). A Phase II study conducted 
at two sites in Australia (Royal Prince Alfred Hospital, Sydney and Royal Adelaide 
Hospital, Adelaide) during 2003 recruited 81 subjects (61 Melanotan and 20 placebo). 
The subjects enrolled into the active arm received 30 subcutaneous injections of 
0.16mg/kg/day of MT 1 for thirty days, given for every 10 days at the beginning of 3 
consecutive months. Significant increases in skin melanin were seen in the active group 
compared to placebo (p < 0.0001) at the end of the 90 day study period (Datapharm 
Australia, 2004). 
The safety and tolerability of a slow-release (depot) formulation of Melanotan is being 
tested in a human trial in Australia. This trial involves the subcutaneous insertion into 
the abdominal wall of biodegradable polylactide rods containing increasing doses of 
Melanotan. Subjects are being monitored for safety, pharmacokinetic levels of the drug 
in the blood and skin tanning effects over a 60 day period. Preliminary results with a 
20mg and 40mg implant have shown the average skin melanin density increases from 
2.81 + 0.33% to 4.03 + 0.29% within 10 days of starting treatment and persisted over 
the 60 day observation period. Adverse events were principally limited to the cosmetic 
effects (rapid tanning, freckling) induced by the rapid onset of melanogenesis. Other 
mild adverse events which have been reported less commonly include headache, satiety, 
rhinitis, chemical taste in the mouth, yawning, muscle twitching, diarrhoea, light- 
headedness and nervousness. Adverse events associated with sustained-release implants 
have been mainly restricted to irregular skin tanning, darkening of nevi (moles) and 
freckling. The darkening of moles and freckling are not strictly adverse events as they 
represent the natural effects of the drug, however the rapidity of the change was such as 
may be recorded as an unexpected event. 
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Recently, Clinuvel Pharmacetical Limited (previously known as Epitan Limited) has 
announced that it has successfully completed a phase II trial on injectable implants of 
Melanotan-I for the treatment of Polymorphous Light Eruptions (PMLE). The results 
show that Melanotan I can be an efficacious drug for the treatment of PMLE. They now 
plan to start the Phase III trial in nine centres across the European continent in early 
2007 (Clinuvel Pharmaceutical Limited, 2006). 
All of the above forms of administration are expensive to administer, time-consuming 
and inconvenient to the subject. If this is to become an over the counter (OTC) product, 
there is a need to establish the pharmacokinetics of a more user-friendly dosage 
regimen. In this study, the TDS® system has been combined with MT-I to assess the 
capabilities of the system to deliver MT-I for the assessment of tanning and it's 
pharmacokinetic properties. This is a more convenient mode of application compared to 
a subcutaneous implant and IV injection. The expected difference in bioavailability in a 
subcutaneous versus a transdermal dose has resulted in the selected dose escalation from 
1 mg up to 40mg administered for 10 consecutive days in this study. The total dose of 
up to 400mg was received by subjects based on the tanning and toxicity criteria. This 
criteria and full dosage regime will be explained in the methods section. 
5.2 Study Objectives 
The main objective of this study was to assess the ability of the TDS® system to deliver 
MT-I systemically to induce the production of skin's melanin and give the tanning 
effect in healthy Caucasian subjects. 
The second objective of this study was to assess the pharmacokinetic properties and 
therapeutic dosage of MT-I in conjunction with the safety and tolerability of MT-I in 
healthy subjects. 
5.3 Study Approval 
The study was approved by the St. Thomas' Hospital Research Ethics Committee. 
Reference no. 04/Q0702/120, dated 11`"' November 2004. 
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5.4 Subjects 
This study involves 30 healthy Caucasian subjects enrolled over a period of 9 months. 
5.5 Study Methodology 
5.5.1 Study treatment 
The TDS® system as prepared under GMP manufacturing and FDA guidelines by 
Natural Vitamin Co., Las Vegas, Nevada, USA and dispensed by Transdermal 
Technologies Inc. (TTI) Lake Park, Florida, USA. TTI was sent TDS® and Melanotan 
to be combined and formulated by Controlled Therapeutics, Glasgow, United Kingdom. 
TDS® - Melanotan 1,5,10,20, and 40mg/mL solutions were supplied in metered pump 
dispenser with one entire spray containing 0.2mL solution. 
5.5.2 Design 
This study was a dose escalation study starting with a 1mg dose for Cohort 1 and ending 
with a 40mg dose for Cohort 5. Each cohort contained 6 subjects who received a dose 
for 10 continous days. The detail of the cohorts and doses are shown in the Table 5.1. 
The lowest dose (1mg/day) is approximately 1/10th of the effective dose established in 
previous studies of ten daily IV doses of 0.16mg/kg/day [100mg delivered over 10 days 
to a 62kg person] (Ugwu et al., 1997). 
Table 5.1 Doses and corresponding cohorts for TDS-Melanotan administration 
Cohort (Treatment) 
Number 
No. of subjects Dose 
(mg/day) 
Total Dose 
(mg) 
1 6 1 10 
2 6 5 50 
3 6 10 100 
4 6 20 200 
5 6 40 400 
5.5.3 Screening Evaluation 
Prospective subjects attended the study site for a screening visit within 4 weeks of study 
commencement. The nature of the study, the procedures and the risks were fully 
explained. Before any screening procedures occured they had signed an Informed 
Page 160 of 249 
Melanotan 
Consent Form for Screening and an Informed Consent Form for tissue storage. At the 
screening sessions, blood samples were taken for routine biochemical, haematological, 
endocrinological and serological screenings. A urine specimen was also obtained for 
urinalysis and drug screening and pregnancy testing for females. A further lOmL of 
blood was taken for the assessment of MC1R genotype. Each subject was then 
provided with Uritainer and requested to collect all of their urine over the following 24- 
hour period for the measurement of 24-hour urinary cortisol levels. Routine physical 
examinations, inclusion/ exclusion criteria and assessment of skin type were also 
conducted during the screening. Skin type has been recorded based on Fitzpatrick scale 
(Fitzpatrick, 1988) as list down below. 
i) Type 1: Never tans, always burns 
ii) Type 2: Sometimes tans, mostly burns 
iii) Type 3: Mostly tans, sometimes burns 
iv) Type 4: Always tans, never burns 
In addition to the subject's skin type assessed according to Fitzpatrick classification, a 
more definitive assessment of skin type will be assessed according to the "melanocortin- 
1 receptor" (MC 1 R) genotype (Palmer et al., 2000). A lOmL blood sample was 
collected into a standard EDTA blood tube for this purpose. After mixing well, the tube 
was labelled and stored refrigerated (not frozen) until further analysis. 
5.5.4 Study Procedures 
5.5.4.1 Dose escalation strategy 
Upon acceptance into the study, volunteers were allocated subject numbers and hence to 
a Cohort number for administration of Melanotan at one of the pre-assigned doses. 
Cohorts 1,2, and 3 were run in parallel. Cohort 4 for the 20mg dose was started 
approximately 1 month after completion of day 30 of the first three cohorts, after review 
of all of the haematology and clinical biochemistry results at Day 30. Upon completion 
of a review of all of the results, (and found) no related grade 3 or 4 toxicity as defined 
by the National Cancer Institute Common Toxicity Criteria (National Cancer Institute, 
1999), no abnormal pathology results and no serious adverse events, another six 
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subjects were enrolled in Cohort 4 to receive the 20mg/day dose. The above procedures 
were also carried out for the enrolment of Cohort 5 (40mg/day dose). 
5.5.4.2 Treatment procedures (per cohort) 
5.5.4.2.1 Day 0 
Subjects reported to the Study Centre at approximately 0830 hours on Study Day 0. 
The volunteers underwent a check-in procedure during which Informed Consent for 
Study Participation was obtained. A urinary pregnancy test was conducted on females to 
make sure that they were not pregnant. Subjects then had skin reflectance measurements 
performed according to the procedures outlined in Section 5.5.8. Prior to discharge from 
the Study Centre, subjects were given Diary Cards which they were asked to fill in on a 
daily basis to record daily exposure to sun, applications of sunscreen to the skin, 
concurrent medications and any adverse events. Subjects were requested to bring these 
diary cards to the Study Centre at each study visit for review. 
5.5.4.2.2 Days 1,2,3,4,5,6,7,8,9 and 10 
On Day 1, subjects attended the Study Centre at about 0730 hours. Subjects were 
checked for any concomitant medications and had a blood pressure (BP) check before 
insertion of a cannulae into an antecubital vein of the left arm. A 10 mL blood sample 
was obtained before the treatment application. The treatment dose was sprayed topically 
to the inner aspect of the right inner upper arm and gently rubbed into the skin. A 
surgical glove was worn when applying the treatment to prevent self-dosing. The 
applied drug was allowed to dry for approximately 5 minutes prior to the subject 
covering the arm with clothing. Following dosing, subjects remained under observation 
at the Study Centre. Serial I OmL blood samples were collected at 20min, 40min, 1,1'/z, 
2,21/2,3,4,5,6,8,10 and 12 hours post dose. On the remaining treatment days (2 - 
10), a 10mL blood sample was drawn just prior to the treatment being applied. The 
treatment was applied at the same application sites for 10 continuous days. On day 5 
and 10, skin reflectance measurement was carried out by using a spectrophotometer. On 
day 10, a blood sample was taken for pathology assessment and subjects were provided 
with a Uritainer and requested to collect their urine over the following 24 hour period. 
Subjects were asked to return the Uritainer on the following day for 24-hour urinary 
cortisol measurement. 
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5.5.4.2.3 Day 20 (+/-1 day) 
On this day, subjects attended Study Centre at about 0830 hours for Skin reflectance 
measurements. Subjects also were also assessed for concomitant medication, vital signs 
and adverse events. 
5.5.4.2.4 Day 30 (+/-1 day) 
On this day subjects attended the Study Centre at about 0830 hours for skin reflectance 
measurements (Section 5.5.8) prior to blood collection for safety measurements 
(haematology, biochemistry and endocrinology), and a urine sample was obtained from 
female subjects for pregnancy testing. Subjects were then provided with a Uritainer and 
repeat the urine collection procedure as mentioned above. 
On each of the above visits, subjects were assessed for concomitant medication, vital 
signs and adverse events. Subjects were also reminded to record their daily activity 
related to sun exposure, any adverse events and medication taken, in the diary book 
supplied. 
5.5.4.3 Restrictions 
5.5.4.3.1 UV Exposure 
Subjects were required to refrain from excessive exposure to UV light from 1 week 
prior to the study start until after the Day 30 visit. Subjects were not permitted to use 
UV beds and had to apply sunscreen to all exposed body regions during prolonged (? 30 
minutes full sun) sun exposure. 
5.5.4.3.2 Concurrent Medications 
Subjects were instructed to abstain from medications (prescribed or over-the-counter, 
including herbal remedies, but excluding oral contraceptives) deemed to be significant 
by the Principal Investigator for the 7 days preceding the dosage phase (Days 1-10), and 
throughout the study (until Day 30). Subjects were asked to inform Study Personnel if 
any additional medication was required. All the details of concomitant medications were 
recorded in the subject's Diary and Case Report Form (CRF). 
Page 163 of 249 It It 
Melanotan 
5.5.5 Parameters for Evaluation 
5.5.5.1 Skin Reflectance Measurements 
Skin reflectance measurements were performed on Days 0,5,10,20 and 30. 
Reflectance by the skin, of wavebands of light that are 15 nm wide were measured at 20 
nm intervals in the wavelength range of 400 to 700nm with a Minolta 2500d 
spectrophotometer. Refer to Appendix 22 for the whole procedures of the skin 
reflectance measurements. Nine different anatomical sites were assessed as follows: 
Site 1: Forehead 
Site 2: Left cheek 
Site 3: Right side of neck 
Site 4: Left shoulder (scapula) 
Site 5 Left inside upper arm 
Site 6: Right inside upper arm 
Site 7: Left medial forearm 
Site 8: Right side of lower back 
Site 9: Left calf 
Four skin reflectance parameters were measured, in triplicate, on an area of 8mm x 
8mm at each anatomical site, these are: L-value, b-value, R420 and R400 (the latter two 
readings were used to calculate Melanin Density (MD)). Reflectance measurements 
were recorded as L-values, corresponding to luminescence or brightness from black to 
white, and b-values, representing colour hues from blue to yellow (Porges et al., 
1988; Seitz and Whitmore, 1988). Visually apparent tans are typically associated with > 
1 unit decrease in the L-value and >1 unit increase in b-value, compared to baseline 
(Ugwu et al., 1997). In addition, the density of cutaneous melanin was estimated from 
reflectance at that site of wavebands of light centred at 400 rim and 420 nm according to 
the results of Dwyer et al. (Dwyer et al., 1998; Dwyer et al., 2000). The equation used is: 
MD = 100 x (0.035307 + 0.009974(R420 - R4oo)) 
Where; 
MD = Melanin density 
R400 and R420 = Reflectance at 400 run and 420 nm, respectively. 
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Figure 5.1 A body diagram shows the 9 anatomical sites (grey shaded area) for the 
skin reflectance measurement. 
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5.5.5.2 Melanotan Assay 
Melanotan concentrations will be measured in plasma using a validated LC-MS-MS 
method. At the time this thesis was submitted, the method is still under development. 
Therefore, the melanotan plasma concentration and pharmacokinetic analysis cannot be 
reported. 
5.5.5.3 MCI R Genotype 
A 10 mL blood sample was collected from each subject at the time of screening for the 
MC1R genotype. The blood samples for the MC1R genotype will be analysed by any 
available technique used in the genetic laboratory such as oligonucleotide DNA 
microarray (Hacia et al., 1999). However, the method is still under development, 
therefore the data cannot be presented in this thesis. 
5.5.6 Statistical Analysis of Skin Reflectance Measurements 
For each subject the change, from baseline, on Days 5,10,20, and 30 were calculated 
for Melanin Density (MD), L, and b for each anatomical site. The analysis of variance 
(ANOVA) was performed for the MD, b, and L values on all of the sites, subjects, and 
observation days together with sites and Days as a fixed factors and subjects as a 
random factor. The Dunnett Simultaneous Test was used to test if the differences 
between day 5,10,20, and 30 and the baseline was significant. The level of statistical 
significance was set at a-level of 0.05. 
5.6 Results 
Thirty healthy Caucasian subjects, divided into 5 cohorts, successfully participated in 
this study. One subject from Cohort 3 refused to finish the study for personal reasons, 
but was replaced by another subject. All of the subjects followed the protocol well and 
restricted their sun esposure. The average length of sun exposure in all of the subjects 
studied for the whole 30 days study period was, mean [range] 25 [0-82] hours. After 
completing the 30 day study on each Cohort, no significant skin tanning was observed 
in any of the subjects. The results of MD, b and L at day 5,10,20, and 30 also showed 
no difference compared to baseline for all anatomical sites and all of the cohorts 
accepted the final cohort, the 40 mg dose was where site 7 (left medial forearm) showed 
a significant increase and a decrease in the MD and `b' values, respectively. Therefore, 
only the results from cohort 5 will be presented and discussed. 
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The analysis of skin reflectance parameters by each subject had found the MD, b and L 
values were inconsistence throughout the 30 day observation period for all the subjects 
and the sites studied. Only site 7 (left medial forearm) appeared to have a significant 
increase in MD and b values, and a significant decreased in L values for most of the 
subjects. For simplicity, the analysis for MD, b, and L were performed at each site. The 
plot of mean MD and b change from baseline showed no increase for all of the 
anatomical sites except site 7 (left medial forearm) (Figure 5.2 and Figure 5.3). 
Similarly, the plot of mean L change from baseline also showed no decreased for all the 
anatomical sites except for site 7 (Figure 5.4). Further detail on site 7 also showed most 
of the subjects had an increase in MD and b, and this correlated with the decrease in L 
values from day 0 to day 30. Figure 5.5, Figure 5.6, and Figure 5.7 show the plots of 
MD, b, and L change from baseline for site 7 for all of the subjects in cohort 5. Whilst 
Figure 5.8 shows clearly the plot of mean MD, b, and L values change from baseline for 
site 7. 
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The analysis of variance (ANOVA) was performed for the MD, b, and L values on all 
sites and subjects together for the difference between Day 5,10,20, and 30 from the 
baseline (n = 270 observations). No significant differences were observed between day 
5,10,20, and 30. The 95 % confidence interval (CI) and the p values are summarised in 
Table 5.2. The ANOVA performed for MD, b, and L on each site also showed no 
difference between day 5,10,20, and 30 for all sites except site 7. The MD and b values 
for site 7 were statistically different at day 10,20 and 30. Although the mean L values 
were decreased at day 10,20, and 30, the differences were not statistically significant. 
The confidence interval and the p values of MD, b, and L for site 7 are summarised in 
the Table 5.3. 
The analysis of all the blood samples for dose 40 mg also showed that MT I were not 
detected in plasma in any of the sampling point in all the subjects. This result showed 
that the TDS system may not be able to deliver MT I systemically and that is the likely 
answer for the lack of tanning in all the subjects studied. 
No serious adverse events were reported by all the subjects studied. From 30 subjects, 
only 6 subjects reported headache at some point during the 30 day study period, but 
were only mild and lasted for a short period of time. Two subjects caught a cold and one 
subject experienced stomach pain, but this was not related to the study drug. All of the 
subjects tolerated the treatment applications and there was no local reaction observed at 
the application site. 
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Melanotan 
5.7 Discussion and Conclusion 
Although the primary endpoint, the skin tanning, was not achieved in this study, the 
analysis of the skin reflectance data have showed a significant increase in the MD and b 
and the decrease in L values at one site of the body. However, the difference is only 
significant for MD and b, but not for L. Therefore we cannot conclude that the TDS®- 
Melanotan worked. 
A few suggestions can be made from the above observations. At the doses used the 
TDS® system may not capable of delivering the necessary therapeutic dosage of MT 1 
through the skin to induce enough production of melanin to give a tanning effect. This is 
may be because of MT-I is a peptide which is by its nature has a large molecular weight, 
is hydrophilic, and is a polar compound (Bodde et al., 1989) presenting difficulties for 
effective transdermal drug delivery. Oral administration for peptides is not feasible as 
peptides are rapidly metabolised in the intestinal tract by pancreatic and intestinal 
proteolytic enzymes to form a smaller structure (Steffansen et al., 2005) Also the large 
molecular size of peptides almost restricts the compounds from entering enterocytes in 
the intestine (Steffansen et al., 2005). Therefore the delivery of a peptide through the 
skin presents a challenge for the future development of the TDS® system. These can be 
confirmed with the result from plasma analysis of all the subjects in 40mg dose group 
which were found no MT I detected at any time points. 
Another parameters that can be considered to influence the tanning capabilities is the 
MC 1R (Melanocortin 1 receptor) polymorphism. MC 1R is a G-protein-coupled 
receptor existing in skin melanocytes, that can activates adenylate cyclase to elevate 
cyclic adenosine monophosphate levels upon stimulation by the proopiomelanocortin- 
derived peptides a-melanocyte-stimulating hormone (a-MSH) and adrenocorticotropic 
hormone (Thody and Graham, 1998). Stimulation of MC1R by a-MSH and other pro- 
opiomelanocortin (POMC) peptides leads to eumelanogenesis and is central to the 
tanning response of human skin under UV exposure (Rouzaud et al., 2005; Suzuki et al., 
1999). MC1R also regulates the balance of two melanin types, the red/yellow 
pheomelanin and black/brown eumelanin. 
The MC1R gene has found to be highly polymorphic in Caucasian populations 
(Rouzaud et al., 2005). More than 30 allelic variants of the human MC1R gene have 
been identified, mostly in European and Australian populations (115,116,120,153). 
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Among the variants reported, R142H, R151C, R160W, and D294H are known to be 
associated with a red hair phenotype (116,118,120,154). It can be seen in a study on a 
series of individuals from a general Irish population. 75 % contained a variant in the 
MC1R gene, with 30% containing two variants. The Argl5lCys, Argl60Trp, and 
Asp294His variants were significantly associated with red hair and fair skin (poor 
tanning capabilities) (p = 0.0015, p<0.001, and p<0.005, respectively) (Smith et al., 
1998). UV induced tanning maybe ineffective in numerous `fair-skinned' individuals, 
which contain functional disruption of MCI -R (D'Orazio et al., 2006). 
Although the MC1R genotype may contribute to the poor tanning capabilities as discuss 
above, the significant of this factor to the result obtained in this study is highly unlikely, 
especially since the blood results of the highest dose, 40mg, were unable to confirm the 
absorption of MT I. 
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Chapter 6 General Discussion 
The aim of this thesis was to: - 
1) Conduct pilot pharmacokinetic and pharmacodynamic studies in healthy human 
subjects for the development of a novel transdermal drug delivery system, TDS® which 
are combined with a few drugs currently used for transdermal delivery. 
TDS® is a state of the art technique for transdermal drug delivery. TDS® is a liquid 
formulation that can be combined with any drug entity to form a novel and more 
convenient transdermal delivery system. The system would provide a method of 
delivering drugs that is simple, easy, fast, and effective. An earlier studies has shown 
that the TDS® system is capable of transporting drug molecules across the human skin 
(Hadley et al., 1998a). The clinical studies outlined in this thesis are among the early 
works ever conducted for the TDS® system on humans. The studies reported in this 
thesis have successfully achieved the aim as outlined in the studies' objectives. 
The TDS® system has been combined with two well known drugs, lidocaine and 
testosterone, and a new drug under investigation the a-melanocyte stimulating hormone, 
melanotan I. For TDS®-Lidocaine, a pilot study for the efficacy and tolerability of the 
system has been conducted in 100 healthy subjects and the results have been published 
in the journal of Anaesthesia (Tucker et al., 2006). Showing that five minutes post 
application of TDS®-Lidocaine can give acceptable anaesthesia is the major 
achievement for the local anaesthetic system. 
The Phase 1 pharmacokinetic study comparing TDS®-Testosterone, AndroGel® and 
TDS® - Placebo has been conducted in 12 healthy males. The analysis of the results 
from the study not only showed that the TDS®-Testosterone was bioequivalent to 
Androgel, but also attained a higher systemic profile of testosterone than Androgel. The 
results and the detail of this study have been published in the British Journal of Clinical 
Pharmacology (Chik et al., 2006a). Due to the existence of endogenous levels of 
testosterone, a few models for correction and removing the influence of endogenous 
testosterone have also been studied. 
The dose escalation for the investigation of the pharmacokinetic and the skin tanning 
properties of TDS®-Melanotan has been conducted in 30 healthy Caucasians. The 
highest dosage, 40mg, given to the subjects did not produce significant tanning on the 
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skin, but an increases in the melanin density in some regions of the body were observed. 
However, these result may not being contributed from the administration of MT I as the 
analysis of melanotan in all the blood samples for the 40 mg dosage have found no MT 
I detected. 
2) Explore, develop, improve and validate the analytical tools available for the analysis 
of lidocaine in plasma, dialysate and tape samples, and testosterone in plasma. 
A few analytical methods have been explored for the analysis of lidocaine in different 
matrixes and testosterone in serum. For lidocaine in plasma obtained from TDS®- 
Lidocaine study, the LC-MS-MS method has been developed and validated to show 
sensitivity, selectivity, accuracy, and precision. This method has improved upon the 
previously published methods in term of the amount of plasma used and the extraction 
strategy. The same method has been further validated and applied for the analysis of 
lidocaine in the dialysate. The method has been shown to be very sensitive as it is 
capable of analysing the small amount of dialysate from the DMD study (- 10 pL). 
A new method to analyse lidocaine in the tape samples from the DPK study has been 
developed and validated by using CE with UV detection. Available methods that have 
been published for the analysis of lidocaine by CE - UV are from the pharmaceutical 
formulation. The CE method developed for the analysis of lidocaine has been modified 
in terms of the capillary length to decrease the analysis time. Also the new extraction 
procedure for the tape samples has been introduced. Whilst for the analysis of 
testosterone in serum, the ELISA method that has been validated, and came in a kit 
which was used for it's the ease and simplicity without sacrificing accuracy and 
precision. To show the necessary accuracy and precision, the controls from a 
commercial company were used when performing the sample analysis. 
3) Explore and compare the various methods available to measure pharmacokinetic 
profiles of transdermal or topical drugs. 
The conventional pharmacokinetic drug measurements in plasma may not be suitable 
for the pharmacokinetic assessment of transdermal or topical drugs delivery as the drug 
is designed to target the local tissue. Hence, the comparison study performing systemic 
measurement, microdialysis and tape stripping has been conducted in 12 healthy 
subjects by using a local anaesthetic system, EMLATM cream as a model drug. In this 
project, the DPK and DMD methods have shown to be far more reliable than systemic 
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measurement for the pharmacokinetic assessment of a transdermal drug delivery 
system, especially a local anaesthetic. 
6.1 Clinical Trials of a new medicine 
Clinical trials as defined by Meinert (Meinert, 1986) are a research activity that involves 
the administration of a test treatment to some experimental unit in order to evaluate the 
treatment. Clinical trials of drugs can be defined as a research activity conducted via 
administration of a drug into healthy subjects or a particular type of patient in order to 
assess the drug's activity. Piantadosi (Piantadosi, 1997) simply defined a clinical trial is 
an experimental test of a medical treatment on human subjects. Refering to the above 
definitions, the investigation of a drug on animals is not considered to be clinical trials. 
Clinical trials involving healthy volunteers or patients have played an important role in 
the understanding, prevention, or treatment of the diseases. It is also a key aspect in the 
development of new medicines or modifications of the existing formulations. Three key 
aspects involved in the clinical trials are the subjects, the treatments, and the 
assessments. 
Subject refers to the study participants or targeted population, such as healthy 
volunteers in specific age groups, or a certain ethnic group of ethnicity. Subjects could 
also be patients with a certain type of disease, etc. The treatment refers to the study drug 
intended for evaluation. It can be an active ingredient or a placebo. Assessment refers to 
the evaluation of efficacy of the treatment. It can be a drug or medical device. Clinical 
trials also, sometimes assess the quality of patient life resulting from the treatment, 
pharmacogenomics, or pharmacoeconomic. In performing a clinical trial, clinical 
researchers need to develop the protocol. A protocol is a study plan that contains the 
details about the study to be carried out and how the samples or data are to be collected 
and analysed. The protocol is used as the basis of all clinical trials (ABPI, 2003). A 
proper plan including the drug handling, storage, randomisation, time frame of the 
study, etc. need to be included in the protocol. The protocol has to be reviewed by the 
Medicine and Healthcare products Regulatory Agency (MHRA), and approved by an 
Independent Ethics Committee. 
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6.2 History and regulations surrounding the clinical trials 
The Committee on Clinical Trials was formed by the Medical Research Council of the 
Great Britain in 1931 (Chow and Liu, 2004) to provide guidelines on the proper conduct 
of clinical trials. However the legal guidance on the conduct of trials only came into 
effect in the late twentieth century. Different laws and regulations have been enacted to 
ensure that clinical trials and their discoveries are effective and safe. A series of suspect 
medical interventions led to the establishment of the Nuremberg code in 1947 and the 
first Declaration of Helsinki in 1964. The Declaration of Helsinki has become an 
important document of ethical code to provide direction for physicians and other 
participants in medical research involving human subjects. Since then, the Declaration 
has been subsequently amended in the years 1975,1983,1989,1996,2000,2002, and 
2004 (World Medical Association, 2004). Many countries including the UK have 
adopted the Declaration of Helsinki into their clinical trial regulations and it forms part 
of Good Clinical Practice (GCP). 
Europen Union Directive 2001/20/EC of 4 April 2001 (Directive 2001/20/EC, 2001) for 
the implementation of good clinical practice (GCP) in the conduct of clinical trials on 
medicinal products for human use was published in May 2001 by the European 
Parliament and the Council of The European Union. It took about three years to 
incorporate into national legislation and compliance by May 2004. This EU Directive 
was incorporated into UK Law by means of `The Medicines for Human Use (Clinical 
Trials) Regulations 2004' (HMSO, 2004). UK Law now requires that all the trials must 
Adhere to the principles of GCP. The Directive requires the "competent authorities" of 
the Member States to perform certain functions in relation to clinical trials. In the UK, 
the competent authority responsible for those functions is the (MHRA). In relation to 
the above directive, the UK's current practice in the clinical trial has had major changes 
as detailed below (MHRA, 2004) 
" Pharmacology studies in healthy human volunteers (Phase I studies) require 
authorisation from the MHRA where previously they only needed a favourable 
opinion of an ethics committee; 
" Investigational medicinal products (IMPs) must be manufactured to good 
manufacturing practice (GMP) standards and the manufacturer must have a 
manufacturing licence; and 
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" Each trial must have an identified sponsor who takes responsibility for its 
initiation, management and conduct. The Regulations allow a group to 
collaborate to take on these responsibilities. 
The above changes have placed all the clinical trials in UK under a further layer of 
bureaucratic scrutiny. The Directive imposes a heavy burden of extra costs, complexity 
and paperwork upon universities and hospitals carrying out low-budget studies on 
medicinal products. With a large number of clinical trials conducted in the UK each 
year, it means that the process to obtain approval for one trial seems to be longer than 
ever. The UK is among the leading countries in the world in the development of 
medicinal products. Nearly a quarter of the world's top 100 medicines were developed 
in the UK (ABPI, 2003). With new legislation, it has caused a major delay to every 
clinical trial to be conducted. The two clinical studies in this PhD project (TDS®- 
Testosterone and TDS®-Melanotan) fell under the remit of the clinical trial regulations, 
therefore needed to comply with new legislation. To comply with all of the above 
requirements, the TDS®-Melanotan study was delayed for nearly one year beyond the 
original schedule. 
6.3 Pharmacokinetics and Pharmacodynamics 
Pharmacokinetic, often abbreviated to "PK" is a concept of describing and predicting 
the time course of a drug's action in the body. The word pharmacokinetics was 
originally derived from the Greek root pharmacon, a drug or poison, and kinetikos, 
meaning movement. Hence pharmacokinetics is a very important area in a drug delivery 
study as it provides the important information regarding the drug's behaviour in the 
body. This can be obtained through the four principles of PK, which are absorption, 
distribution, metabolism, and excretion or usually abbreviated to ADME. In other words 
pharmacokinetics explore how the body handles a foreign substance following it's 
administration into the body. 
Following drug administration, through oral, intravenous injection, trasdermal methods, 
etc., the goal is to achieve the desired therapeutic outcome. The desired therapeutic 
outcome only can be achieved if the amount of drug administered is sufficient enough to 
interact with the specific receptor site, which will then provide the response or outcome. 
The evaluation of the responses or outcomes from the results of a drug's reaction with 
the receptor sites with time is called pharmacodynamics. This means that any changes in 
pharmacokinetics will effects the pharmacodynamic outcomes. It is often assumes that 
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drug doses and the therapeutic effects or the outcome are linearly or log linearly related. 
This can be seen in the application of local anaesthetic, where the degree of anaesthesia 
is log linearly related to the lidocaine content in the skin as observed in microdialysis 
study of EMLA cream in this project. In addition, pharmacodynamic outcome is useful 
to support the pharmacokinetic data. 
6.4 Which pharmacokinetic methods for the study of 
transdermal drug delivery? 
The body can be represented as a series of compartments such as blood and tissue that 
have a close relationship between each other. In the compartmental analysis, the 
pharmacokinetics of drugs entering the body has always been evaluated through it's 
plasma/serum or sometime urine profiles. Theoretically, the pharmacokinetics of drugs 
should be evaluated at the receptor site, at which the drug binds for its action. However, 
this evaluation is not possible as some of the receptor sites for drugsare not clearly 
understood. Therefore the easiest way to assess a drug concentration related to its effect 
is via the blood. Blood is easily accessible and the concentration of drug in the blood is 
always in equilibrium with the receptor. 
For topical drugs that are designed to target the local tissue, it is quite clear that the 
receptor sites are located within the skin and probably at the application site. Therefore 
it is possible to monitor the drug profile directly at the receptor site rather than in blood. 
In recent years, various methods to monitor the pharmacokinetics of drugs within the 
local tissue have been established and evaluated including DMD, DPK, skin blister 
fluids methods, etc. Among them, DMD and DPK are widely used due to their 
reliability and convenience. Despite being widely and successfully used in drug delivery 
studies, the question arises as to why DMD and DPK are not yet accepted as the 
standard methods for the pharmacokinetic assessment of a transdermal drug. A few 
issues still need to be addressed before they can be regarded as generally applicable 
routine techniques for cutaneous drug delivery assessments. 
A major limitation of the DMD technique is the low recovery for molecules with large 
molecular weights such as insulin (Jansson et al., 1993) or those with a high 
lipophilicity (Groth, 1996). Sensitive analytical techniques such as LC-MS-MS are also 
required due to the small sample volumes and low drug concentrations obtained in the 
DMD experiments. High variabilities in the results obtained are also a subject of 
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argument against DMD. The implantation depth of the probe may contribute to the large 
variability of the pharmacokinetic parameters, as variability appears to be larger 
between individuals, compared to within individuals when multiple probes are used in a 
cutaneous drug penetration studies (Benfeldt and Serup, 1999; Kreilgaard, 
2001; Kreilgaard et al., 2001). (Kreilgaard, 2002) reported that large variability is often 
found in cutaneous drug delivery determined by the DMD technique (CV typically 50- 
100%). In a human microdialysis study, pharmacokinetic profiles of lidocaine were 
similar for paired DMD probes under the same application site (CV 4% of lag time). 
However, the inter-individual, CV 38% was obtained in the lag time result (Kreilgaard 
et al., 2001). The good reproducibility of the DMD technique for sampling in the skin 
and subcutaneous tissues was shown by lower variability of DMD following oral 
administration of acetaminophen in healthy subjects (Muller et al., 1995). In this study, 
the CV, 30% obtained for DMD was not substantially different from the variability of 
parameters determined directly from plasma samples. 
On the other hand, DPK is a method with great potential and requires thorough 
consideration as a pharmacokinetic method in the skin. Although DPK showed a good 
reproducibility and relatively is simple to perform, many factors remain to be 
investigated. There are many opportunities for experimental artifacts to develop. For 
example, tape strip samples have high surface area to volume ratios, and losses by 
evaporation can be significant especially for a volatile compound. The analysis of the 
samples should be completed soon after tape strip removal from the skin (Islam et al., 
1999) or to minimise this condition, the stripping tape should be kept in dry ice 
immediately after the stripping process for labile drugs 
Other factors that may contribute to the source of variation include the pressure applied 
to the tape prior to stripping, and the peeling force applied for removal. There are no 
standard methods to describe how the tape can be applied to the skin. This fact may 
increase inter-subject and inter-investigator variations if not given proper consideration. 
In the study by Saqib et al. (Bashir et al., 2001) they attempted to improve 
standardisation, quantifying the mass and thickness of stratum corneum removed by the 
tapes utilized. The tapes were pressed onto the skin with a standardised 10 kPa pressure 
for 2 seconds. This study provides clear guidance on how to standardise the amount of 
SC removed. The study also quantified the mass of SC removed for different types of 
tapes and at different sites. For the DPK performed on the dorsal and volar forearm of 
each subject, with three types of tape (D-Squame®, Transpore®, and Micropore®) there 
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was no significant difference in the amount of SC removed by any of the tapes utilised, 
although there was a difference in the degree of barrier disruption to water. Also there 
was no significant difference in the amount of SC removed between the dorsal and the 
ventral site for each tape. The conclusion made following this study is for the tapes and 
sites tested, neither the site nor the type of tape significantly influenced the mass of SC 
removed by the tapes. 
Another factor that can influence the amount of stratum corneum that can be removed 
by a piece of tape is the existence of furrows in the human epidermis. Van der Molen 
(van der Molen et al., 1997) validated the tape-stripping method with X-ray 
microanalysis in the mapping mode by scanning electron microscopy using Ti02 as a 
marker. They have found that Ti02 applied on the skin still present even after ten tapes 
were stripped and specifically located on the rim of the furrows. A histological section 
that was tape stripped 20 times also showed non-stripped skin in the furrows. This 
finding gave some impact to the question concerning concerns regarding consistency of 
the tape stripping method. If the materials applied to the skin accumulated in the 
furrows, the interpretation of the tape stripping result will have a slight variation. This 
consequence is very important, especially when performing the bioequivalence study. 
Recent publication by Shah (Shah, 2005) on the in vitro-in vivo correlation for topically 
applied preparations contained a contradiction results of DPK study. The results of a 
bioequivalence tretinoin + isotretinoin (Ortho and Bertek products) study conducted by 
Franz (FDA, 2001 a) and Pershing (Pershing et al., 2003) on the same brand were found 
them to be different. Although the two studies obtained the same conclusion of 
bioinequivalence, the order of DPK profiles of the two products was reversed in the two 
studies. Pershing's study showed that the Ortho product had a higher DPK profile than 
Bertek, but Franz's study showed the opposite. These contradictory results have had an 
adverse impact on the perceived reliability and accuracy of the DPK method. 
6.5 Progress in transdermal delivery system 
The development of alternative routes of drug administration, such as a transdermal 
route compared to the conventional oral route has gained considerable importance 
during the recent decade. Transdermal delivery systems have been evaluated for more 
than 20 years, since the first scopolamine patches for the prevention of motion sickness, 
approved in 1979 (Langer, 2004). It is now regarded as one of the important routes for 
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drug administration especially for orally problematic drugs. The transdermal delivery 
systems such as patches, cream, ointment, liquid formulations, or gel have been widely 
discussed as the most popular mode of application in transdermal drug technology. 
However, there are a few more systems currently under investigation that have potential 
to be a powerful drug delivery system such as a liposomal drug delivery sytem, 
iontophoresis, magnetophoresis, sonophoresis, etc. 
Liposomes, also known as lipid vesicles, which fully surround by an aqueous volume. 
Liposomes can trap hydrophilic molecules within their aqueous region. Liposome 
structures are made of amphiphilies which can be characterised by a hydrophilic (head), 
and hydrophobic (tale) (Yarosh, 2001). When created, the hydrophilic heads align along 
the vesicle surface with hydrophobic tales pointed inward. Multilamellar vesicles can be 
created by repeating this pattern. Liposomes were first used in transdermal delivery by 
(Mezei and Gulasekharam, 1980). Encapsulation of a drug into a lipid vesicle can 
increase the drug permeation across the skin. Various liposomes have been evaluated 
for transdermal delivery such as topical anaesthesia (Fisher et at., 1998), liposomal 
tacrolimus (Dutta et at., 1998), liposomal triamcinolone acetonide (Abraham et al., 
1983), inhaled liposome-encapsulated fentanyl (Hung et at., 1995), etc. also showed a 
good result. There are many other `somes' that have been evaluated such as ethosomes 
(Dayan and Touitou, 2000; Touitou et at., 2000), niosomes (Uchegbu et al., 1994), etc. 
With all of the positive results obtained, liposomal delivery system might be useful in 
the treatment of various skin diseases (Schmid and Korting, 1994). 
The most significant progressions in transdermal delivery have been seen in the 
application of electrical potential gradient to move charged of drug molecules across the 
skin. Iontophoresis has been shown recently, to provide enhanced transportation for 
topically applied therapeutic agents (Fang et al., 2000; Huang et at., 2005; Jaw et al., 
1995). The combination of iontophoresis with chemical penetration enhancers such as 
sodium dodecyl sulphate also increased the drug flux as studied by (Wang et at., 2000b) 
on the delivery of hydrocortisone . Electroporation like iontophoresis, involves the 
application of electric pulses to the skin which has been suggested to induce the 
formation of transient pores. The pores are responsible for an increase in skin 
permeability (Weaver et al., 1999). Magnetophoresis, by using magnetic fields to 
deliver drug through the skin has also has been evaluated. It has been shown that 
increasing the magnetic field can increase the diffusion flux of a drug (Murthy, 1999). 
Low-frequency ultrasound was also shown to increase the permeability of human skin 
It . Page 183 of 249 
General Discussion 
to many drugs, including high molecular weight proteins such as insulin (Mitragotri et 
al., 1995). 
6.6 Hypogonadism: The treatments and the consequences 
Male hypogonadism is a disturbing factor which significantly reduces quality of life. 
Hypogonadism can affect men at any stage of life, but is mostly seen through ageing. 
Ageing can be a major cause of testosterone deficiency. (Vermeulen and Kaufman, 
1995) estimate that 7% of men aged 40-60 years have serum total testosterone 
concentrations of < 12 nmol/L, and this percentage increases to 21% and 35% of 60-80 
and > 80 year olds, respectively. Many hypogonadism patients are untreated due to lack 
of diagnosis or possibly due to the taboo surrounding `maleness' and sexuality 
(Nieschlag et al., 2004). Testosterone replacement therapy is the only option for the 
treatment of hypogonadism. 
Although hypogonadism can be treated by using testosterone replacement therapy, most 
of the therapies that have been developed were not really effective or were inconvenient 
to the patients as widely discussed in Chapter 3. Among the many treatments options for 
hypogonadism, only the transdermal preparation is widely used due to its effectiveness 
and convenience of use. Testosterone gel formulations provide stable levels of serum 
testosterone within the normal range, and little skin irritation compared to patches. The 
only deficiency of testosterone gel treatment is the possibility of transfer of testosterone 
from the patient to another person if there is skin contact at the application site, and the 
application site cannot be washed for several hours after application. According to the 
World Health Organisation Guidelines for use of Androgens in Men (1992) (Nieschlag 
et al., 2004), the ideal testosterone replacement therapy should offer: safety, efficacy, 
value for money, convenience, a good release profile, dosing, flexibility, and effective 
normalisation of testosterone levels. Refering to this definition, none of the currently 
available replacement therapies can be considered as an ideal therapy. TDS® - 
Testosterone is hoped to be an ideal testosterone replacement therapy as the results 
obtained in this PhD project are considerably promising. 
Although testosterone replacement therapy can successfully restore the physiological 
level of testosterone, there are some adverse events reported following the treatments. 
Some of the testosterone replacement therapies as mentioned above have been reported 
to cause some adverse side effects including gynaecomastia, polycythemia, weight gain, 
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and increased prostate size (Arver et al., 1996; Dobs et al., 1999; Meikle et al., 1997). A 
change in lipid profile has also been noted, such as decreased HDL-cholesterol and 
increased LDL-cholesterol under testosterone replacement therapy (Jockenhovel et al., 
1999). In the meta analysis of 19 studies associated with testosterone replacement and 
males >_ 45 years old, a significantly higher cases of adverse events were recorded for 
the replacement therapy (Calof et al., 2005). The combined rates of all prostate events 
were found to be higher in testosterone-treated men than in placebo-treated men. Rates 
of prostate cancer, prostate-specific antigen, and prostate biopsies were also higher in 
the testosterone group rather than in the placebo group. Testosterone treated men are 
also nearly four times as likely to have a hematocrit level of > 50 % higher than placebo 
treated men. 
6.7 Conclusion 
The end of the 20th Century had seen an explosion in the discovery of medicinal 
products. These included the development of new drugs or modifications of existing 
drugs. The development of new drugs is essential due to the increasing number of 
untreated diseases and for the enhancement of the quality if life. Modifications of an 
existing drug include improvement in the formulations or the creation of new delivery 
systems to enable the drug to be more effective. Progress in the drug delivery has seen 
transdermal delivery method became increasingly popular especially for the various 
skin treatments and for systemic delivery of orally problematic drugs as discussed in the 
earlier chapters. 
The TDS® delivery system has been created to offer this advantage and act as 
alternative to the oral and other delivery systems. The TDS® system has been found to 
be effective in transporting lidocaine and testosterone through the skin in this project. 
However, the delivery of the peptide drug, MT I cannot be confirmed until the plasma 
samples obtained from the study are assayed. The phase II pharmacokinetic study of 
TDS®-Testosterone in hypogonadal patients is essential for further development of this 
system as a hormone replacement therapy. A proper pharmacokinetic study in healthy 
subjects is needed for the future development of TDS®-Lidocaine as a local anaesthetic 
system. The outcomes from this project give an early indication of the future acceptance 
of the TDS® system which can be combined with any drugs to form a powerful tool in 
drug delivery. 
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The requirement to develop analytical techniques that are sensitive, accurate and have 
short analysis time is important. Simple and effective analytical techniques should be 
available to cope with the increasing number of drugs being developed. This has led to a 
growing number of immunoassay techniques which are as reliable and comparable in 
costs to chromatographic techniques. 
The increasing number of developing transdermal drug delivery systems has also 
contributed to the establishment of a few methods to study the behaviours of the drugs 
in the body. In vivo methods for the pharmacokinetic assessment of topical drug 
products such as DMD and DPK have been studied extensively for transdermal delivery 
drugs. These methods have been shown to offer clinically relevant advantages over 
conventional systemic measurements in blood. From the overall perspective, DMD and 
DPK have the potential to be standardised as pharmacokinetic methods for transdermal 
drugs, but thorough consideration of certain aspects of the methods are necessary for 
their validity. 
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Appendix 1 Ethics approval letter for TDS®-Lidocaine study 
North East London 
Health Authority 
Aneurin Bevan House 
81 Commercial Road 
London E1 IRD 
Tel: 020 7655 6600 
Arthur T. Tucker PhD SRCS Fax: 020 7655 6666 
Research Scientist 
The Ernest Cooke Clinical Microvascular Unit 
4"' Floor, Dominion House 
Department of Clinical Physics 
Clinical Support Services St Bartholomew's Hospital 
London EC1A 7BE 
Our Ref: RS/SA/P1021/087 8th August 2002 
Dear Mr Tucker 
Re: P1021087-Study of a combined percutaneous local anaesthetic and the 
TDS system for venepuncture 
Thank you for your letter dated 30th July 2002 regarding the above protocol. I 
acknowledge that the following have been received and added to our files: 
" Details of the Medicines Control Agency Exemption Certificate (DDX) 
" Indemnity cover for both the BLT and the Medical School. 
As written confirmation of indemnity has now been received, you may proceed with the 
study. 
I can also confirm approval under Chairman's Action on behalf of the North East London 
Research Ethics Committee to your proposal of using internal e-mail to recruit 
volunteers to the study. 
You ncerely 
Mr Richard Smith 
Chairman 
North East London Research Ethics Committee 
Chairman: Professor Elaine Murphy 
Chief Executive: Carolyn Regan 
, Covering the London Boroughs of Barking and Dagenham. Hackney, Havering, Newham, 
Redbridge, Tower Hamlets, Waltham Forest and the Corporation of London 
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Appendix 2 Ethics approval letter for TDS®-Testosterone study 
m 
East London and The City Local Research Ethics Committee 
Aneudn Bevan House, 81 Commercial Road, London El 1RD 
Telephone Number: 020 7 655 6622 
Fax Number: 020 7 655 6678 
Email Address: Sand, 
. 
Burke[a)nebndon. nhs uk 
Arthur Tucker PhD SRCS 
Research Scientist 
The Ernest Cooke Clinical Microvascular Unit 
4" Floor, Dominion House 
Department of Clinical Physics 
Clinical Support Services 
St Bartholomew's Hospital 
London ECIA 7BE 
Our Ref RS/SB/P03180 9'" October 2003 
Dear Dr Tucker 
Re: P/031180 - Study of a combined percutaneous testosterone and the TDS 
System for hormone replacement 
Thank you for your recent letter addressing the points of the Committee's earlier letter. 
am happy to tell you that I am now able to approve this study on Chairman's action to be 
noted at future meeting of the Committee. 
Please note the following conditions to the approval: 
1. The Committee's approval is for the length of time specified In your application. II 
you expect your project to take longer to complete 0. e. collection of data), a letter 
from the principal Investigator to the Chairman will be required to further extend 
the research. This will help the Committee to maintain comprehensive records. 
2. Any changes to the protocol must be notified to the Committee. Such changes 
may not be implemented without the Committee or Chairman's approval. 
3. The Committee should be notified immediately of any serious adverse events or 
if the study is terminated prematurely. 
4. You are responsible for consulting with colleagues and/or other groups who may 
be involved or affected by the research, such as extra work for laboratories. 
5. You must ensure that, where appropriate, nursing and other staff are made 
aware that research in progress on patients with whom they are concerned has 
been approved by the Committee. 
6. The Committee should be sent one copy of any publication arising from your 
study, or a summary If there is to be no publication. 
An advisory committee to North East London Strategic Health Authority 
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I should be grateful if you would inform all concerned with the study of the above 
decision: 
Your application has been approved on the understanding that you comply with Good 
Clinical Practice and that all raw data is retained and available for inspection for 15 
years. 
Please quote the above study number In any future related correspondence. 
Yours sincerely 
P. p. Senior Administrator 
MR RICHARD SMITH 
Chairman 
East London and The City Research Ethics Committee 
An advisory committee to North East London Strategic Health Authority 
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Appendix 3 Ethics approval letter lör comparative pharmacokinrtir study of 
dermatopharmacokinetic, microdialysis and systemic measurement 
East London & The City HA Local Research Ethics Committee 3 
3rd Floor, Aneunn Bevan House 
81-91 Commercial Road 
London 
El 1RD 
Telephone 020 7655 6812 
Facsimile 020 7655 6655 
09 September 2005 
Professor Atholl Johnston 
Professor of Clinical Pharmacology 
Barts and The London, Queen MaryaET'As School of Medicine & Dentistry 
Clinical Pharmacology 
William Harvey Research Institute 
Charterhouse Square, London 
EC1M6BQ 
Dear Professor Johnston 
Full title of study: Comparative pharmacokinetic study of a combined 
percutaneous local anaesthetic/Nitric Oxide generating 
system and EMLA cream: Evaluation by systemic 
measurement, skin stripping and microdialysis 
REC reference number: 05/Q0605/98 
Thank you for your letter of 08 September 2005, responding to the Committee's request for 
further information on the above research and submitting revised documentation. 
The further information has been considered on behalf of the Committee by the Chair 
Confirmation of ethical opinion 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised. 
The favourable opinion applies to the research sites listed on the attached form. Confirmation 
of approval for other sites listed in the application will be issued as soon as local assessors 
have confirmed they have no objection. 
Conditions of approval 
The favourable opinion is given provided that you comply with the conditions set out in the 
attached document. You are advised to study the conditions carefully. 
Approved documents 
Page 21 () of'249 
The final list of documents reviewed and approved by the Committee is as follows: 
Appendices 
051QO605/98 
Copies of Advertisements 1 03 May 2005 
GP/Consultant Information Sheets 1 25 April 2005 
Participant Information Sheet 2 (None Specified) 
Participant Consent Form 2 03 May 2005 
Response to Request for Further Information 19 Au st 2005 
Response to Request for Further Information 08 September 
2005 
Patients Information Sheet 2 08 September 
2005 
e-mail from MHRA 17 August 2005 
Covering Letter 1 04 May 2005 
Checklist 2 03 May 2005 
Letter to Sponsor 1 25 A rd 2005 
Letter to Clinical Trials Unit 1 04 May 2005 
Letter to R&D - Indemnity 1 25 A rä 2005 
Management approval 
The study should not commence at any NHS site until the local Principal Investigator has 
obtained final management approval from the R&D Department for the relevant NHS care 
organisation. 
Membership of the Committee 
The members of the Ethics Committee who were present at the meeting are listed on the 
attached sheet. 
Notification of other bodies 
The Committee Administrator will notify the research that the study has a favourable ethical 
opinion. 
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
05/Q0605198 Please quote this number on all correspondence 
With the Committee's best wishes for the success of this project, 
Yours sincerely 
Dr David Ingram 
Chair 
Email: sandra. grote©nelondon. nhs. uk 
SF1 list of approved Rea 
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Appendix 4 Ethics approval letter for TDS®-Melanotan study 
f ty- / RIff 
Dr AT Tucker 
The Ernest Cooke Clinical Microvascular Unit 
4s' Floor, Dominion House 
Department of Clinical Physics 
Clinical Support Services 
St Bartholomew's Hospital 
London EC1A 7BE 
11 November 2004 
Dear Dr Tucker 
ST THOMAS' HOSPITAL 
RESEARCH ETHICS COMMITTEE 
Ethics Committee Office 
Block 5, South Wing, 
St Thomas' Hospital 
London SEI 7EH 
Chairman - Dr A Hopper! Dr AJ Williams 
Administrator " Ms 3 Hirsch 
Phone: 020 7188 2257 
Fax: 020 7188 2238 
Email: Stella. hirsch©ystt. sthamss. nhs. uk 
REC reference number: 04/Q0702/120 
Full title of study: A Dose-Escalation study of topical application of T S-Melanotan to Assess the 
Pharmocokinetlcs and skin melanin density to Healthy Adult Subjects 
Thank you for your letter of 10 November 2004, responding to the Committee's request for 
further information on the above research. 
The further information has been considered on behalf of the Committee by the Chairman on 
11 November 2004. 
Confirmation of ethical opinion 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation. 
The favourable opinion applies to the following research site: 
Site: Barts and the London NHS Trust, Barts and the London School of Medicine and Dentistry 
Chiel7Principal Investigator: Dr Charlotte Mary Proby Consultant Dermatologist & Senior Lecturer 
Conditions of approval 
The favourable opinion is given provided that you comply with the conditions set out in the 
attached document. You are advised to study the conditions carefully. 
Approved documents 
The final list of documents reviewed and approved by the Committee is as follows: 
Document Type: Application 
Dated: 24)09/2004 
Date Received: 06/10/2004 
Document Type: Investigator CV 
Dated: 24109/2004 
Data Received: 04/10/2064 
Document Type: Protocol 
Version: 4.3 
Dated: 16/09/2004 
Date Received: 04/'. 0/2004 
An advisory committee to South East London Strategic Health Authority 
rage L 14 01 L4Y 
Appendices 
Document Type: Covering Letter 
Dated: 2010912004 
Date Received: 04/10/2004 
Document Type: Sumtury/Synopsis 
Version: 4.3 
Dated: 16)09/2004 
Date Received: 04/10/2004 
Document Type: Letter from Sponsor 
Dated: 29/09/2004 
Date Received: 04/10/2004 
Document Type: Peer Review 
Dated: 0'7)09)2004 
Date Received; 04/111/2004 
Document Type: Compensation Arrangements 
Dated: 06/108004 
Date Received: 06/10/2004 
Document Type: Sample Diary/Patient Card 
Venion: 1.0 
Dated: 16109/2004 
Date Received: 04/10! 2004 
Document Type: Copies of Advertisements 
Version: 1.0 
Dated: 16/09/2004 
Date Received: 04/10! 2004 
Document Type: OP/Consultant Information Sheets 
Version: 1.0 
Dated: 16/09! 2004 
Date Received: 04/102004 
Document Type: Participant Information Sheet 
Version: 1.1 
Dated: 10/11/2004 
Date Received: 11111/2004 
Document Type: Participant Consent Farm 
Versdon: 1.0 
Dated: 16/09/2004 
Date Received: 04/10/2004 
Document Type: Investigator's Brochure 
Version: Edition No: 6 
Dated: 14/0512004 
Date Received: 04/10/2004 
Document Type: Response to Request for Further Information 
Dated: 10/11/2004 
Date Received; 11/1 1)2004 
Management approval 
The study may not commence until final management approval has been confirmed by the 
organisation hosting the research. 
All researchers and research collaborators who will be participating in the research must 
obtain management approval from the relevant host organisation before commencing any 
research procedures. Where a substantive contract is not held with the host organisation, it 
may be necessary for an honorary contract to be issued before approval for the research can be 
given. 
An advisory committee to South East London Strategic Health Authority 
. Page 215 of 249 10 
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Notification of other bodies 
We shall notify the research sponsor, Barts and the London School of Medicine and Dentistry 
that the study has a favourable ethical opinion. 
Statement of compliance (from I May 2004) 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees (July 2001) and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK 
REC reference number: 04/00702/120 Please quote this number on all correspondence 
Yours sincerely, 
rJ Williams 
Chairman 
Enclosed: Standard approval conditions SL-AC2 
Membership list 
Copy: R&D 
An advisory committee to South East London Strategic Health Authority 
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Appendix 5 Informed consent form (sample) 
WRITTEN CONSENT FORM: REC Number: 051Q0605/98 Ver. 3.1 
Title of research proposal: Study of a combined percutaneous local anaesthetic/Nitric Oxide 
generating system and EMLA cream: Evaluation by systemic measurement, skin stripping and 
microdialysis. 
Name of Patient / Volunteer (Block Capitals): 
Address: 
The study organisers have invited me to take part in this research. 
I understand what is in the leaflet about the research. 
I have a copy of the Patient's Information leaflet version 5.0 to keep. 
I have had the chance to talk and ask questions about the study. 
know what my part will be in the study and I know how long it will take. 
I have been told about any special drugs, operations, tests or other checks I might be given. C 
I know how the study may affect me. I have been told if there are possible risks. 
I understand that I should not take part in more than one study at a time. I know that the 
local North East London and City Health Authority Research Ethics Committee 
Has seen and agreed to this study. 
I understand that personal information is strictly confidential: I know the only people who may 
see information about my part in the study are the research team or an official representative 
of the organisation which funded the research. 
I freely consent to be a subject in the study. No-one has put pressure on me. 
I know that I can stop taking part in the study at any time. 
I 
know that if there are any problems, I can contact: C 
Prof. Atholl Johnston Dr Arthur T. Tucker 
Department of Clinical Pharmacology, 
William Harvey Research Institute, 
Charterhouse Square, 
London. EC1M 6BQ. 
The Ernest Cooke Clinical Microvascular 
4th Floor Dominion House, 
St. Bartholomew's Hospital, 
London. EC1A 7BE. 
rel. No: (020) 78823414 
Patient's /Volunteer's Signature: 
(020) 76018498 
................. Date:............................................. 
The following should be signed by the Clinician/Investigator responsible for obtaining consent 
As the Clinician / Investigator responsible for this research or a designated deputy, 
I confirm that I have explained to the patient / volunteer named above the nature and 
purpose of the research to be undertaken. 
Investigator's Name seeking consent: ................................................... 
Investigator's Signature: ........................................................ Date:............................. 
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Appendix 6 Study Information Sheet (sample) 
Study of a combined percutaneous local anaesthetic/Nitric Oxide generating system 
and EMLA cream: Evaluation by systemic measurement, skin stripping and 
microdialysis. 
Lay title: "Study of skin anaesthetic drug delivery" 
Study no. : 05/LA 003/01 
Invitation to participate in a Research Project 
We invite you to take part in a research project, which we think may be important. 
The information, which follows, tells you about it. It is important that you understand 
what is in this leaflet. It says what will happen if you take part and what the risks 
might be. Try to make sure you know what will happen to you if you decide to take 
part. Whether or not you do take part in the study is entirely your choice. Please ask 
any questions you want to know about the research and we will try our best to 
answer them. 
Why have we approached you? 
Procedures which involve insertion of needles through the skin are commonly 
perceived as painful and may lead to apprehension and anxiety, especially in 
children. Bad experiences with needles can often lead to problems with future 
procedures. The introductions of anaesthetic creams, which are applied on the skin 
have been a great help. However, current anaesthetic creams are slow to have an 
effect (30 minutes to 1% hours) and this may lead to difficulties in organising clinics, 
wards and operating theatre routines around their application time. A local 
anaesthetic cream with a more rapid effect would be an important development both 
for the patient and for the smooth running of hospital procedures. 
Nitric Oxide [NO] is a simple gas of huge importance for the circulation system and it 
was also found to exert a series of other functions. We know today that NO also acts 
as a signal in the nervous system, as a weapon against infections, as a controller of 
blood pressure and blood flow. NO is present in most living creatures and made by 
many different types of cells. We have found a simple way of making NO by 
combining two substances together (Sodium nitrite and Vitamin C). We have already 
found that this mixture increases blood flow when placed on the skin and is very safe. 
Lidocaine has been used for many years as a local anaesthetic. Normally it takes a 
very long time to penetrate skin and hence it is mainly given by injection. In this 
study, we will mix the nitric oxide system with lidocaine, apply it onto your skin, and 
carry out a series of studies called "pharmacokinetics" in order to measure the 
effectiveness of the system. We believe that the nitric oxide produced by this system 
may increase the speed of penetration of lidocaine and produce a more rapid 
anaesthesia. We will compare this new drug mixture with EMLA cream. EMLA cream 
is a local anaesthetic skin cream currently used for skin anaesthesia in the 
venepuncture and minor procedure. 
Most drug content studies in the body are normally done by the measurement of 
blood. However, measurement of a drug in the blood is not always useful for 
evaluating skin-based medications (especially local skin anaesthetics). Anaesthetics 
designed to target the local skin to which they are applied do not readily diffuse into 
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the rest of the body and the blood system. For this reason normal methods of drug 
measurement using blood samples have proved unhelpful. 
In this study, we will therefore measure the amount of drug in the surface layers of 
the skin using adhesive tape and a needle procedure, called microdialysis This will 
allow us to carefully compare the drug levels in the blood with the drug levels in the 
skin at any moment in time. We will then be able to decide which of the methods is 
most effective. 
Microdialysis is a technique which allows measurement of the amount of the test drug 
in the skin itself and involves placing a special needle (or cannula) under the skin for 
the duration of the study. This is a safe procedure, but you may feel some transient 
discomfort when the needle is inserted. Skin samples are taken with normal everyday 
sticky tape by applying and then removing the tape. This results in removal of those 
outermost layers of the surface of skin which are normally shed into clothing during 
the course of the day. Both methods will allow measurement of the varying amount 
of drug in the skin during the study period. 
The main purpose of this study is to find the best technique for measuring the dose 
and effectiveness of skin based drug delivery. The results from this study will, 
however, also be of indirect benefit as they may lead to improvements in anaesthetic 
delivery systems for clinical use. 
What would I do in the study, if I took part? 
If you agree to take part, we will take a detailed medical and a physical examination, 
including blood pressure, pulse rate and rhythm. Signs of drug and alcohol abuse will 
also be checked. We will treat all the drug screening results as confidential and 
the results will not be used for any purpose other than inclusion or exclusion 
from this study. 
The study involves three visits with a minimum of one-week gap in between. The 
study will last for the maximum of six hours for every visit. 
Visit 1: Microdialysis and systemic measurement of EMLA 
Upon entry to the study ward for the initiation of the study, we will check your blood 
pressure and heart rate. The hairs from forearm on both of your arms will be removed 
by using a shaver and thoroughly cleaned with water and wiped dry with a towel. 
Your arms will be checked for cuts or scrapes which could complicate the study. You 
will be asked to lay down on a bed and we will start by inserting a small cannula (a 
small tube, same size as a blood test needle) into a vein in your arm. By using the 
cannula we will be able to take regular small blood samples during the study without 
having to insert a blood test needle each time. 
On your other arm, a circular area of 10 cm2 will be marked with a pen in the centre 
of the forearm. The microdialysis guide needle will be inserted in the just under the 
skin about 1 cm from the marked area. The microdialysis probe will be inserted 
through the tip of needle, which is then removed, leaving the probe (about 3 cm long) 
below the marked area. Inlet and outlet tubing will be attached to the sampling probe 
and secured to the skin using adhesive tape. The inlet tube will be connected to the 
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microdialysis pump and the outlet tubing connected to a small collection pot. You will 
have to carry the pump (about the size of a mobile phone) with you during the study. 
This pump moves a special liquid through the probe in order to measure the drug 
concentration in the skin. Please take care of it. These are safe procedures, but you 
may feel some discomfort when the needles are inserted, which should quickly fade 
After the microdialysis probe implantation, you will be allowed to rest for 60 minutes 
to allow the skin to recover before the start of the measurements. For 20 min a 
special fluid will be pumped through the microdialysis probe and collected for later 
testing. This fluid is very safe, used frequently in research and, in fact, you will not 
even notice this pumping through implant. A five-millilitre blood sample (about a 
teaspoon full) will also be collected from the needle in your other arm. After these 
measurements, the test drug (EMLA cream) will be applied to the skin at the marked 
area and covered with a dressing for 1 hour. After one hour, the remaining drug will 
be removed and your skin gently cleaned. The special fluid will be passed through 
the microdialysis probe and collected for 4 hours after the drug is applied. Five 
millilitre blood samples (about a teaspoon full) will be collected at 20 and 40 minutes 
and at 1,1.5,2,2.5,3,3.5, and 4 hours after applying the drug. 
At the end of the study day, we will remove the small cannula and the microdialysis 
probe from your arms and put on a dressing before you leave to prevent bleeding. 
One week later you will come again for tape stripping study. 
Visit 2: Tape stripping study 
In this study, we will measure the amount of the drugs, which enter the outermost 
layers of skin (known as the "stratum corneum"). We will mark nine 2x3 cm 
rectangular sites (sites 1-9), on your forearms which is used for microdialysis study, 
with a pen. Site 1, positioned 3 cm above the elbow will be served as a control (no 
drug). One gram of EMLA cream will be applied on all the sites 2 to 9. We will 
remove the cream from the application site at 15,30,45 min., and 1h. We will 
perform the tape strip at 0,15,30,45 min., 1,1.5,2,3, and 4 h. Before performing 
the tape strip, we will measure the effectiveness of the anaesthetic by assessing your 
abilty to perceive a small pinprick in the areas of the drug application on your skin. 
We will ask you about any sensation you feel by touching your skin with the needle 
(without puncturing it) and ask you a few questions about what you felt. 
Visit 3 and 4: NO Lidocaine study 
After a minimum of one week from visit 2, you will come again to repeat the above 
procedures with NO Lidocaine treatment 
" If you have any medical problems or have to take any medicines, e. g. a course 
of antibiotics, during the two weeks before the study or during the time 
immediately afterwards it is important that you let us know as soon as 
possible. 
If you have any problems after the study you should contact Dr Art Tucker (020) 
7601 8498 or Professor Atholl Johnston in the Clinical Pharmacology Department 
(020) 7882 3413. Outside working hours you can contact us via the hospital 
switchboard. 
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The study has been seen and approved by the local East London and City Authority 
Research Ethics committee. Any personal information will remain strictly confidential. 
If you agree to join the study we will notify your GP that you are taking part. 
If you feel any discomfort during the investigations, you must say so and we 
will stop the tests at any time. 
Will this study help me? 
This study may not benefit to you directly. It may, however, lead to the development 
of more effective skin anaesthesia. 
Will I be paid? 
For attending the Screening session we will compensate you with £10-00. Having 
completed the first two visits, we will pay you £100-00 and pay you another £100-00 
if you completed the visit 3 and 4. 
Could I come to any harm if I take part in the study? 
The doses of the drugs have been chosen so that it should cause an effect only on 
the skin of your hands and not the rest of your body. The two substances used in the 
gels have both been used already in patients and volunteers for other reasons. 
Ascorbic acid (Vitamin C) is used as a vitamin supplement and is known to be safe. 
Sodium nitrite is used for the treatment of chemical poisoning. 
The anaesthetic (lidocaine) used in this study has been used safely for many years 
and is used at a very low concentration. 
EMLA cream is safe and widely used currently as a skin-based local anaesthetic. 
There are very few risks involved in inserting a needle into a vein in the hand for 
venous sampling and subcutaneous tissue for microdialysis sampling. You may feel 
transient pain when the needle is placed under the skin which is similar to having a 
blood test. You may also experience discomfort and there may be a small bruise 
around the area which may last for a couple of days. 
If you feel unacceptable discomfort or for any reason you do not wish to continue, than 
we will stop the test immediately. 
Are there any factors which would exclude me from taking part in the 
research? (and which are not known by the investigators) e. g. Pregnancy or 
other medications. 
We need to know whether you are taking any medication or if you have had any 
reactions to drugs in the past as this may also exclude you from the study. 
There may be a risk that taking part in this trial might harm an unborn child and 
therefore pregnant women will not be included in this study. If you think that there is 
any chance that you might be pregnant, please inform the investigator and, with your 
consent, a pregnancy test will be performed. 
You should not take part in this study if you are already involved in any other study. 
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You will also not be able to take part in the study if you are taking drugs of abuse, 
either short or long term. 
How will confidentiality be protected? 
All the information obtained about you in the course of the study is confidential and 
will be kept in a locked room. Only the investigators will have access to the data. 
The investigators performing the study will have access to the data collected in this 
study. Official representatives of the Drug Regulatory Authorities may at some stage in 
the future request access to the data collected in this study. You will not be identifiable 
in any publication arising from the study. 
If you would like more information about the study or are worried about any aspect of 
it please feel free to contact: 
Dr Arthur Tucker 
Ernest Cooke Clinical Microvascular 
Unit, 
4th floor, Dominion House, 
St Bartholomew's Hospital, 
London ECIA 7BE. 
Tel No. (020) 7601 8498 
Mr. Zamri Chik 
Clinical Pharmacology, 
William Harvey Research 
Institute, 
Charterhouse Square, 
London EC1M 6BQ. 
Tel No. (020) 7882 3413 
You don't have to join the study. You are free to decide not to be in this trial or to 
drop out at any time. 
What happens if you are worried or if there is an emergency? 
You will always be able to contact an investigator to discuss your concerns and/or to 
get help 
Name: Prof. Atholl Johnston 
Post: Professor of Clinical Pharmacology 
Address: Department of Clinical Pharmacology, Charterhouse Square, 
London. 
Telephone/Fax: (020) 7882 3413 
What happens if something goes wrong? 
We believe that this study is basically safe and do not expect you to suffer any harm 
or injury because of your participation in it. However, we carry insurance to make 
sure that if your health does suffer as a result of your being in the study, then you will 
be compensated. In such a situation, you will not have to prove that the harm or 
injury, which affects you, is anyone's fault. If you are not happy with any proposed 
compensation, you may have to pursue your claim through legal action. 
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Appendix 10 Raw data of pain score (VAS and VRS) for TDS®- B in Chapter 2 
Subject Sex Age Treatment/ Result 
TDS"- B (Active) TDSL- ß (Placebo) 
VRS VAS VRS VAS 
(Y) (Unit) (mm) (Unit) (mm) 
1 F 25 4 48 2 11 
2 F 34 4 62 3 46 
3 M 30 4 71 4 82 
4 F 29 3 38 2 13 
5 M 23 4 71 3 39 
6 F 28 3 35 3 30 
7 F 32 3 23 4 41 
8 F 30 4 34 4 46 
9 M 28 2 22 3 29 
10 M 23 2 21 5 76 
11 F 36 4 63 3 47 
12 F 26 3 45 4 69 
13 M 23 2 26 3 48 
14 F 32 4 72 4 65 
15 M 35 2 30 3 38 
16 F 29 2 16 3 70 
17 M 25 2 18 3 44 
18 M 31 3 39 3 39 
19 F 33 4 71 5 88 
20 F 28 4 57 4 64 
21 F 28 3 46 4 76 
22 F 40 3 27 4 41 
23 F 32 2 22 3 50 
24 F 24 3 24 2 1 
25 F 23 3 39 3 53 
26 F 23 4 77 3 48 
27 F 23 4 74 4 86 
28 F 27 4 74 2 22 
29 F 23 3 41 4 63 
30 F 25 2 30 4 53 
31 M 37 3 29 2 7 
32 F 30 2 26 4 58 
33 M 29 2 38 3 47 
34 F 31 3 18 4 51 
35 F 42 3 41 3 42 
36 M 26 4 52 2 25 
37 M 29 2 38 2 14 
38 F 34 3 48 2 24 
39 M 22 3 33 3 40 
40 M 25 2 22 4 60 
41 M 38 2 24 2 23 
42 M 21 3 52 2 22 
43 M 32 3 34 3 31 
44 F 30 4 59 2 25 
45 F 21 3 30 3 16 
46 F 21 2 18 3 27 
47 F 27 2 27 4 60 
48 F 20 3 37 2 16 
49 F 28 4 80 4 78 
50 F 27 3 30 3 11 
0 Page 228 of 249 
Appendices 
51 F 21 3 27 3 24 
52 F 30 4 69 5 88 
53 M 22 3 36 2 24 
54 F 24 2 55 4 67 
55 M 23 3 22 4 34 
56 M 22 2 30 2 47 
57 F 27 3 48 3 47 
58 F 25 2 40 3 48 
59 F 22 3 26 4 25 
60 F 25 2 10 3 39 
61 M 28 2 15 2 24 
62 F 30 1 14 2 17 
63 F 40 3 48 4 73 
64 F 22 3 19 4 43 
65 M 20 1 15 2 34 
66 M 21 2 22 3 44 
67 F 25 2 26 4 70 
68 M 21 2 33 4 64 
69 F 20 3 56 3 63 
70 F 20 2 20 3 39 
71 F 22 3 35 4 75 
72 M 21 3 32 3 33 
73 M 22 3 22 2 34 
74 F 20 3 23 2 14 
75 M 21 2 18 3 40 
76 M 20 3 41 3 42 
77 M 21 3 44 2 22 
78 M 22 3 71 4 88 
79 M 23 3 38 2 16 
80 F 21 3 35 3 47 
81 M 26 3 48 3 40 
82 F 29 2 24 3 37 
83 F 25 2 29 3 41 
84 M 23 3 37 4 57 
85 F 26 3 35 4 61 
86 M 32 3 31 3 39 
87 F 22 4 67 3 53 
88 M 22 3 37 4 69 
89 F 31 4 49 4 52 
90 M 20 2 35 4 63 
91 M 21 3 57 2 35 
92 M 24 4 50 3 38 
93 F 26 4 73 3 47 
94 F 24 3 45 4 65 
95 M 39 3 44 4 64 
96 M 35 2 28 1 3 
97 F 29 3 20 2 11 
98 M 24 3 39 3 31 
99 F 22 4 63 5 78 
100 F 28 3 18 4 62 
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Appendix 11 Raw data of pain score (VRS and VAS) for TDS®-a in Chapter 2 
Subject Sex Age Treatment/ Result 
TDS'O- a (Active) TDS'O- a (Placebo) 
VRS VAS VRS VAS 
(Y) (Unit) (mm) (Unit) mm 
1 F 25 3 45 3 37 
2 F 34 4 53 3 54 
3 M 30 4 76 3 55 
4 F 29 3 51 2 33 
5 M 23 3 31 4 72 
6 F 28 3 36 2 25 
7 F 32 2 20 4 52 
8 F 30 2 14 3 40 
9 M 28 3 61 5 84 
10 M 23 4 69 2 21 
11 F 36 2 22 4 59 
12 F 26 5 94 4 75 
13 M 23 4 73 2 32 
14 F 32 4 90 4 75 
15 M 35 3 33 2 20 
16 F 29 4 64 3 44 
17 M 25 2 34 4 57 
18 M 31 2 33 4 79 
19 F 33 3 34 2 10 
20 F 28 4 67 3 52 
21 F 28 2 29 4 66 
22 F 40 4 65 2 18 
23 F 32 4 64 4 60 
24 F 24 3 39 4 60 
25 F 23 3 30 3 59 
26 F 23 3 55 4 73 
27 F 23 4 85 4 73 
28 F 27 5 96 4 67 
29 F 23 3 41 3 38 
30 F 25 2 16 2 16 
31 M 37 2 15 3 41 
32 F 30 4 75 2 23 
33 M 29 4 62 4 60 
34 F 31 4 60 2 22 
35 F 42 2 26 3 38 
36 M 26 4 42 4 64 
37 M 29 2 19 2 12 
38 F 34 2 9 3 31 
39 M 22 1 36 3 65 
40 M 25 4 68 2 28 
41 M 38 2 11 2 14 
42 M 21 2 21 3 45 
43 M 32 3 37 2 15 
44 F 30 2 19 2 18 
45 F 21 2 11 4 51 
46 F 21 2 12 3 41 
47 F 27 2 11 4 72 
48 F 20 3 34 2 18 
49 F 28 3 50 5 93 
50 F 27 4 66 2 5 
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51 F 21 2 8 2 22 
52 F 30 4 72 5 91 
53 M 22 3 52 4 74 
54 F 24 2 28 4 63 
55 M 23 2 23 2 10 
56 M 22 4 59 3 50 
57 F 27 2 20 2 16 
58 F 25 3 50 2 37 
59 F 22 3 39 3 40 
60 F 25 2 14 3 46 
61 M 28 1 16 3 26 
62 F 30 2 6 2 9 
63 F 40 2 32 2 33 
64 F 22 5 86 5 85 
65 M 20 3 41 2 16 
66 M 21 4 67 3 55 
67 F 25 2 33 3 57 
68 M 21 3 44 4 66 
69 F 20 3 44 4 66 
70 F 20 2 16 3 23 
71 F 22 4 66 3 52 
72 M 21 2 17 2 18 
73 M 22 4 49 3 24 
74 F 20 3 48 2 11 
75 M 21 1 3 2 30 
76 M 20 4 65 3 49 
77 M 21 3 45 2 27 
78 M 22 4 62 3 35 
79 M 23 2 4 3 33 
80 F 21 3 29 3 38 
81 M 26 2 32 4 76 
82 F 29 3 35 3 26 
83 F 25 2 36 3 48 
84 M 23 2 37 3 45 
85 F 26 4 49 3 32 
86 M 32 2 18 2 28 
87 F 22 3 45 4 70 
88 M 22 2 27 4 74 
89 F 31 4 50 3 37 
90 M 20 3 42 2 21 
91 M 21 4 56 3 48 
92 M 24 3 47 3 44 
93 F 26 4 74 3 55 
94 F 24 5 88 4 61 
95 M 39 3 56 2 36 
96 M 35 4 74 3 50 
97 F 29 3 26 4 25 
98 M 24 4 59 4 61 
99 F 22 4 66 3 36 
100 F 28 4 58 3 26 
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Appendix 12 Plasma concentrations at 2 hours post dose for TDS®- a and TDS®- ß in 
Chapter 2 
Subject TDS -a TDS -ß 
(ng/mL) (ng/mL) 
1 0.97 0.53 
2 0.00 0.00 
3 1.87 5.19 
4 1.88 0.00 
5 0.00 0.00 
6 0.00 0.00 
7 55.90 46.51 
8 0.77 0.00 
9 0.00 0.00 
10 0.00 0.00 
11 0.52 0.00 
12 0.00 0.00 
13 0.55 2.02 
14 0.00 0.46 
15 0.49 0.00 
16 0.00 1.10 
17 0.60 1.19 
18 0.54 16.59 
19 0.00 0.00 
20 0.00 0.00 
21 0.52 25.75 
22 0.00 0.00 
23 0.00 0.00 
24 0.00 0.00 
25 0.51 1.00 
26 0.00 0.00 
27 0.00 0.00 
28 0.00 0.00 
29 0.00 0.00 
30 0.86 0.00 
31 0.00 7.18 
32 0.43 0.56 
33 1.24 0.00 
34 0.00 0.00 
35 0.00 0.00 
36 3.08 0.00 
37 0.00 0.00 
38 0.65 1.15 
39 0.00 0.00 
40 0.92 1.09 
41 7.24 1.79 
42 0.62 0.00 
43 1.00 2.22 
44 1.00 0.92 
45 1.23 0.00 
46 7.27 0.00 
47 2.45 5.51 
48 1.68 0.95 
49 0.00 0.00 
50 0.00 5.08 
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51 1.23 0.41 
52 0.00 0.41 
53 0.00 1.00 
54 4.90 2.81 
55 2.29 0.00 
56 0.00 0.00 
57 0.75 0.00 
58 0.55 0.00 
59 0.00 0.00 
60 0.00 0.00 
61 0.00 0.00 
62 1.91 13.52 
63 1.96 1.17 
64 0.99 1.45 
65 1.11 0.79 
66 0.00 3.58 
67 0.96 6.22 
68 4.43 0.54 
69 1.53 10.20 
70 0.00 0.00 
71 0.00 0.00 
72 2.24 4.96 
73 21.87 6.88 
74 0.55 5.75 
75 2.05 0.00 
76 0.00 2.08 
77 5.04 0.53 
78 0.00 0.00 
79 1.86 8.88 
80 3.13 1.30 
81 1.63 0.00 
82 1.75 0.00 
83 0.93 0.00 
84 1.95 0.91 
85 3.07 0.44 
86 0.00 0.00 
87 5.86 2.12 
88 1.43 1.53 
89 0.64 0.44 
90 0.00 0.00 
91 0.00 0.00 
92 8.51 3.77 
93 1.62 28.57 
94 6.22 1.83 
95 24.39 2.48 
96 0.00 0.00 
97 2.06 0.76 
98 1.89 2.22 
99 4.59 1.17 
100 1.11 2.15 
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Appendix 13 Raw data for Figure 3.2 in Chapter 3 
Time (h) Testosterone concentration n mL 
10m 20m 30 m 40m 50m 
0 7.53 4.90 9.33 5.96 7.77 
0.5 8.13 5.00 8.91 6.71 8.78 
1 7.41 4.74 9.45 8.18 11.09 
2 7.00 5.20 10.22 8.52 11.77 
3 7.58 9.24 5.80 8.27 10.29 
4 7.28 4.43 9.76 8.97 11.63 
6 6.60 3.28 7.82 6.77 8.63 
8 7.11 3.44 8.54 7.45 9.16 
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Appendices 
Appendix 20 Verbal Rating Score (VRS) in 12 subjects in Chapter 4 
Time (h) / Result (unit) 
Subject 0.25 0.5 0.75 1 1.5 2 3 4 
1 4.0 3.0 2.5 1.0 1.0 1.0 2.0 2.0 
2 3.0 2.0 2.0 1.0 1.0 1.0 1.0 2.0 
3 2.0 2.0 2.0 2.0 2.0 3.0 2.0 1.0 
4 2.0 2.0 2.0 1.0 1.0 1.0 1.0 1.0 
5 4.0 3.0 3.0 1.0 1.0 1.0 1.0 1.0 
6 3.0 2.0 2.0 1.0 1.0 1.0 1.0 1.0 
7 3.0 3.0 2.0 1.0 1.0 1.0 1.0 1.0 
8 4.0 3.5 2.0 2.0 1.0 1.0 1.0 2.0 
9 4.0 3.5 3.5 2.5 2.0 2.0 1.0 2.0 
10 2.0 2.0 2.0 1.0 1.0 1.0 1.0 1.0 
11 3.0 3.0 2.0 1.0 1.0 1.0 1.0 1.0 
12 3.0 3.0 3.0 3.0 1.0 1.0 2.0 1.0 
Average 3.08 2.67 2.33 1.46 1.17 1.25 1.25 1.33 
SD 0.79 0.62 0.54 0.72 0.39 0.62 0.45 0.49 
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Appendix 21 Visual Analog Score (VAS) in 12 subjects in Chapter 4 
Time / Result (unit) 
Subject 0.25 0.5 0.75 1 1.5 2 3 4 
1 91.0 70.0 50.0 12.0 11.0 3.0 23.0 56.0 
2 61.0 47.0 35.0 5.0 5.0 3.0 8.0 32.0 
3 34.0 39.0 19.0 20.0 22.0 70.0 44.0 5.0 
4 23.0 22.0 22.0 2.0 0.0 0.0 0.0 0.0 
5 78.0 66.0 59.0 9.0 0.0 0.0 0.0 0.0 
6 68.0 35.0 30.0 9.0 12.0 10.0 13.0 10.0 
7 60.0 60.0 49.0 15.0 4.0 2.0 3.0 4.0 
8 100.0 85.0 49.0 38.0 0.0 0.0 0.0 32.0 
9 100.0 82.0 82.0 52.0 30.0 31.0 0.0 29.0 
10 31.0 42.0 39.0 23.0 16.0 17.0 16.0 21.0 
11 60.0 57.0 46.0 7.0 0.0 0.0 0.0 0.0 
12 77.0 69.0 61.0 68.0 9.0 13.0 27.0 12.0 
Average 65.3 56.2 45.1 21.7 9.1 12.4 11.2 16.8 
SD 25.9 19.5 17.7 20.6 9.7 20.4 14.1 17.5 
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Appendix 22 Skin reflectance measurement procedures in Chapter 5 
SPECTROPHOTOMETER CM-2500d 
1. Switch on the spectrophotometer [power switch at rear of machine]. The display 
will show the <COND> 1 window. Use wheel at top front of device to move to 
CALIBRATION mode and press white dot to activate. If the cursor is on ZERO 
CALIBRATION, use wheel to change to WHITE CALIBRATION. Place the 
instrument on the white calibration device and press the measuring button located 
on side of the instrument. Three measurements will be taken and the 
spectrophotometer will automatically change to measurement mode. Remove the 
white calibration device. White calibration must be performed before any 
measurements can be taken and is required every time the machine is switched on. 
2. TAKING MEASUREMENTS: 
i) Ensure spectrophotometer is in measurement mode (press BREAK repeatedly 
until SPECTRAL GRAPH or L* a* b* appears on display). 
ii) Rest the head of the spectrophotometer measuring aperture on the surface of the 
skin site to be measured (site 1- forehead). Ensure that there is a complete seal 
with the skin surface but no depression of the skin (to avoid surface blanching or 
flushing). Care must be taken to avoid areas of irregular pigmentation such as 
moles etc or hairy skin. Press the measuring button. The Xenon lamp will make 
three recordings. Take care not to move the spectrophotometer until the entire 
measurement cycle has been completed and the results displayed [if movement 
occurs delete this data - see item 4 below and repeat measurement]. Note the 
instrument has been set to allow 1 second between the 3 readings and between 
pressing the button and the first measurement. 
iii) Record exact position of measurement on chart diagram together with the 
specimen number recorded in upper left corner of display panel. Move to next 
measurement area and repeat exercise 2. ii until all eight areas of skin are recorded. 
iv) Upon completion of subject, check that nine specimen numbers have been 
recorded (1-9 for subject 1; 10-18 for subject 2 etc). The sequence of 
measurements of skin areas should be the same for each subject. If during the 
course of measurement an erroneous reading was taken either because the 
spectrophotometer was moved during a reading or an "air" reading was 
inadvertently taken, this can be deleted as follows; - 
3. DELETING DATA FOR SINGLE SPECIMEN MEASUREMENT: Select the 
desired specimen number to be deleted (move wheel to DEL is highlighted). Press 
white spot and a confirmation message will come on screen, highlight "OK" and 
press white spot again. The selected specimen measurement will be deleted and 
the spectrophotometer will return to measurement mode and the remaining 
specimen numbers will be renumbered. 
4. To switch between subject numbers, move highlight to tº position and press 
white dot, symbol will change to V A. Moving the wheel will now allow screen 
to move between subjects. 
5. Using the "SPEC GRAPH" setting, record all values for 400nm, using the SCI 
values. 
6. Change wavelength to 420 using the SCI values (or vice versa by firstly resetting 
4º and moving back to "nm". Pressing the white spot at this position will allow 
the wheel to move across the spectral graph. 
7. Once all "SPEC GRAPH" 400 and 420nm readings have been recorded, the 
display screen can be changed to "L* a* b*" mode by selecting "PREY" to return 
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to <COND> 1 and selecting <FILE> by moving to highlight FILE and pressing the 
white spot. Move the wheel until "sel" is highlighted and press the white button 
continuously until DISPLAY is highlighted. Then move wheel to select "DIFF & 
ABS" and continue pressing white spot to end of this programme. Taking care not 
to alter any of the other settings. The screen will return to highlight break. Press 
white spot to return to the measurement mode screen which will now show L* a* 
b* results (note if OLab screen is shown, change by highlighting "DISP" and 
pressing white button. All L*, a* and b* values for each subject can now be read 
in the same way as for spectral results by changing to fA and wheeling between 
subjects. Use the values listed under Sc!. 
Note that if L* a* b* results are the first to be displayed the procedure outlined 
above should be reversed. THE SEQUENCE DOES NOT MATTER. 
When all data has been recorded from all subjects, the spectrophotometer can be 
switched off. 700 data readings can be stored in the memory. The data must be 
recorded on the CRFs or downloaded to a printer after each set of results are taken 
at any one measuring session (i. e. baseline, day 10 etc). 
MEASUREMENT SEQUENCE 
1. Forehead 
2. Left cheek 
3. Right side of neck 
4. Left scapula 
5. Right inside upper arm 
6. Left inside upper arm 
7. Left medial forearm 
8. Right side of lower back 
9. Left calf 
SPECTROPHOTOMETER STANDARD SETTINGS 
Pgl/2 
Mask/gloss M/I+E 
UV setting UV 100% 
Illuminantl D65 
Illuminant2 --- 
Observer 10° 
Display SPECT. GRAPH or DIFF&ABS - depending on whether you want Lab 
or nm. 
Pg2/2 
color space L*a*b*, iE* 
Manual Avg times deviation --- 
Auto Avg 3 
Delay time 0.5s 
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Appendix 23 Skin reflectance data for all the subjects and all the sites in Cohort 5 in Chapter 
Subject Site Day L*(D65) a*(D65) b*(D65) 400nm 420nm MD 
1 1 1 63.64 10.48 17.79 16.77 16.56 3.32 
1 1 5 63.37 11.03 16.71 17.47 17.06 3.12 
1 1 10 63.45 11.02 18.1 16.44 16.1 3.19 
1 1 20 63.45 11.6 16.99 17.49 17.03 3.07 
1 1 30 63.92 10.62 18.64 16.18 16.22 3.57 
2 1 1 61.56 13.34 16.52 14.98 14.8 3.35 
2 1 5 62.2 12.56 16.8 15.01 15.07 3.59 
2 1 10 62.03 12.89 17.19 14.7 14.55 3.38 
2 1 20 63.54 12.4 17.32 16.11 15.77 3.19 
2 1 30 62.2 13.13 16.91 15.38 15.12 3.27 
3 1 1 61.97 13.28 17.02 15.53 15.46 3.46 
3 1 5 63.06 11.97 18.04 15.29 15.56 3.80 
3 1 10 63.87 12.4 17.6 16.4 16.34 3.47 
3 1 20 64.22 12.35 17.65 16.65 16.7 3.58 
3 1 30 64.09 12.76 17.62 16.83 16.63 3.33 
4 1 1 62.01 13.25 13.78 17.93 17.4 3.00 
4 1 5 59.62 14.83 15.6 14.32 14.43 3.64 
4 1 10 60.62 13.5 16.06 14.51 14.91 3.93 
4 1 20 62.28 12.65 16.3 16.55 16.17 3.15 
4 1 30 56.94 17.03 14.67 13.13 13.34 3.74 
5 1 1 66.46 10.97 14.29 21.36 20.1 2.27 
5 1 5 65.4 11.89 15.88 19.06 18.49 2.96 
5 1 10 66.68 11.03 16.53 19.67 19.04 2.90 
5 1 20 66.4 11.6 15.64 20.09 19.36 2.80 
5 1 30 68.1 9.54 14.91 22.25 20.83 2.11 
6 1 1 66.17 10.53 16.37 19.51 19.17 3.19 
6 1 5 63.57 11.49 17.05 16.72 16.73 3.54 
6 1 10 65.37 11.07 18.27 17.44 17.21 3.30 
6 1 20 64.45 12.04 17.3 17.64 17.1 2.99 
6 1 30 64.58 11.23 18.57 16.73 16.58 3.38 
1 2 1 59.57 11.14 21.64 10.61 11.91 4.83 
1 2 5 60.8 11.4 19.78 12.57 13.67 4.63 
1 2 10 61.27 10.72 21.49 11.36 12.89 5.06 
1 2 20 61.66 10.75 21.63 11.68 13.12 4.97 
1 2 30 61.14 11.38 21.19 11.57 13.03 4.99 
2 2 1 61.68 12.25 16.52 14.69 14.99 3.83 
2 2 5 62.52 12.19 17.11 14.82 15.24 3.95 
2 2 10 63.71 11.49 18.2 14.68 15.06 3.91 
2 2 20 63.56 12.14 18.05 14.68 15.52 4.37 
2 2 30 66.83 9.03 18.77 15.86 17.14 4.81 
3 2 1 59.28 13.82 17.84 12.44 13.16 4.25 
3 2 5 62.23 12.48 19.01 13.5 14.43 4.46 
3 2 10 63.75 11.45 19.17 14.21 15.2 4.52 
3 2 20 63.78 10.06 19.78 13.97 15.01 4.57 
3 2 30 64.09 11.41 19.15 14.51 15.48 4.50 
4 2 1 55.3 10.15 14.56 11.56 12.03 4.00 
4 2 5 58.23 11.25 16.85 11.99 12.75 4.29 
4 2 10 57.86 9.17 15.01 13.11 13.41 3.83 
4 2 20 56.84 9.56 16.19 11.75 12.26 4.04 
4 2 30 55.1 11.24 14.13 11.68 12.06 3.91 
5 2 1 66.19 10.32 16.74 18.12 18.21 3.62 
5 2 5 65.35 11.69 17.49 17.21 17.3 3.62 
5 2 10 67.04 9.22 17.98 18.13 18.11 3.51 
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5 2 20 67.07 9.75 17.9 18.29 18.49 3.73 
5 2 30 69.55 9.25 15.8 22.04 21.58 3.07 
6 2 1 66.69 9.39 17.06 18.84 18.89 3.58 
6 2 5 65.71 10.72 17.72 17.4 17.96 4.09 
6 2 10 68.34 8.88 17.08 20.76 20.14 2.91 
6 2 20 65.84 11.8 16.08 19.29 19 3.24 
6 2 30 64.24 12.53 16.97 17.19 17.39 3.73 
1 3 1 60.36 10.6 20.81 11.22 12.03 4.34 
1 3 5 61.72 10.27 21.66 11.61 12.44 4.36 
1 3 10 61.94 9.82 21.74 11.5 12.49 4.52 
1 3 20 61.89 10.08 22.07 11.32 12.32 4.53 
1 3 30 59.69 11.6 21.61 10.46 11.31 4.38 
2 3 1 65.32 8.35 16.45 16.45 16.87 3.95 
2 3 5 65.75 9.15 16.88 17.21 17.12 3.44 
2 3 10 66.28 8.28 17.35 17.13 17.22 3.62 
2 3 20 66.09 8.47 18.59 16.13 16.48 3.88 
2 3 30 65.62 9.11 17.34 16.67 16.63 3.49 
3 3 1 57 14.55 19.28 10.49 10.84 3.88 
3 3 5 61.66 11.88 21.52 11.76 12.39 4.16 
3 3 10 62.54 10.86 20.71 12.43 13.06 4.16 
3 3 20 60.79 12.58 18.84 12.78 13.18 3.93 
3 3 30 61.45 13.27 18.75 13.35 13.68 3.86 
4 3 1 66.2 9.87 17.77 17.13 17.36 3.76 
4 3 5 68.2 7.72 17.19 18.81 19.12 3.84 
4 3 10 67.31 8.67 17.48 18 18.2 3.73 
4 3 20 68.47 7.48 17.91 19.09 19.14 3.58 
4 3 30 64.3 11.31 16.44 16.6 16.6 3.53 
5 3 1 68.43 6.75 15.61 19.78 19.7 3.45 
5 3 5 70.11 5.04 14.64 22 22.08 3.61 
5 3 10 70.39 5.56 17.59 20.2 20.41 3.74 
5 3 20 68.82 7.42 17.32 19.09 19.13 3.57 
5 3 30 70.74 5.67 17.68 20.79 20.98 3.72 
6 3 1 68.73 7.8 17.72 20.01 19.47 2.99 
6 3 5 69.88 6.86 16.91 21.68 20.82 2.67 
6 3 10 69.52 7.39 16.12 22.29 21.11 2.35 
6 3 20 66.63 7.07 16.01 19.35 18.9 3.08 
6 3 30 67.64 8.86 17.26 19.61 18.76 2.68 
1 4 1 58.28 10.89 19.77 10.61 11.48 4.40 
1 4 5 60.62 9.79 19.59 12.04 12.91 4.40 
1 4 10 65.2 6.34 19.75 14.9 16.15 4.78 
1 4 20 64.26 7.33 20.77 13.69 14.94 4.78 
1 4 30 62.23 9.35 20 12.77 13.8 4.56 
2 4 1 70.61 5.55 17.19 20.71 20.89 3.71 
2 4 5 71.43 5.29 18.41 20.56 21.02 3.99 
2 4 10 70.55 6.53 17.45 20.1 20.4 3.83 
2 4 20 71.18 6.29 17.46 20.93 21.35 3.95 
2 4 30 70.61 6.52 16.4 21.52 21.55 3.56 
3 4 1 67.89 6.38 14.02 21.53 21.13 3.13 
3 4 5 65.99 8.35 20.04 15.28 16.53 4.78 
3 4 10 65.32 8.88 20.26 14.46 15.71 4.78 
3 4 20 63.59 10.11 20.66 12.82 13.96 4.67 
3 4 30 63.86 10.85 19.36 14.11 14.82 4.24 
4 4 1 70.63 6.72 14.23 24.52 23.76 2.77 
4 4 5 71.47 6.13 15.01 24.32 23.65 2.86 
4 4 10 69.16 7.14 15.35 21.96 21.39 2.96 
4 4 20 69.13 7.5 15.69 22.48 21.7 2.75 
4 4 30 68.32 8.39 14.76 21.81 21.12 2.84 
5 4 1 61.78 9.99 23.21 11.25 12.07 4.35 
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5 4 5 61.48 11.1 22 11.58 12.18 4.13 
5 4 10 63.7 8.58 22.93 12.41 13.39 4.51 
5 4 20 61.47 11.81 21.43 12.01 12.52 4.04 
5 4 30 63.17 10.04 22.19 12.5 13.19 4.22 
6 4 1 64.22 9.47 22.55 13.3 13.79 4.02 
6 4 5 65.95 8.92 21.48 15.33 15.57 3.77 
6 4 10 64.94 10.36 20.54 15.03 15.21 3.71 
6 4 20 63.19 10.69 20.54 13.82 14.22 3.93 
6 4 30 64.98 9.15 20.11 15.14 15.54 3.93 
1 5 1 69.5 5.56 16.46 20.74 20.76 3.55 
1 5 5 69.98 4.87 15.99 21.9 21.94 3.57 
1 5 10 70.84 4.64 15.64 23.24 23.04 3.33 
1 5 20 71.63 4.33 16.27 23.36 23.15 3.32 
1 5 30 71.1 4.6 15.98 23.15 23.09 3.47 
2 5 1 72.52 4.03 12.93 26.68 25.85 2.70 
2 5 5 71.56 4.24 13.58 24.72 24.47 3.28 
2 5 10 71.86 3.78 13.74 24.48 24.18 3.23 
2 5 20 73.2 4.04 13.19 27.45 27.04 3.12 
2 5 30 71.66 4.19 13.89 24.64 24.24 3.13 
3 5 1 68.05 6.52 15.26 20.44 20.35 3.44 
3 5 5 69.27 5.86 14.35 22.81 22.68 3.40 
3 5 10 70.38 5.68 14.06 24.37 23.66 2.82 
3 5 20 70.73 5.8 14.7 23.84 23.31 3.00 
3 5 30 70.65 5.32 15.09 23.68 23.16 3.01 
4 5 1 74.14 3.81 13.3 29.34 27.71 1.90 
4 5 5 73.57 3.87 13.85 27.47 25.94 2.00 
4 5 10 72.6 3.98 14.17 26.47 24.82 1.88 
4 5 20 73.21 3.71 14.77 27.01 25.14 1.67 
4 5 30 73.84 3.9 12.73 28.84 27.04 1.74 
5 5 1 69.42 5.45 14.37 21.25 21.4 3.68 
5 5 5 71.31 3.99 14.38 23.16 23.5 3.87 
5 5 10 69.99 4.81 15.49 20.84 21.06 3.75 
5 5 20 70.28 5.12 15.99 20.64 21.08 3.97 
5 5 30 71.62 4.12 14.71 23.7 23.82 3.65 
6 5 1 70.2 5.53 13.49 25.29 24.19 2.43 
6 5 5 72.03 4.48 13.1 27.87 26.87 2.53 
6 5 10 71.65 4.38 12.64 27.84 26.59 2.28 
6 5 20 71.25 4.42 12.16 27.57 26 1.96 
6 5 30 69.59 5.28 13.97 23.44 22.78 2.87 
1 6 1 69.84 5.04 14.73 22.9 22.91 3.54 
1 6 5 69.18 5.19 15.35 21.8 21.99 3.72 
1 6 10 69.6 4.73 14.73 22.74 22.82 3.61 
1 6 20 69.25 4.87 15.6 21.63 21.71 3.61 
1 6 30 68.87 5.41 15.78 21.07 21.04 3.50 
2 6 1 72.12 4.22 13.89 25.03 24.47 2.97 
2 6 5 72.45 4.28 14.22 25 24.63 3.16 
2 6 10 72.93 3.47 12.52 27.57 26.22 2.18 
2 6 20 73.21 4.1 13.53 26.93 26.42 3.02 
2 6 30 72.62 3.85 12.6 27.4 26.35 2.48 
3 6 1 61.65 10.93 18.46 13.28 13.89 4.14 
3 6 5 69.19 6.11 14.88 22.07 22.39 3.85 
3 6 10 69.9 5.84 15.74 21.69 21.61 3.45 
3 6 20 70.12 5.77 15.84 22.05 22.07 3.55 
3 6 30 71.14 5.26 15.21 23.99 23.69 3.23 
4 6 1 73.52 3.93 12.2 29.69 27.84 1.69 
4 6 5 73.5 3.55 13.29 27.9 26.4 2.03 
4 6 10 73.19 4.16 12.28 28.87 26.99 1.66 
4 6 20 73.59 3.68 12.5 30.19 28.47 1.82 
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4 6 30 73.78 3.12 10.15 32.25 30.08 1.37 
5 6 1 70.72 4.6 14.5 22.8 22.83 3.56 
5 6 5 70.62 4.74 15.75 21.12 21.75 4.16 
5 6 10 70.9 4.19 15.29 22 22.42 3.95 
5 6 20 71.84 4.23 14.8 23.76 23.88 3.65 
5 6 30 71.29 4.44 14.77 23.25 23.64 3.92 
6 6 1 70.43 5.22 15.06 24.28 23.67 2.92 
6 6 5 71.82 4.73 14.37 26.61 25.83 2.75 
6 6 10 70.86 4.82 14.84 24.51 23.94 2.96 
6 6 20 71.33 4.46 13.6 26.53 25.46 2.46 
6 6 30 68.48 5.48 14.36 22.05 21.4 2.88 
1 7 1 63.3 8.27 17.88 14.44 14.88 3.97 
1 7 5 61.56 8.57 19.34 12.71 13.49 4.31 
1 7 10 62.89 7.66 21.46 12.46 13.62 4.69 
1 7 20 60.74 8.12 21.29 11.36 12.33 
4.50 
1 7 30 61.99 8.45 22.89 11.39 12.44 4.58 
2 7 1 67.5 5.95 17.63 16.52 17.52 4.53 
2 7 5 67.99 5.16 17.04 17.07 17.95 4.41 
2 7 10 66.79 6.5 18.12 15.48 16.71 4.76 
2 7 20 66.29 7.4 20.81 13.94 15.3 
4.89 
2 7 30 66.17 7.12 20.13 14.21 15.53 4.85 
3 7 1 62.5 9.12 17.64 14.03 14.53 
4.03 
3 7 5 64.99 8.04 17.58 16 16.49 4.02 
3 7 10 65.08 8.11 18.41 15.26 15.99 4.26 
3 7 20 64.06 8.47 19.54 13.84 14.73 4.42 
3 7 30 66.2 7.44 19.5 15.19 16.37 4.71 
4 7 1 69.92 5.38 12.3 23.85 23.88 
3.56 
4 7 5 66.81 6.66 12.76 20.18 20.26 
3.61 
4 7 10 66.52 6.3 13.45 19.41 19.38 
3.50 
4 7 20 67.51 5.85 14.52 19.89 20.14 
3.78 
4 7 30 65.82 6.77 15.07 17.45 17.88 
3.96 
5 7 1 68.34 5.98 16.13 18.65 19.18 4.06 
5 7 5 69.34 5.22 16.59 19.3 19.93 4.16 
5 7 10 66.86 6.75 19.69 15.56 16.35 
4.32 
5 7 20 66.63 7.31 20.59 14.97 15.97 
4.53 
5 7 30 66.73 7.39 21.17 14.61 15.55 4.47 
6 7 1 67.53 6.82 17.85 17.63 17.87 3.77 
6 7 5 69.5 5.6 16.59 20.59 20.65 3.59 
6 7 10 68.54 5.87 16.83 19.46 19.94 4.01 
6 7 20 68.6 6.61 17.84 18.88 19.46 4.11 
6 7 30 67.02 6.68 18.69 16.59 17.55 4.49 
1 8 1 69.78 5.77 14.41 23.37 21.93 2.09 
1 8 5 70.83 4.86 14.86 24.43 22.74 1.85 
1 8 10 69.4 5.53 13.79 23.82 22.16 1.88 
1 8 20 70.99 5 13.48 25.92 24.39 2.00 
1 8 30 70.07 5.21 13.74 24.37 22.91 2.07 
2 8 1 74.75 3.35 15.52 27.34 25.82 2.01 
2 8 5 74.47 4.16 16.73 25.63 24.53 2.43 
2 8 10 73.96 3.9 17 24.48 23.38 2.43 
2 8 20 75.06 4.02 16.59 26.73 25.66 2.46 
2 8 30 74.46 4.01 16.49 26.29 24.96 2.20 
3 8 1 66.74 7.77 17.77 17.08 16.68 3.13 
3 8 5 69.49 6.42 18.76 18.69 18.89 3.73 
3 8 10 68.73 7.1 18.54 18.19 17.91 3.25 
3 8 20 70.07 6.35 19.23 18.82 18.49 3.20 
3 8 30 70.57 5.36 17.91 20.21 20.03 3.35 
4 8 1 69.12 6.63 14.81 21.61 20.38 2.30 
4 8 5 66.4 6.57 14.06 19.46 18.68 2.75 
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4 8 10 68.94 6.51 12.86 22.74 21.25 2.04 
4 8 20 67.94 6.84 13.62 21.63 20.04 1.94 
4 8 30 67.41 7.63 13.37 20.93 19.59 2.19 
5 8 1 67.02 6.88 19.8 16 16.47 4.00 
5 8 5 68.95 5.89 19.61 17.59 18.08 4.02 
5 8 10 66.91 7.05 20.59 15.32 15.81 4.02 
5 8 20 66.31 6.91 19.05 15.38 15.82 3.97 
5 8 30 66.99 6.97 18.67 16 16.27 3.80 
6 8 1 66.3 8.07 20.63 15.79 15.85 3.59 
6 8 5 66.54 7.41 20.3 15.83 15.76 3.46 
6 8 10 68.22 6.75 17.34 19.26 19.18 3.45 
6 8 20 66.98 7.02 17.95 17.56 17.4 3.37 
6 8 30 66.32 7.8 20.67 15.26 15.48 3.75 
1 9 1 69.82 4.35 13.84 22.52 22.5 3.51 
1 9 5 68.6 3.78 11.67 23.18 22.57 2.92 
1 9 10 68.03 5.38 13.39 21.67 21.49 3.35 
1 9 20 68.94 3.87 13.85 21.56 21.48 3.45 
1 9 30 66.99 6.5 13.64 20.77 20.53 3.29 
2 9 1 62.26 7.48 17.97 12.25 13.21 4.49 
2 9 5 62.22 6.57 18.37 12.16 13.23 4.60 
2 9 10 64.14 5.27 17.18 13.66 14.69 4.56 
2 9 20 64.13 6.64 19.15 12.85 14.14 4.82 
2 9 30 65.31 5.78 17.42 14.6 15.63 4.56 
3 9 1 55.68 13 17.53 9.56 10.17 4.14 
3 9 5 56.13 10.64 16.79 10.07 10.73 4.19 
3 9 10 57.64 10.59 17.07 10.49 11.13 4.17 
3 9 20 56.41 11.76 16.53 10.1 10.7 4.13 
3 9 30 57.29 11.59 17.73 9.89 10.61 4.25 
4 9 1 67.78 5.26 12.12 21.86 21.39 3.06 
4 9 5 64.44 7.25 12.51 18.17 17.72 3.08 
4 9 10 63.78 7.23 11.68 18.32 17.6 2.81 
4 9 20 67.37 4.99 13.59 20.75 20.09 2.87 
4 9 30 68.46 6.2 12.89 21.65 21.06 2.94 
5 9 1 66.15 7.74 18.23 15.55 16.11 4.09 
5 9 5 64.07 7.89 16.88 14.4 14.73 3.86 
5 9 10 65.54 6.46 15.8 16.63 16.84 3.74 
5 9 20 65.81 7.13 16.71 16.38 16.74 3.89 
5 9 30 67.87 5.49 16.46 18.26 18.66 3.93 
6 9 1 59.96 11.01 19.23 10.89 11.44 4.08 
6 9 5 65.15 7.62 18.48 15.24 15.21 3.50 
6 9 10 63.59 7.87 15.18 15.82 15.29 3.00 
6 9 20 64.54 8.14 13.9 17.7 17.12 2.95 
6 9 30 62.9 8.86 15.46 14.79 14.83 3.57 
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Validation and application of capillary electrophoresis for the analysis of 
lidocaine in a skin tape stripping study. 
Z. Chikl, A. Johnston', A. T. Tuckerl, R. T. Burnt, D. Perrett2 
Clinical Pharmacology, William Harvey Research Institute, Barts and The London, Queen Mary's 
School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK. 
2 BioAnalysis, William Harvey Research Institute, Barts and The London, Queen Mary's School of 
Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK. 
Abstract 
A fast and simple capillary zone electrophoresis (CE) method was developed and validated for the 
determination of lidocaine in skin using tape samples. Separation was performed in 350mm (265mm to 
window) x 50µm i. d fused silica capillary using a background electrolyte of phosphoric acid/TRIS pH 
2.5. The extraction of lidocaine from tape samples was achieved with methanol, which was diluted to 
50% with water before injection. Procaine was the internal standard. The migration times for procaine 
and lidocaine were 2.9 and 3.2min, respectively. The limit of quantification for lidocaine was 50µg, 
with S/N ratio was greater than 10. The calibration curve was linear from 50 to 1000µg with r2 greater 
than 0.99. The CV for both within and between assayed imprecision and the percentage of inaccuracy 
for the quality control samples including LLOQ and ULOQ were <_ 2% and <_ 14%, respectively. The 
absolute recovery of lidocaine was >97%. Accuracy and selectivity of this method allowed the 
measurement lidocaine in tape samples obtained from a skin tape stripping study of local anesthetics in 
healthy subjects. 
Keywords: Capillary electrophoresis, lidocaine; tape stripping: method validation. 
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Lidocaine is commonly used as local anaesthetic and anti arrhythmic. Lidocaine is applied onto skin in 
either cream or patches for local anaesthetic effects. Due to the local activity of lidocaine its 
concentration is higher in the local tissue compared to systemic circulation. Some in vivo methods such 
as microdialysis and tape stripping are available to sampling drugs in the local tissue and outermost 
layer of the skin, respectively (Benfeldt & Groth 1998; Kenkel et al. 2004; Kreilgaard 2001; Kreilgaard 
et al. 2001; Pershing et al. 2002; Reddy et al. 2002) . Various techniques are available to measure 
lidocaine in plasma such as HPLC with UV detection (Lotfi et al. 1997), LC-MS-MS (Bo, 
Mazzucchelli, & Marzo 1999), and GCMS (Watanabe et al. 1998). Most of the analysis of drugs 
including lidocaine (Pershing et al. 2003; Pershing, Corlett, & Nelson 2002; Weigmann et al. 1999) from 
tape samples have been by HPLC with UV detection since the drug content in tape samples is normally 
higher than in plasma, especially for local anaesthetic study. Therefore, the high sensitivity techniques 
such as LC-MS-MS or GCMS are not required since UV detection is sufficiently sensitive to detect 
such level of drugs. Moreover, the analysis cost of using UV detection is less compared to MS 
detection. 
On the other hand, capillary electrophoresis (CE) is an alternative to the chromatography techniques in 
drug analysis which can separate a variety of compounds by using an electric field. The separation of 
the compounds by electrophoresis in CE is based on the differences in electrophoretic mobility and the 
voltage applied. Like HPLC, CE also can be coupled with UV detector (CE-UV) and MS (CE-MS) 
forming a powerful analytical method for drug analysis. Capillary electrophoresis with UV and MS 
detection for the analysis of lidocaine in pharmaceutical formulations have been reported previously 
(Geiser, Rudaz, & Veuthey 2003; Geiser, Rudaz, & Veuthey 2005; Wang et al. 2001). In this study, we 
have performed a method validation for the CE analysis of lidocaine in tape samples obtained from 
tape stripping study on healthy subjects. 
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2. Experimental 
2.1 Chemicals 
Biomedical Chromatography 
Lidocaine Hydrochloride (99.9% purity) and Procaine Hydrochloride (100% purity) (internal standard) 
were obtained from Sigma-Aldrich Company, Poole, UK. The chemical structure of lidocaine and 
procaine are shown in Figure 1. All HPLC grade solvents were obtained from Rathburn Chemicals 
Limited, Walkerburn, Scotland. All AnalaR grade reagents were obtained from Merck (BDH) Limited, 
Poole, Dorset, England. 
N Y"'N iý CH3 
O 
CH3 
- 
CH3 
Lidocaine 
Figure 1 
2.2 Background electrolyte 
(CH3 0 
O/\i N 
ýCH3 
H2N 
Procaine 
Chemical structures of lidocaine and procaine 
The aqueous background electrolyte used in this analysis was 100mM Tris-phosphate buffer at pH 2.5. 
To prepare this solution, 20mL phosphoric acid 0.5M was diluted with 80mL water and l5mL Tris 
0.5M was added to obtain a solution at pH 2.5. The solution was topped up to 100mL with deionised 
water. 
2.3 CE instrumentation and capillaries 
Separations were carried out on an Agilent 3D CE G1600AX capillary electropherograph (Agilent, West 
Lothian, UK) controlled by Chemstation B. 02.01 (Agilent, West Lothian, UK). 350mm (265mm to 
window) x 50µm i. d., fused silica capillaries (Composite Metal Services, Ilkley, UK) were conditioned 
on first use by flushing with 1M NaOH (BDH, Poole, UK) at >950 mbar, 40°C for 20 minutes. Pre- 
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conditioning on injection was a3 min flush with 0.1M HCl (BDH, Poole, UK), then 2 minutes flush 
with background electrolyte (BGE). Separation was at a potential difference of +25.0kV. The capillary 
was thermostated at 25.0°C. Detection was by photodiode-array over 195 - 300nm, but 200nm with 
bandwidth 6nm, was used for quantitation. Run time was 4 min. Both BGE vials were replenished 
every 12 injections. All samples and standards in the autosampler were kept at ambient temperature. 
The injections of the samples into the system were carried out hydrodynamically for 12 seconds at 
5OmBar. 
2.4 Assay Procedure 
2.4.1 Preparation of stock solution 
A stock solution of lidocaine and procaine were prepared in 50% methanol. All the sub-stock solutions 
were stored at -20°C. All the calibrators and QC sample concentrations were prepared by appropriate 
dilution of sub-stock dilution. 
2.4.2 Preparation of tape samples and extraction 
For the purpose of validation and assay calibration, a length of self adhesive polypropylene tape (Tesa 
4204 PVS, Beiersdorf, Hamburg Germany) was cut into 10 samples so that each was approximately 3x 
2cm. 100µL volume of standard or quality control solution were spiked on the adhesive part of the 
tape. The solution was distributed approximately evenly on all the tapes. The samples were left to dry 
naturally at room temperature. This required, approximately 30 minutes. The samples then transferred 
into IOmL polypropylene tube and stored frozen at -20°C until analysis. Samples were obtained from 
patients by applying the tape (3 x 2cm) on the skin and stripped off by using the forceps. The procedure 
was repeated 10 times to obtain 10 samples at each skin site. The samples were placed in lOmL 
polypropylene tube and stored frozen at -20°C until analysis. 
http: //mc. manuscriptcentral. com/bmc 
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2.4.3 Extraction procedure 
Biomedical Chromatography 
A 5mL methanol was dispensed into the tube containing standard/QC tape or samples. The contents 
were vigorously mixed for 45 minutes by using a vortex mixer. 5mL of a 120µg/ml, procaine (I. S. ) in 
water solution was added to the tube to make a 50% methanol solution. The contents were mixed again 
using a vortex mixer for a further 15 minutes. A 200µL of the solution was transferred into 250µL auto 
injector vial for CE analysis. 
3. Validation procedures and results 
3.1 Specificity 
Six samples of blank tape and six samples of tape spike with lidocaine were prepared and carried 
through the extraction. The concentration of lidocaine used was 50µg (LLOQ) and the internal standard 
was 600µg. No significant interfering peaks were found at the migration time of lidocaine or procaine. 
The signal to noise ratio for both drugs were greater than 10. Figure 2 shows the electropherogram 
obtained from blank tape spiked with 5011g lidocaine and added IS of 600µg procaine. Whilst Figure 3 
and Figure 4 show the electropherograms of EMLA cream solution and one of the tape samples from 
the study, respectively. 
3.2 Calibration curve/ linearity 
Calibration curve consists of six non - zero calibrators with nominal values of 50,100,250,500,750, 
and 1000µg lidocaine and 600µg procaine. Five batches of calibration curves were prepared for 
validation purposes. Calibration curve was plotted using area ratio of lidocaine to IS versus known 
concentrations of lidocaine. All the results were calculated using ay= Ax +B linear regression. The 
regression coefficient for all the calibration curves obtained were greater than 0.99. Regression 
parameters obtained from five curves are summarised in Table 1. 
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3.3 Inaccuracy and Imprecision 
Inaccuracy and imprecision were measured both within-batch and between-batch by repeated analysis 
of low, medium and high quality control samples, together with the LLOQ and ULOQ samples. The 
nominal values for low, medium and high control samples were 80,400 and 800µg, respectively. The 
nominal values for the ULOQ and LLOQ were the same nominal concentration as the highest and the 
lowest calibration standards, respectively. All the control samples, LLOQ, and ULOQ were each 
assayed six times in three separate assays. Within-batch and between-batches imprecision and 
inaccuracy were calculated using internationally agreed method (FDA 2001). 
3.4.1 Within-assay reproducibility 
The three quality control samples, LLOQ and ULOQ were, initially, each extracted six times in one 
batch. Subsequently, they were extracted six times in two additional batches. On each occasion a 
separate calibration curve was extracted. The CV for imprecision and the percent inaccuracy for all the 
quality control samples including LLOQ and ULOQ were below than 2% and 14%, respectively. 
3.4.2 Between-assay repeatability 
For each of the three assays mentioned above, the mean concentration from each assay was used to 
calculate the between assay reproducibility. The CV for imprecision and the percentage inaccuracy for 
for all the quality control samples including LLOQ and ULOQ were below than 2% and 11%, 
respectively. 
Table 2 summarises the within and between-batch, and the total variability obtained from the nested 
Analysis of Variance. From the nested ANOVA, the within and between-batch and the total variability 
for all the QC samples including ULOQ and LLOQ were all <7%. 
http: //mc. manuscriptcentral. com/bmc 
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3.4 Recovery 
Biomedical Chromatography 
Absolute recovery of lidocaine was determined using tape samples spiked with lidocaine at the same 
nominal concentrations as the quality control samples. Peak area measurements obtained from the 
extracted samples were compared to the peak area measurements obtained from direct solvent injection 
of the test compounds. Mean and standard deviation were calculated from at least three measurements 
at each level. The absolute recovery of lidocaine was ranging from 97 to 103%. 
Discussion 
Clinical trial of drugs, especially pharmacokinetic studies, normally consists of large numbers of 
samples. Therefore, the development of rapid and fully validated techniques to analyse the samples in a 
short a period of time as possible is important. In the development of this CE method we attempted to 
reduce the migration time even further by short - end injection (Geiser, Rudaz, & Veuthey 2005). This 
resulted in the migration time of procaine at about 1 minute and lidocaine at about 1.2 minutes. 
Unfortunately, the prilocaine also found in the EMLA cream could not be fully separated from 
lidocaine so the optimized method employed the standard separation mode. 
Reducing the capillary length to 35cm from the original, 48.5cm, resulted in lidocaine and prilocaine 
being fully separated and only about 2 minutes more than by short- end injection (Figure 3& 4). The 
short migration times obtained for procaine (2.7 minutes) and lidocaine (3.2 minutes) is an advantage 
of CE compared to the 5 minutes retention time for lidocaine using LC-MS-MS in our previous 
publication (Chik et al. 2006). All the validation results meet the international requirements as outlined 
by the FDA's 2001 bioanalytical method validation guidelines (FDA 2001). This method has been used 
for the analysis of lidocaine in tape samples obtained from tape stripping study in 12 healthy subjects. 
For the purpose of the study, only lidocaine content was analysed from the tape samples. 
http: //mc. manuscriptcentral. com/bmc 
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Conclusions 
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A fast and reliable method to analyse lidocaine from skin stripping tape samples has been developed 
and validated by using capillary electrophoresis with UV detection. The method has successfully been 
used to analyse hundreds of tape samples from tape stripping study. 
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Table 1 Regression parameters for five calibration curves during validation. 
Batch Slope Intercept r 
(A) (B) 
1 0.0257 0.0867 0.9986 
2 0.0262 0.0816 0.9974 
3 0.0255 0.0995 0.9967 
4 0.0257 0.0661 0.9997 
5 0.0240 0.1232 0.9914 
Linear equation: y= Ax +B 
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Table 2 Within and between batch variability from the nested analysis of variance (ANOVA). 
LLOQ QC I QC2 QC3 ULOQ 
Nominal concentration (µg/mL) 50.0 80.0 400.0 800.0 1000.0 
Mean; n =18 (µg/mL) 45.1 81.9 415.0 822.4 1013.0 
SDw 0.00 0.31 0.11 0.00 2.78 
SDb 0.06 0.39 2.28 2.13 5.73 
SDt 0.06 0.50 2.28 2.13 6.37 
CVw (%) 0.0 3.8 0.3 0.0 2.7 
CVb (%) 1.4 4.7 5.5 2.6 5.7 
CVt (%) 1.4 6.1 5.5 2.6 6.3 
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Figure 3 Electropherogram obtained from EMLA cream solution containing 50µg lidocaine and 
prilocaine and added IS of 600µg procaine. Displayed at 200nm. 
Figure 4 Electropherogram obtained from tape sample at 4 hours post dose with added IS of 600 
µg procaine. Displayed at 200nm. 
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Abstract 
A sensitive and simple liquid chromatography-tandem mass 
spectrometry method is developed and validated for the 
determination of lidocaine in human plasma. Bupivacaine is used 
as an internal standard, and the plasma extraction is performed by 
a simple liquid-liquid extraction. The limit of quantitation (LOQ) is 
04 ng/mL with a signal-to-noise ratio greater than S. The 
calibration curve is linear from 0.5 to 250 ngfmL with an r2 greater 
than 0.99. The coefficients of variation for within- and between. 
assay imprecision, including LOQ, are!; 13% and :5 8%, 
respectively. The percentage of inaccuracy for within- and 
between-assay, including LOQ, are !5 9% and 55%, respectively. 
The absolute recovery of lidocaine and bupivacaine are greater 
than 84% and 82%, respectively. The higher sensitivity and 
accuracy of this method allow the measurement of low 
concentrations of lidocaine in plasma from a clinical study of 
topically applied lidocaine in healthy subjects. 
transdermal delivery of lidocaine, a sensitive and accurate 
method was needed. In this study, a simple and rapid method 
for the analysis of lidocaine in human plasma was developed 
and validated using bupivacaine as an internal standard (IS). 
Various analytical methods have been based on high-per- 
formance liquid chromatography (HPLC) with W detection 
(3,4), liquid chromatography (LC)-tandem mass spectrometry 
(MS) (5,6), and gas chromatography (GC)-MS (7) for the 
quantitation of lidocaine. However, the HPLC with W detec- 
tion and CC-MS methods are not sensitive enough for dermal 
absorption studies, as the limit of quantitation (LOQ) of the 
published methods range from 4 to 100 ng/mL. Only the 
LC-MS methods are sensitive enough to detect the low con- 
centrations of lidocaine in plasma seen in these studies as 
the LOQ needs to be of the order of 0.2 ng/mL (5). 
Experimental 
Introduction 
Lidocaine is a commonly administered drug used both as a 
local anesthetic and antiarrhythmic. Lidocaine is administered 
intravenously or parenterally as the oral bioavailability of lido- 
caine is poor because of the first pass metabolism effect (1,2), 
and high concentrations of its principal metabolites are neu- 
rologically toxic drugs. Procedures involving the insertion of a 
needle through the skin are painful and may induce great fear 
and anxiety, especially in children. Bad experiences with a 
needle may reduce future compliance to the needle procedure. 
For the described reason, many researchers have searched for 
a "needle-less" and pain-free local anesthetic method via trans- 
dermal delivery. 
Absorption from the intact skin for transdermal delivery is 
poor. Therefore, the systemic absorption is considerably low. To 
analyze the plasma samples obtained from the clinical study of 
" Author to whom cunmpondemce should be addressed: email LChikegmuLac. uk. 
Chemicals 
Lidocaine hydrochloride (99.9% purity) and bupivacaine 
hydrochloride (100% purity) (IS) were obtained from Sigma- 
Aldrich (Poole, U. K. ). All HPLC-grade solvents were obtained 
from Rathburn Chemicals (Walkerbum, Scotland). All analyt- 
ical reagent-grade reagents were obtained from Merck (BDH) 
(Poole, Dorset, U. K. ). 
Apparatus 
Solvent delivery was achieved using a PerkinElmer series 
200 pump (Boston, MA) set at I mVmin. Sample injection 
was carried out using a PerkinElmer series 200 autoinjector. A 
Shimadzu CTO-10A column oven (Columbia, MD) was used. 
Detection was by PE SCIEX API2000 MS (Warrington, U. K. ), 
All PE SCIEX software was supplied by Applied Biosystems 
(Warrington, U. K. ). The NM20ZA high-purity nitrogen and air 
generators were supplied by Peak Scientific Instruments (Rein- 
frew, Scotland). 
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Chromatographic system 
The analytical column was a Supelcosil LC-Si (100 x 4.6-mm 
i. d. ), obtained from Merck (BDH) and was maintained 
at 50°C. The mobile phase was 2% formic acid in acetoni- 
trile- water (50: 50). The flow rate was fixed at 1 mlmin. APE 
SCIEX API2000 triple quadrupole MS equipped with a turbo- 
ion spray (heated electrospray) was used to introduce the 
sample into the MS through off-axis at an angle of 45°. The 
sample was introduced through 10: 1 splitter, which meant 
only 10 µL of the sample entered the MS. Nitrogen was used as 
the collision gas. PE SCIEX Analyst software (Version 1.3) was 
used to control the HPLC-MS, record the output from the 
detector, perform integration of peak areas, and calculate the 
lidocaine concentrations. 
Bupivacaine was used as an IS. All calculations were based on 
peak-area ratios of lidocaine and IS. The selection of operating 
ions is shown in Figure 1. The precursor ions for lidocaine and 
bupivacaine were m/z 234.99 and 289.09, respectively, and 
after collisional dissociation, the product ions were 85.98 and 
140.09, respectively. The retention times for lidocaine and 
bupivacaine during the assay were 5.1 and 4.9 min. 
Assay procedure 
Preparation of stock solution 
A stock solution of lidocaine and bupivacaine were prepared 
in 50% methanol. All the sub stock solutions were stored 
frozen at approximately -20°C. All of the calibrators and quality 
control (QC) sample concentrations were prepared by appro- 
priate dilution of sub stock dilution. 
Extraction procedure 
A 0.5-mLvolume of plasma, 0.1-ml, IS solution (500 ng/mL), 
0.1 mL IM NaOH, and 3 mL of methyl-tert-butyl ether were 
placed in a 4.5-ml, propylene tube. The contents were mix for 
a minimum of 5 min by the shaker and then centrifuged at 
3000-3500 rpm for 5 min. The top layer was then transferred 
to a 4.5-ml, polypropylene tube containing 0.25 ml, of 0.1% 
NH-C-CH= NBC= 
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Figure 1. Chemical structure of precursor and product ions of protonated 
lidocaine (A) and bupivacaine (B). 
formic acid. The tube was mixed again for a minimum of 5 min 
by the shaker and then centrifuged at 3000-3500 rpm for 
5 min. The top solvent layer was discarded by vacuum, and the 
remaining solution was transferred into an autosampler vial. A 
100-uL volume was injected into the analytical column. 
Results 
Selection of operating protonated ions 
Figure 1 shows the chemical structure and the protonated 
ions of lidocaine and bupivacaine used in this study related to 
their mass. The fragment ions at m/z 86 for lidocaine and m/z 
140 for bupivacaine were selected for the assay. The mass spec- 
trum scans for the two analytes are shown in Figure 2. 
Specificity 
No significant interfering peaks were found at the retention 
times of lidocaine or bupivacaine. The signal-to-noise ratios for 
both drugs were greater than S. Figure 3 shows the chro- 
matogram obtained from blank plasma spiked with 0.5 ng/mL 
lidocaine and blank plasma spiked with 500 ng/mL bupivacaine. 
Calibration curve 
The calibration curve covered the range from 0.5 to 250 
ng/mL of plasma with seven calibrators. All of the results were 
calculated using a Ux2 weighted quadratic regression. The 
peak-area ratio, regression coefficient, and parameters of the 
calibration line were calculated from the peak area data by the 
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Analyst program. The regression coefficient for all the cali- 
bration curves was greater than 0.99. Mean results obtained 
from five curves are summarized in Table I. 
Imprecision and inaccuracy 
Table II summarizes the within- and between-batch and 
total variability obtained from the nested analysis of variance 
(ANOVA). Precision and accuracy were assessed using three QC 
samples with nominal lidocaine values of 1.5,45, and 150 
ng(mL and a lower limit of quantitation (LLOQ) of 0.5 ng/mL 
and upper limit of quantitation (ULOQ) of 250 ng/mL. 
Within-assay reproducibility 
The three QC samples, LLOQ, and ULOQ were, initially, each 
extracted six times in one batch. Subsequently, they were 
extracted six times in two additional batches. On each occasion 
a separate calibration curve was extracted. The coefficient of 
variation (CV) and the percentage for imprecision and inaccu- 
racy, including the LLOQ and ULOQ, were all within the 
accepted range, which was 1.7-13% and 0-9%, respectively. 
Between-assay repeatability 
For each of the three assays previously mentioned, the mean 
concentration from each assay was used to calculate the 
between-assay reproducibility. The CV and the percentage for 
between-assay precision and accuracy, including LLOQ and 
ULOQ, were all within the accepted range, which was 1.9-8.396 
and 1-5%, respectively. 
From the nested ANOVA, the within- and between-batch 
and total variability for all the QC samples, including ULOQ 
and LLOQ, were all below than 11%. 
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Figure 3. Chromatograms obtained from extracted blank plasma spiked 
with 0.5 ng/mL lidocaine (A) and 500 ng/ml bupivacaine (B). 
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Table I. Regression Parameters for Five Calibration 
Curves During Validation* 
Curvature Slope Intercept 
Batch (C) (A) (B) ri 
1 6.12 E-6 0.00743 0.000394 0.9995 
2 7.75 E-6 0.00772 0.000682 0.9995 
3 7.51 E"6 0.00783 0.000210 0.9987 
4 7.79 E-6 0.00816 0.000282 0.9994 
5 8.52 E-6 0.00830 0.000434 0.9997 
" Second-order equation: y  Cx2 +Ax+ B. 
Table ti. Within and Between Batch Variability from the 
Nested ANOVA" 
I LLOQ Qa Qc2 QC3 ULOQ 
Nominal concentration 0.5 
(ng/mL 
Mean (ng/ml); n =18 0.50 
SDwt 0.03 
SDb 0.04 
SDt 0.06 
CVw 1%) 6.6 
Cvb (T. ) 8.7 
CVt (%) 10.9 
1.47 44.98 149.8 250 
1.43 45.72 154.54 263.04 
0.09 1.34 5.34 6.99 
0.08 1.55 2.38 11.18 
0.12 2.05 5.88 13.18 
6.1 2.9 3.5 2.7 
5.9 3.4 1.5 4.2 
8.5 4.5 3.8 5.0 
" Abbreviations w. within batch; b. between batch; I  total. 
SD   standard deviation 
Table Ill. Results of Stability Tests Carried Out on 
Lidocaine" 
Concentration (ng/mL) 
1.47 44.98 149.80 
Time 0 stability Mean In   4) 1.34 45.58 151.25 
data 
In plasma, after n 4.00 4.00 4.00 
three freeze. Mean 1.52 44.58 141.70 
thaw cycles Difference (Ye) 14.04 -2.20 -6.31 
In plasma after n 4.00 4.00 4.00 
48 h room Mean 1.47 40.19 134.29 
temperature Difference (%) 10.40 -11.84 -11.21 
In plasma after n 4.00 4.00 4.00 
48 hat 4°C Mean 1.54 44.94 149.24 
Difference (%) 15.46 -1.41 -1.33 
" Values express in percentage of the concentration difference between before and 
after test. 
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Recovery 
The absolute recovery of lidocaine was tested using human 
plasma spiked with lidocaine at the same nominal concentra- 
tions as the QC samples. The absolute recovery of bupivacaine 
was tested at a nominal concentration of 100 ng/mL. Peak 
area measurements obtained from the extracted samples were 
compared with the peak area measurements obtained from 
direct solvent injection of the test compounds. Mean and stan- 
dard deviations were calculated from at least three measure- 
ments at each level. The absolute recoveries of lidocaine and 
bupivacaine ranged from 84% to 89% and 82% to 86%, respec- 
tively. 
Stability 
Table III lists the stability data for lidocaine in plasma after 
three freeze-and-thaw cycles, after 48 h at room temperature, 
and after 48 hat 4°C. Figure 4 shows the graph of log concen- 
tration (ng/mL) versus time (h) for the autosampler stability 
test. The stability of lidocaine was measured in a sample of ana- 
lyte-free human plasma spiked with lidocaine at the same 
nominal concentrations as the QC samples. A minimum of 
three freeze-and-thaw cycles were tested. The stability of these 
control samples was further examined at ambient tempera- 
ture, approximately 20°C, and at approximately 4°C for a period 
of at least 24 h. For the stability of the sample extracts, the 
three control samples were each extracted such as to yield a 
total volume of extract sufficient to allow aliquots to be placed 
in the autosampler at room temperature and injected over a 
period of not less than 24 h. The autosampler was operated at 
ambient temperature, approximately 20°C (maximum tem- 
perature 20.5°C, minimum temperature 18.0°C). From all the 
results obtained, lidocaine was found to be stable in all of the 
parameters tested. 
Discussion 
This method validation has been conducted in accordance 
with the Good Laboratory Practice Regulations, Department of 
Health, London (U. K. ), and the Organization for Economic 
Cooperation and Development (OECD) Principles on Good 
Laboratory Practice (Paris, France). All the validation results 
2.5 
2 ;k 
Ak 
1.5 '. " QCJ 
-a- QC2 
1 -t-. QC3 
0.5 
0 4.3 6.7 17 22.1 24.5 
Mme (6) 
Figure 4. Graph of log concentration (ng/mL) versus time (h) for autosam- 
pler stability test. 
meet the international requirements as outlined in the Bioan- 
alytical method validation, Food and Drug Administration, 
2001 (8). This metjºod has been used for the analysis of human 
plasma obtained from the clinical studies of transdermal 
delivery of lidocaine on 100 healthy subjects. Although the 
procedure of liquid-liquid extraction used in this study was 
similar to the method published by Bo et al. (5), their proce- 
dures have been improved by reducing the amount of plasma 
used in the extraction and the length of the extraction process. 
The amount of plasma used in this study is suitable to analyze 
small amount of blood samples, especially from pediatric 
patients. 
Conclusion 
A simple liquid-liquid extraction and analysis method for 
lidocaine in plasma has been developed and validated. The sen- 
sitivity and accuracy of the assay is suitable for the analysis of 
low concentrations of lidocaine in plasma for the transdermal 
delivery study. 
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., treatments and 
three periods with a minimum of a1 week washout period was 
conducted. Twelve healthy males received 50 mg TDS®-testosterone, TDSt-placebo, 
and 50 mg of a commercially available topical testosterone preparation (Androgel, 
Keywords 1% topical testosterone gel). 
bioequivalence, pharmacokinetics, 
TDS®, testosterone, transdermal Results 
delivery The mean AUC(0,12 h) was higher following application of TDS'-testosterone 
(61.8 ng ml-' h), compared with Androgen (57.7 ng ml'' h) and TDS'-placebo 
(50.7 ng mM h. The mean C,,,,, (0,12 h) was similar for TDS"-testosterone 
(6.6 ng ml-1) and Androgel® (6.5 ng ml'') and these values were higher than those 
for TDS®-placebo (5.7 ng ml''). Analysis of variance showed that the 90% confidence Received intervals on the relative difference of the ratio for the AUC(0,12 h) and the C,, , 3 May 2005 (0,12 h) between TDS®-testosterone and Androgel®, were contained within the Accepted bioequivalence limit (80,125%) (C,,., 89.2,112.3% and AUC 93.5,120.5%). Serum 27 September 2005 testosterone concentrations were lower following TDS'-Placebo and were not Published arly bioequivalent either to the gel or spray. December r 2005 2005 20 
Conclusions 
The TDS® preparation was shown to deliver testosterone systemically to humans and 
the concentrations of the hormone in the 12 h following TDS' administration were 
bioequivalent to an existing topical delivery gel. 
Introduction 
Testosterone (17 (x-hydroxyandrost-4-ene-3 -one), is the 
most important androgen secreted into the blood. 
About 95% of the circulating testosterone present in 
men is secreted by the testes, which produce between 
3 and 10 mg of the hormone per day. Testosterone is 
responsible for the development of secondary male sex 
characteristics (e. g. increased growth of body hair, 
beard, and sexual libido). Hormone concentrations are 
higher during puberty, but decline with age [1] and 
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testosterone replacement therapy may be indicated, 
especially for hypogonadal (testosterone deficiency) 
men. 
A number of testosterone preparations have been 
tested for replacement therapy. These include subcuta- 
neous implants [2], scrotal transdermal patches [3], 
non scrotal transdermal patches [4], oral and sublin- 
gual preparations [5,6], testosterone gel [7-9], and the 
testosterone esters, enanthate and cypionate [10]. With 
the exception of the transdermal preparations, none is 
suitable for replacement therapy. Oral administration 
of testosterone leads to absorption into the hepatic cir- 
culation and rapid metabolism by the liver [11]. Behre 
[12] reported that oral administration of testosterone 
gives rise to wide fluctuations with high within and 
between individual variability in serum testosterone 
concentrations. It has been reported that methyltest- 
osterone can cause hepatic toxicity and adversely 
affect cholesterol concentrations following long-term 
usage [13-15]. 
Sublingual preparations of testosterone result in 
rapid increases in serum concentrations, which 
decline to below the normal range after 2h [6]. 
Occasional mild redness or itching is common with 
transdermal patches. Although scrotal patches causes 
less skin irritation than conventional transdermal 
preparations, usage of the former leads to an increase 
in dihydro-testosterone (DHT) concentrations after 
3 months of treatment [16]. Testosterone gels have 
also been developed, but care must be taken to pre- 
vent the transfer of testosterone to another person. 
Patients must wash their hands after applying the gel 
to a substantial surface area of the body and they 
must cover the application site with clothing once the 
gel has dried [17]. We have developed a more conve- 
nient method to deliver testosterone through the skin 
via a metered pump dispenser, using the TDS® deliv- 
ery system (Transdermal Technologies Inc., Florida, 
USA). This is a proprietary technology, which has 
been developed for use in pharmaceutical, cosmetic 
and over-the-counter products. The system consists of 
a true solution of ethanol, propylene glycol, monolau- 
rins, vitamins and pro-vitamins and cAMP energy 
donors. The safety of the TDS® system has been 
evaluated and confirmed by the Institute for In Vitro 
Sciences in Gaithersburg, Maryland USA, with 
respect to primary dermal irritation, skin sensitization 
and toxicity. 
The aims of this study were to assess the ability of 
the TDS® preparation to deliver testosterone systemi- 
cally and to characterize its pharmacokinetics in healthy 
males. 
Methods 
Study materials 
TDS®-testosterone (batch number MBR-BFLIQ84), 
TDS®-placebo and Androgel® (batch number 20293 RC) 
were supplied by TransDermal Technologies, Inc., Flor- 
ida, USA. TDS®-testosterone and TDS®-placebo were 
supplied as a liquid formulation, delivered by metered 
pump, with each spray containing 10 mg testosterone. 
Androgel® was supplied as a gel in unit-dose aluminium 
foil packets of 5 g, each containing 50 mg testosterone. 
Study design and treatments 
This was a single dose, randomized, three-way cross- 
over study (with three treatments, three periods, and six 
sequences) with a minimum of 1 week washout period 
between each treatment. The three treatments were 
TDS®- testosterone 50 mg, TDS®-placebo, and Andro- 
gel® 1% (50 mg). 
Subjects 
Twelve healthy males successfully completed the proto- 
col. Six subjects were Caucasian, and six were from 
other racial groups. The mean (SD) age of the subjects 
was 29.0 (6.2) years, and the mean (SD) BMI was 24.1 
(3.2) kg m-2. The study was approved by the East Lon- 
don and The City Health Authority Research Ethics 
Committee and received a Doctors and Dentists Exemp- 
tion Certificate (DDX) from MHRA (Medicines and 
Healthcare Products Regulatory Agency), UK. All the 
subjects gave written informed consent before taking 
part in the study, and each fulfilled all entry criteria 
based on physical examination, medical history, and 
clinical laboratory tests. 
Study protocol 
On the morning of each study day, blood pressure and 
heart rate were measured after subjects had rested for 
10 min. A 20G cannula was placed in a large antecubital 
vein for blood collection. The drug formulation was then 
applied to the left arm and gently rubbed into the skin. 
Regular meals and beverages were provided throughout 
the study day. After dosing, subjects were permitted to 
engage in normal daily activities, but were excluded 
from significant physical exertion or activities likely to 
stimulate endogenous testosterone production. 
Approximately 4 ml of blood was collected at -0.5 
(30 min before dosing) and 0h (immediately prior to 
dosing), to establish a baseline measurement of serum 
testosterone concentration. Subsequently, serial blood 
samples were collected at 0.5,1,1.5,2,2.5,3,3.5,4,5, 
6,7,8,10,12, and 24 h post dose. Samples were 
allowed to clot for approximately 20 min at room tem- 
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perature (26 °C) and were then centrifuged at 1800 g for 
10 min. The serum was transferred to labelled tubes and 
stored at -20 °C until analysis. 
Testosterone analysis 
Testosterone concentrations were measured in serum 
using an Enzyme Link Immunosorbent Assay (ELISA) 
method. The kit was obtained from DRG Instruments 
GmBH, Germany, lot no. 29K064. The three sets of 
testosterone control standards were obtained from Bio- 
Rad Laboratories, USA (lot no. 40631,40632, and 
40633 for set 1,2, and 3, respectively). The plate reader 
used was a GENios, computer controlled fluorometer 
from TECAN Company, Austria. The kit was validated 
to demonstrate adequate sensitivity, specificity, recov- 
ery, accuracy and precision (within and between assays). 
The limit of quantification was 0.2 ng ml-' for the assay. 
All the study samples were analyzed together with qual- 
ity control samples containing three different concentra- 
tions. The coefficients of variation for imprecision and 
inaccuracy were all below 15%. 
Data analysis 
Pharmacokinetic parameters were determined and the 
statistical analysis was performed using Kinetica Ver- 
sion 4.2 software. Cm. and t. were determined directly 
from the individual serum concentration-time curves, 
and the AUC was calculated using the linear trapezoidal 
method. The difference between treatments for 
AUC(0,12 h) and Cm were analyzed after logarithmic 
transformation using analysis of variance (ANOVA) for 
crossover studies which accounts for variation due to 
sequence, subject, formulation, and period. 
Bioequivalence testing was based upon the 90% con- 
fidence interval (CI) for the ratio of population means 
between two treatments. This method is equivalent to 
the corresponding two one-sided test procedure, with 
the null hypothesis of bioequivalence at the 5% signifi- 
cance level. For formulations to be bioequivalent, the 
ratio (test : reference) must fall between the 0.8,1.25 
confidence interval [18]. 
Results 
Figures 1 and 2 show the plots of mean serum 
concentration of testosterone vs. time and mean serum 
concentration changes from baseline. Testosterone con- 
centrations fluctuated slightly in most of the subjects 
during all the treatments. Most of the subjects treated 
with Androgel® and TDS®-testosterone achieved higher 
concentrations compared with placebo at 24 h post 
dose. 
The pharmacokinetic parameters AUC, C,,,.,,, and t 
are listed in Table 1 for each treatment. The AUC and 
Cm., values were calculated for both 0-12 and 0-24 h. 
The mean AUC(0,12 h) was higher following applica- 
tion of TDS®-testosterone compared with Androgel® 
and TDS®-placebo. However, the mean AUC(0,24 h) for 
Androgel® was higher than TDS®-testosterone and 
TDS®-placebo. The mean Cmu (0-12 h) was similar for 
TDS®-testosterone and Androgel® and these values were 
higher than that obtained for TDS®-placebo. Owing to 
the higher concentrations of testosterone at 24 h in some 
subjects, the mean C,,,. x (0-24 h) value 
for Androgel® 
was higher than those for TDS®-testosterone and TDS®- 
placebo. Only the 0-12 h data were used for the deter- 
mination of bioequivalence. 
The 90% confidence intervals on the relative differ- 
ence of the ratio for the AUC(0,12 h) and the C,,,,,, (0- 
12 h) between TDS®-testosterone and Androgel®, were 
contained within the bioequivalence limit (80,125%) 
Figure 1 6.5 
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Figure 2 
Plots of mean serum testosterone concentration 
change from baseline (ng mi-) vs. time (h) for 
each treatment MS*-placebo (0), TDS"- 
testosterone ( ), Androgel® (6) 
C.. (ng mr') tm.. (h) AUC (ng ml-' h) 
0-12 h 0-24 h 0-12 h 0-24 h 0,12 h 0,24 h 
TDSktestosterone 6.64 8.38 2.42 11.75 61.85 135.77 
(22.4) (49.7) (58.4) (92.3) (24.7) (34.1) 
TDS-placebo 5.72 5.95 3.29 9.00 50.67 101.67 
(21.1) (22.2) (111.5) (107.4) (23.6) (25.5) 
Androgei® 6.54 13.17 1.83 16.79 57.67 157.41 
(24.1) (99.2) (52.4) (63.5) (19.3) (57.7) 
Table 1 
Geometric mean (CV percentage) values 
for C. tn,,, and AUC for each treatment 
(C,.: 89.2,112.3% and AUC(0,12 h): 93.5,120.5%). 
Serum testosterone concentrations were lower following 
TDS®-placebo and were not bioequivalent either to the 
gel or the spray. 
Discussion 
No serious or unexpected adverse events were reported 
or observed during the study day. The drug formulations 
and protocol requirements were well tolerated by all 
subjects. Currently licensed transdermal delivery systems 
are available as patches, gels and buccal tabs. Patients 
report to us that patches may irritate the skin, gels can 
take time to dry and leave a residue, while the buccal 
tabs may be intrusive and have to be applied twice a day. 
The TDS preparation appears to provide a more conve- 
nient transdermal delivery of testosterone with rapid 
drying, and low to no skin residue or irritation compared 
with other transdermal systems. Based on these data we 
now plan a phase II study in hypogonadal males. 
The TDS®-testosterone preparation was shown to 
deliver testosterone systemically to humans. The con- 
centrations of hormone in the first 12 h following TDS® 
administration were found to be bioequivalent to an 
existing topical delivery gel. 
This work was supported by a grant from the William 
Harvey Research Foundation, QMUL UK and The 
Langford Institute, Florida USA. 
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Study of a combined percutaneous local anaesthetic 
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Summary 
Transdermal Delivery System (TDS®) is a liquid formulation which can be applied to the skin via a 
metered pump spray to deliver drug across skin. This placebo controlled, double blind trial 
compared anaesthetic properties of two TDS® systems (TDS®a and TDS®(3) with placebo. The 
active and placebo treatments were applied to the dorsum of the hands, bilaterally and simultan- 
eously for 5 min on 100 healthy volunteers. Following cannulation, pain perception was measured 
using the verbal rating score (VRS) and visual analogue score (VAS). Lidocaine plasma levels were 
assessed at 0 and 2 h. The VRS and VAS results show that TDS®ß significantly decreased pain 
score compared to placebo (p < 0.02). Blood lidocaine at 2h post application was also higher for 
TDS®ß than for TDS®a, suggesting that a5 min application of TDS®(3 was effective in delivering 
local anaesthetic and accelerating the onset of skin anaesthesia prior to venous cannulation in adults. 
....................................................................................................... Correspondence to: A. T. Tucker 
E-mail: a. t. tucker®gmul. ac. uk 
Accepted: 22 September 2005 
The pain caused by common minor procedures such as 
venepuncture and minor surgery is often ignored by 
clinicians. While it may be a trivial problem in adults, 
for young people, especially children, the pain is 
significant and can lead to the development of 'needle 
phobia', an intense fear of needles that triggers imme- 
diate anxiety. This also affects some adults. Local 
anaesthetics are normally given through injection and 
used to reduce the pain by inducing a loss of feeling 
(numbness) of skin and mucous membranes. To avoid 
the pain and anxiety of venepuncture, topical anaesthet- 
ics have been in use to provide needleless induction of 
local anaesthesia. 
Current topical local anaesthetics such as EMLA® 
(Astra Pharmaceuticals Ltd, Luton, UK) [1] and AME- 
TOP® gel [2] (Smith & Nephew Healthcare Ltd, Hull, 
UK), whilst effective, require institutional support. One 
hour prior application of EMLA® [3] and 30-45 min 
prior application of AMETOP® [4] limit clinical and 
patient acceptance. Thus, topical anaesthetics are exclu- 
ded from the procedures requiring acute anaesthesia, as 
well as those outside the institutional environment. The 
development of a topical delivery system with faster time 
of anaesthetic onset would be helpful in emergency cases 
and to increase the number of surgical day cases seen, 
especially in paediatrics. 
The Transdermal Delivery System (TDS®) is a paten- 
ted process for creating a formulation to deliver drug 
across skin using a liquid vehicle, measured by unit dose 
or metered pump spray. The dose is routinely compoun- 
ded into approximately I ml of very stable fluid. There is 
no patch or application appliance required other than unit 
dose packaging or metered pump sprayer. The system 
is composed of substances that are nutritional and/or 
neutral and harmless at their respective concentrations. 
TDS® systems are typically composed of a compatible 
solvent, supplemented by other excipients that enable a 
sufficient dose of the drug to be put into a relatively small 
volume of liquid. TDS® also contains excipients designed 
to support the skin and maintain the integrity of the 
barrier and the health of the skin. A TDS® may also 
contain excipients that can affect the rate of absorption of 
the drug. The TDS® is usually designed to enable 
extremely rapid delivery and bioavailability of drugs 
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equivalent to needle injection, with the added benefit of 
design, which enables rapid physiological response and 
blood levels equivalent to oral dosing. 
The TDS has been successfully tested in preclinical 
models with the following diverse molecules: cystamine, 
hydroxyzine, acyclovir, morphine sulphate, ibuprofen 
(three studies), paracetemol (two studies), imidazolinium 
methyl sulphate, testosterone, progesterone and the 
peptide alpha melanocyte-stimulating hormone. These 
drugs vary with molecular weights from the low 100 Da 
to nearly 2000 Da, both hydro- and lipophilic com- 
pounds and doses of 1-500 mg. ml-t of TDS® drug 
product. The safety of TDS® systems has been evaluated 
and confirmed by the Institute for In Vitro Sciences in 
Gaithersburg, Maryland, USA, for primary dermal irrita- 
tion, skin sensitisation and toxicity. In this study, two 
TDS® local anaesthetic systems (TDS®c and TDS®ß) 
have been evaluated for their speed of onset of anaesthe- 
sia, and drug penetration into the circulation. 
Method 
Study materials 
Study materials were supplied by Transdermal Technol- 
ogies Inc., Florida. 
1 TDS®ei Anaesthetic System (alcohol based) containing 
4% w/v lidocaine and 2% w/v tetracaine. 
2 TDS®ß Anaesthetic System (water based) containing 
4% w/v lidocaine and 2% w/v tetracaine. 
3 TDS®a, and TDS®ß placebo. 
Study design and subjects 
This study was prospective, double blinded and placebo 
controlled, with a 1-week washout period, involving 100 
healthy volunteers. Based on our previous study [5], 100 
subjects recruited in this study would have an 80% power 
to detect a difference of 25% in the primary outcome 
measures at p<0.05. Prior to enrolment, each subject 
was screened for standard blood biochemistry, drugs of 
abuse, and answered a questionnaire for demographics. 
Skin was assessed for erythema, oedema, itching, broken 
skin, or other signs of pathology. Body mass, height, body 
mass index, systolic and diastolic blood pressure, and heart 
rate were recorded. Subjects outside the age range of 20- 
40 years, with signs of skin pathology, haematology 
`out of standard limits' or with positive drug abuse tests 
were excluded. Subjects were not permitted any form 
of analgesia within 1 week of the trial. The study was 
approved by the East London and City Authority 
Research Ethics Committee and received a Doctors and 
Dentists Exemption Certificate (DDX) from the MHRA 
(Medicines and Healthcare Products Regulatory Agency, 
UK). Subjects were admitted to the investigation having 
been provided with a verbal and written explanation and 
signed a consent form. 
Admission and procedure 
Subjects were admitted to the Study Unit having fulfilled 
all the inclusion criteria. Blood pressure and heart rate 
were measured after subjects rested for 10 min. A sample 
was taken from an antecubital vein to establish a base- 
line measurement of plasma lidocaine concentration. All 
subjects were dosed according to the randomisation 
schedule. In the Phase I study, TDS® (active) was applied 
to the dorsal surface of a randomly selected hand and 
the TDS® (placebo) was simultaneously applied on the 
contralateral hand. Administrations of the formulations 
were achieved by metered pump spray of 1 ml to the 
area of 4 cm2. Five minutes after application, the hands 
were routinely cleaned using alcohol wipes prior to 
venepuncture. 
A vein on each hand within the treatment area was 
then cannulated using a 20G butterfly needle. The success 
of cannulation was confirmed by the ability to withdraw 
1-2 ml of blood. Two methods of pain assessment, Verbal 
Rating Score (VRS) and Verbal Analogue Score (VAS), 
were used to assess the pain of the procedure. Both 
systems have been fully validated in the literature [6,7] 
and the investigators trained in their use [5]. Following 
successful bilateral cannulation, a VRS pain classification 
was used for each hand. The volunteers were asked the 
following question: 'How strong was the pain of the 
procedure? ' and provided with a choice of five categories: 
1 no pain 
2 minimal sensation 
3 mild pain 
4 moderate pain 
5 severe pain 
The volunteer selected one answer for each hand by 
circling the number. 
In the VAS assessment, a 100 mm horizontal line with 
endpoints that are anchored by descriptors 'no pain' and 
'severe pain' was used. For each hand, the volunteer was 
asked 'What did the procedure feel like? ' and then 
requested to make a vertical line on the horizontal line 
which represented the intensity or unpleasantness of their 
pain by the procedure. Values were measured in milli- 
metres from the left hand edge of the horizontal line. 
Two hours after the treatment application, another 
blood sample was taken to assess the systemic level 
of lidocaine. The plasma was transferred to cryo-vials 
and stored at - 20 °C until analysis. All the procedures, 
including treatment applications, bilateral cannulation and 
data recording were each performed blindly by separate 
investigators. One week later, the volunteers repeated the 
above procedure using the second formulation (TDS®ß). 
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Analytical method 
Plasma concentration of lidocaine was analysed by using 
the liquid chromatography-mass spectrometry (LC-MS/ 
MS) method. Sample separation and detection was 
achieved on a Supelcosil LC-Si 10 cin column and I'E 
SCIEX API 2000 mass spectrometer. The method svgs 
validated to demonstrate adequate sensitivity, specificity, 
accuracy and precision. The lower limit of quantification 
(LOQ) was 0.5 ng. ml-' and bupivacaine was used as an 
internal standard. 
Statistical analysis 
All the data were analysed using Graphpad prime 4. (1 
(http: //www. graphpad. com/prism/Prisin. htm) and Mini- 
tab 14 statistical software (http: //www. niinitab. com/). 
The active treatments were compared to the placebo 
control using Wilcoxon's Signed Rank test. The lido- 
caine concentrations at 2h for TDS©a and TI)S®ß were 
Coinparedl using Student's paired t-test. 
Results 
One hundred healthy volunteers were successfully recrui- 
ted, and the demographics data are presented in Table 1. 
Of the 100 subjects, 65 were Caucasian, 22 Asian, four 
African/Caribbean, and nine from other ethnic groups. 
The cannulation procedures were successfully completed 
at the first attempt for all 100 volunteers. All the subjects 
tolerated the procedure well and complied with the study 
protocol. 
The median for VRS and VAS scores were different 
between active and placebo for both TDS®a and 'I'DS 0. P. 
In the VRS pain classification, the active treatment of 
TDS9a was not significantly different from the placebo 
(p = NS; Fig. 1). However, the active treatment of 
TDS®13 resulted in a significant reduction in pain 
response to cannulation compared to the placebo treat- 
ment (p < 0.02; Fig. 2). 
Similarly, the VAS also showed no significant differ- 
ence between placebo and active treatment with TDS'50( 
but was significantly different for TDS'(3 (p < 0.02; 
Fig. 3). The distribution of scores of the active treatment 
group in phase II (TDS(g'(3) was generally shifted from the 
two highest scores (moderate and severe) to the lower 
Table 1 1)enwgraphic data of study volunteers. 
Parameter Mean (SD) 
Sex; M: F 41 : 59 
Age; years 26.45 (5.2) 
Body mass index (BMI) 23.3 (3.9) 
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level of score (mild), with no subjects on active treatment 
rating the pain as severe. There was a reduction of those 
who scored the pain as moderate by 36.4% (Fig. 2). 
The above result was further supported by the plasma 
lidocaine concentrations 2h after the active treatment 
was applied. Lidocaine was detected in plasma for almost 
all subjects at 2h post dose. Although the level of 
lidocaine was not significantly different between TDS®a 
and TDS®ß (p = 0.287, NS; paired t-test), the mean 
plasma level for TDS®ß was slightly higher than TDS®a: 
mean (SD) [range] 3.51 (9.31)[0-64.5] ng. ml-I and 2.51 
(6.8)[0-55.9] ng. ml-1, respectively. 
Discussion 
The result from this exploratory study suggests that 
immediately following application of a TDS® anaesthetic 
system, there is a fast onset of effective anaesthesia for the 
venous cannulation in adults. The fact that 5 min 
application of TDS® anaesthetic system can produce an 
acceptable level of anaesthesia is a major advance in the 
anaesthetic system compared to EMLA® and AMETOP® 
gel, which must be applied 1h and 30-45 min, respect- 
ively, before cannulation is attempted. For operational 
reasons, randomisation was only performed within the 
treatment between active and placebo and not between 
the two systems (TDS®a and TDS®(3). However, the first 
treatment (TDS®a) could not have affected the second 
treatment (TDS®ß) due to the I week washout period. 
This gave more than enough time for the lidocaine to 
clear from the body and made carry over effects highly 
unlikely. 
Between the two TDS® systems tested, the water based 
anaesthetic system was more effective than the alcohol 
based product in providing both transdermal delivery of 
local anaesthetic and anaesthesia. The TDS® anaesthetic 
system can thus be manipulated to adjust the onset and 
degree of topical anaesthesia, and will be used as a basis for 
investigations into application periods and increased levels 
of anaesthesia. Other TDS® anaesthetic systems, such as 
those using alternative combinations of local anaesthetic 
agents rather than the lidocaine/tetracaine used in this 
study, are currently under investigation. The develop- 
ment of a rapid onset topical local anaesthetic would 
enable the replacement of invasive methods of local 
Anaesthesia, 2006,61, pages 123-126 
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anaesthesia, and free this procedure from the institutional 
environment. 
Conclusion 
In conclusion, topical application of the TDS® local 
anaesthetic system was effective in providing skin anaes- 
thesia for dorsal hand vein cannulation in healthy subjects, 
after 5 min of application. TDS®(3 (water based) was 
found to be more effective than TDS®a (alcohol based) 
and can be used for further development of this system. 
These findings also indicate the rapid transdermal drug 
delivery by the TDS® system. 
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